Assessing the potential population-level impacts of HIV self-testing distribution among key populations in Côte d'Ivoire, Mali, and Senegal: a mathematical modelling analysis. Supplement material.

Table of contents

Contents

Methods: model description	3
Overview	
Model equations	4
Model initiation (1970)	
Seeding of HIV in the population	
Population recruitment of sexually naïve populations	
Recruitment of sexually active population	
Turnover in sex-work	
Non-HIV mortality	
Population ageing	
HIV infection	
HIV disease progression and mortality	
HIV conventional testing, and diagnosis	
HIV treatment initiation and drop-out	
HIV self-testing	
Model fitting overview	
Model fitting data	
Fitting data (Côte d'Ivoire)	
Fitting data (Mali)	
Fitting data (Senegal)	
Methods: simulated HIVST scenarios	
Results: model fits (Côte d'Ivoire)	
Demography	
HIV epidemiology	
HIV treatment cascade	
Results: model fits (Mali)	
Demography	
HIV epidemiology	
HIV treatment cascade	74
Results: model fits (Senegal)	
Demography	
HIV epidemiology	
HIV treatment cascade	

Results: HIVST distribution and impact	91
Sensitivity analysis	
References	

Methods: model description

This model description was adapted from Maheu-Giroux et al.¹

Overview

The deterministic compartmental model used for this analysis was adapted from a previously published model of HIV transmission in Côte d'Ivoire¹⁻³ and coded in C++. Our model was fitted to country-specific demographic, behavioural, HIV epidemiological and intervention data in Côte d'Ivoire, Mali and Senegal over 1980-2020.

The sexually active modelled population is noted $X_{i,u,s}^{r,a}(t)$, where

- The subscript "*r*" corresponds to gender-risk groups combinations: low-risk females (*r*=0), intermediate-risk females (*r*=1), female sex worker (FSW, *r*=2), low-risk males (*r*=3), intermediate-risk males (*r*=4), clients of FSW (*r*=5), men who have sex with men and women (MSMW) (*r*=6), and men who have sex with men exclusively (MSME) (*r*=7). See **Figure S1a**.
- The subscript "*a*" corresponds to age group: 15-19 years olds (*a*=0), 20-24 years olds (*a*=1), 25-49 years olds (*a*=2), and 50-59 years olds (*a*=3). See **Figure S1b**.
- The subscript "i" corresponds to HIV infection status: susceptible (i=0), acute infection (i=1), chronic infection with CD4>500 cells/µL (i=2), with CD4 between 350 and 500 cells/µL (i=3), with CD4 between 200 and 350 cells/µL (i=4), and with CD4 <200 cells/µL (i=5). See Figure S1c.
- The subscript "u" corresponds to HIV testing/diagnosis/treatment status: never tested (u=0), ever tested and undiagnosed if PLHIV (u=1), had a reactive self-test but is not diagnosed (u=2), diagnosed by conventional test and without having had a reactive self-test) (u=3), diagnosed via a confirmatory test following a reactive self-test (u=4), treated (u=5), ever treated but dropped-out from treatment (u=6). See Figure S1d.
- The subscript "*s*" corresponds to the population history of HIV self-testing: have never used self-test (*s*=0), have ever used self-tests (*s*=1). See **Figure S1d**.
- Our equations also use the subscript "g", which corresponds to the population sex, with females (g=0), and males (g=1).

The sexually naïve population is noted $V_r(t)$, with everyone being assumed to be aged 15-19 year old, HIV uninfected, and never having tested for HIV.

Model equations

The model can be expressed as a set of ordinary differential equation reflecting changes in modelled number of sexually naïve (V_r) and sexually active individuals ($X_{i,u,s}^{r,a}$).

$$\frac{dV_r}{dt} = L_r(t) - G'_r(t) - Y'_r(t)$$

$$\frac{dX_{i,u,s}^{r,a}}{dt} = E_{i,u,s}^{r,a}(t) + J_{i,u,s}^{r,a}(t) + Y_{i,u,s}^{r,a}(t) + G_{i,u,s}^{r,a}(t) + D_{i,u,s}^{r,a}(t) + Q_{i,u,s}^{r,a}(t) + T_{i,u,s}^{r,a}(t) + U_{i,u,s}^{r,a}(t) + S_{i,u,s}^{r,a}(t)$$

Where

- L_r represents recruitment of sexually naïve populations into the model
- $E_{i,u,s}^{r,a}$ represents the recruitment of sexually active population through sexual debut of sexually naïve populations or migration of 25-49 years old adults
- $J_{i,u,s}^{r,a}$ represents the turnover in sex-work between female sex workers and intermediate-risk females
- $Y_{i,u,s}^{r,a}$ represents non-HIV mortality among sexually active, and Y'_r among sexually naïve
- $G_{i,u,s}^{r,a}$ represents ageing among sexually active, and G'_r among sexually naïve
- $D_{i.u.s}^{r,a}$ represents HIV acquisition
- $Q_{i,u,s}^{r,a}$ represents HIV infection progression and mortality
- $T_{i,u,s}^{r,a}$ represents HIV conventional testing and diagnosis
- $U_{i,u,s}^{r,a}$ represents HIV treatment (ART) initiation and drop-out
- $S_{i,u,s}^{r,a}$ represents HIV self-testing

Each of the components of the two equations above is described in the section that follows the characterization of the population at model initiation

Model initiation (1970)

The model starts in 1970 with a population of size N_0 (estimated by the United Nations Population Division (UNPD))⁴, and using the age-distribution for the year 1970. The initial population is assumed to be HIV uninfected (*i*=0) and having never tested for HIV (*u*=0, *s*=0).

The relative sizes of the KPs are constant over time from simulation start, and reflect estimates from country-specific surveys spanning over 1995-2020. As in ¹, the risk-distribution of the sexually naïve population mirrors the one of the sexually active populations to keep the size of KP constant over time.

 $X_{i,u,s}^{r,a}(1970) = 0$ if i=0 or u=0 or s=0

In 1970, the female population is distributed as follows:

1) Lower-risk females (*r*=0) of age *a* (sexually active and naïve):

$$\begin{cases} X_{0,0,0}^{0,a}(1970) = N_0 PR_{Fem} PR_{A_a}(1 - PR_{FSW})(1 - PR_{IRF})(1 - Vir_0(1970)) \\ V_0(1970) = N_0 PR_{Fem} PR_{A_a}(1 - PR_{FSW})(1 - PR_{IRF})Vir_0(1970) \end{cases}$$
 if $a=0$

$$X_{0,0,0}^{0,a} = N_0 PR_{Fem} PR_{A_a} (1 - PR_{FSW}) (1 - PR_{IRF})$$
if $a > 0$

2) Intermediate-risk females (*r*=1) of age *a* (sexually active and naïve):

$$\begin{cases} X_{0,0,0}^{1,a}(1970) = N_0 PR_{Fem} PR_{A_a}(1 - PR_{FSW}) PR_{IRF} (1 - Vir_0(1970)) \\ V_1(1970) = N_0 PR_{Fem} PR_{A_a}(1 - PR_{FSW}) PR_{IRF} Vir_0(1970) \end{cases}$$
 if $a=0$

$$X_{0,0,0}^{1,a} = N_0 PR_{Fem} PR_{A_a} (1 - PR_{FSW}) PR_{IRF} \text{ if } a > 0$$

3) Female sex workers (*r*=2) of age *a* (sexually active and naïve):

 $\begin{cases} X_{0,0,0}^{2,a}(1970) = N_0 PR_{Fem} PR_{A_a} PR_{FSW} (1 - Vir_0(1970)) \\ V_2(1970) = N_0 PR_{Fem} PR_{A_a} PR_{FSW} Vir_0(1970) \end{cases} \text{ if } a=0$ $X_{0,0,0}^{2,a}(1970) = N_0 PR_{Fem} PR_{A_a} PR_{FSW} \text{ if } a>0$

Where PR_{Fem} is the proportion of females in the model, PR_{A_a} is the relative size of the age group *a* at model start, $Vir_0(1970)$ the fraction of females aged 15-19 years old that are sexually naïve in 1970 (this fraction being assumed to be equal to the fraction in the first data point), PR_{FSW} the fraction of FSW among all females, PR_{IRF} the fraction of intermediate-risk females among all non-KP females. Empirical studies suggested slightly higher proportions of FSW among adult females in Côte d'Ivoire, (e.g. > 1% in ^{5,6}) compared to Mali and Senegal.

In 1970, the male population is distributed as follows:

4) Lower-risk males (*r*=3) of age *a* (sexually active and naïve):

$$\begin{cases} X_{0,0,0}^{3,a}(1970) = N_0 \left(1 - PR_{Fem}\right) PR_{A_a}(1 - PR_{Cli})(1 - PR_{MSM})(1 - PR_{IRM}) \left(1 - Vir_1(1970)\right) \\ V_3(1970) = N_0 \left(1 - PR_{Fem}\right) PR_{A_a}(1 - PR_{Cli})(1 - PR_{MSM})(1 - PR_{IRM}) Vir_1(1970) \end{cases}$$
 if $a=0$
$$X_{0,0,0}^{3,a}(1970) = N_0 \left(1 - PR_{Fem}\right) PR_{A_a}(1 - PR_{Cli})(1 - PR_{MSM})(1 - PR_{IRM})$$
 if $a>0$

5) Intermediate-risk males (*r*=4) of age *a* (sexually active and naïve):

$$\begin{cases} X_{0,0,0}^{4,a}(1970) = N_0 (1 - PR_{Fem}) PR_{A_a} (1 - PR_{Cli}) (1 - PR_{MSM}) PR_{IRM} (1 - Vir_1(1970)) \\ V_4(1970) = N_0 (1 - PR_{Fem}) PR_{A_a} (1 - PR_{Cli}) (1 - PR_{MSM}) PR_{IRM} Vir_1(1970) \end{cases}$$
 if $a=0$
$$X_{0,0,0}^{4,a}(1970) = N_0 (1 - PR_{Fem}) PR_{A_a} (1 - PR_{Cli}) (1 - PR_{MSM}) PR_{IRM}$$
 if $a>0$

6) Clients of FSW (*r*=5) of age *a* (sexually active and naïve):

$$\begin{cases} X_{0,0,0}^{5,a}(1970) = N_0 (1 - PR_{Fem}) PR_{A_a} PR_{Cli} (1 - Vir_1(1970)) \\ V_5(1970) = N_0 (1 - PR_{Fem}) PR_{A_a} PR_{Cli} Vir_1(1970) \end{cases} \text{ if } a=0$$

$$X_{0,0,0}^{5,a}(1970) = N_0 (1 - PR_{Fem}) PR_{A_a} PR_{Cli} \text{ if } a>0$$

7) Men who have sex with men and women (MSMW, r=6) of age a (sexually active and naïve):

$$\begin{cases} X_{0,0,0}^{6,a}(1970) = N_0 \left(1 - PR_{Fem}\right) PR_{A_a} PR_{MSM} PR_{Bi} \left(1 - Vir_1(1970)\right) \\ V_6(1970) = N_0 \left(1 - PR_{Fem}\right) PR_{A_a} PR_{MSM} PR_{Bi} Vir_1(1970) \end{cases}$$
 if $a=0$

 $X_{0,0,0}^{6,a}(1970) = N_0 (1 - PR_{Fem}) PR_{A_a} PR_{MSM} PR_{Bi} \text{ if } a > 0$

7) Men who have sex with men exclusively (MSME, r=7) of age *a* (sexually active and naïve):

$$\begin{cases} X_{0,0,0}^{7,a}(1970) = N_0 \left(1 - PR_{Fem}\right) PR_{A_a} PR_{MSM}(1 - PR_{Bi}) \left(1 - Vir_1(1970)\right) \\ V_7(1970) = N_0 \left(1 - PR_{Fem}\right) PR_{A_a} PR_{MSM}(1 - PR_{Bi}) Vir_1(1970) \end{cases}$$
 if $a=0$
$$X_{0,0,0}^{7,a}(1970) = N_0 \left(1 - PR_{Fem}\right) PR_{A_a} PR_{MSM}(1 - PR_{Bi})$$
 if $a>0$

Where $(1 - PR_{Fem})$ is the proportion of males in the model, PR_{A_a} is the relative size of the age group *a* at model start, $Vir_1(1970)$ the fraction of males aged 15-19 years old that are sexually naïve in 1970 (again, this fraction being assumed to be equal to the estimate from each country first data point), PR_{IRM} the fraction of intermediate-risk males among all non-KP and non-client males, PR_{Cli} the fraction of FSW clients among all males, PR_{MSM} the fraction of MSM among all males, PR_{Bi} the fraction of MSM that ever had a female partner.

The fraction PR_{Cli} is calculated using the multiplier method⁷, accounting for partner change rates reported by FSW and their clients, as well as the size of the FSW population¹. As in ^{1,3}, simulations were discarded when the estimated fraction PR_{Cli} was over 20%.

Seeding of HIV in the population

HIV is assumed to start spreading into a very small fraction of the modelled population between 1975 and 1979 (using a parameter HIV_{start}). At that particular time point, fractions $Prev_{FSW}$, $Prev_{Cli}$, and $Prev_{MSM}$ of FSW, clients and MSM respectively are assumed to become infected by HIV (and all with a CD4>500 cells/µL) (see **Table S1a**).

Population recruitment of sexually naïve populations L_r

Recruitment of sexually naïve populations of each risk group (L_r) is determined at each time step using the following formula:

$$\begin{split} L_{r}(t) &= \left(Y'_{r}(t) + \sum_{a,i,u,s} \mu_{a} X^{r,a}_{i,u,s}(t) + \sum_{a,i>0,u\neq 5,s} \gamma_{4} X^{r,a}_{i,u,s}(t) + \sum_{a,i>0,s} \frac{\gamma_{4}}{RR_{\omega}} X^{r,a}_{i,5,s}(t) \right. \\ &+ \varepsilon' \left(\sum_{a,i,u,s} X^{r,a}_{i,u,s}(t) + V_{r}(t) \right) + \sum_{i,u,s} G^{r,3}_{i,u,s}(t) \right) Vir_{g}(t) \end{split}$$

Where Y'_r (= $\mu_0 V_r$) and $\mu_a X_{i,u,s}^{r,a}$ are the number of sexually naïve and sexually active individuals exiting the model due to non-HIV mortality at each time step, γ_4 the rate at which PLHIV in the last stage of infection (<200 CD4 cells/µL) die from AIDS. The parameter RR_{ω} reflects the increase in survival among PLHIV on ART compared to PLHIV not on ART⁸. The term ε' is the population growth due to fertility and is calculated as $\varepsilon' = \varepsilon - (\chi PR_A_2)$, where ε is the total population growth rate, χ the migration rate and PR_A_2 the fraction of people aged 25-49 years old in the model. As suggested by census data for Côte d'Ivoire, the large majority of immigrants are aged between 25 and 49 years⁹. The term $G_{i,u,s}^{r,3}$ is the number of people leaving the model having reached the age of 60 years old. Finally, the time-dependant parameter $Vir_g(t)$ is the fraction of female or male entering the 15-19 years old age group as sexually naïve and was informed using data from the countries successive DHS's.

Recruitment of sexually active population $E_{i,u,s}^{r,a}$

Sexually active individuals of each risk group are recruited at each time step through ageing of sexually naïve 15-19 years old or migration of sexually active 25-49 years old (which are assumed to have the same HIV prevalence as adults in Côte d'Ivoire but are assumed to have never tested for HIV).

$$\begin{split} E_{i=0,u=0,s=0}^{r,a=0} &= \left(Y'_{r}(t) + \sum_{a,i,u,s} \mu_{a} X_{i,u,s}^{r,a}(t) + \sum_{a,i>0,u\neq 5,s} \gamma_{4} X_{i,u,s}^{r,a}(t) + \sum_{a,i>0,s} \frac{\gamma_{4}}{RR_{\omega}} X_{i,5,s}^{r,a}(t) + \\ \varepsilon' \left(\sum_{a,i,u,s} X_{i,u,s}^{r,a}(t) + V_{r}(t)\right) + \sum_{i,u,s} G_{i,u,s}^{r,3}(t)\right) \left(1 - Vir_{g}(t)\right) \\ E_{i=0,u=0,s=0}^{r,a=1} &= Age_{0} V_{r}(t) \\ E_{i,u=0,s=0}^{r,a=2} &= \chi PR_{-}A_{2} \sum_{a,u,s} X_{i,u,s}^{r,a}(t) \end{split}$$

Where χ is the migration rate and *PR_A*₂ the fraction of people aged 25-49 years old in the model




Figure S1a: modelled risk populations and their sexual contacts in the model, adapted from Maheu-Giroux et al. ¹. Female sex workers (FSW) only have sexual contacts with clients but can retire from sex work and move into the compartment of non-KP women with intermediate risk of infection. Clients of FSW have sexual contacts with all women risk groups. Non-KP women (low- and intermediate-risk women) have sexual contacts with all male risk groups, except MSME. The latter are assumed to form partnerships with other male exclusively, whereas MSMW form partnerships with both men and women.

Population	Symbol	۲	Value/ Prior distribution	1	References
^	•	Côte d'Ivoire	Mali	Senegal	
Demography					
Total population aged 15-59 years in 1970	N ₀	2,583,135	3,152,660	2,176,151	4
Population growth rate (year ⁻¹)	ε	3.40%	2.30%	2.85%	4
Immigration rate of 25-49 years old (year ⁻¹)	χ	U(0.0, 0.025)	U(0.0, 0.025)	U(0.0, 0.025)	4
Mortality rate (year ⁻¹)	$\mu_{0:1} \ \mu_2 \ \mu_3$	U(0.0201, 0.0207) U(0.0240, 0.0252) U(0.0455, 0.0475)	U(0.0186, 0.0198) U(0.0220, 0.0240) U(0.0425, 0.0440)	U(0.0172, 0.0183) U(0.0205, 0.0218) U(0.0398, 0.0406)	(1/life expectancy at 15, 25, and 50 years)
Proportion of females in population	PR _{Fem}	47.3%	51.1%	51.8%	⁴ (for the year 2000)
Age distribution (15-19, 20-24, 25-49, 50-59 years old) in 1970	$\begin{array}{c} PR_{A_0} \\ PR_{A_1} \\ PR_{A_2} \\ PR_{A_3} \end{array}$	18.2% 14.7% 56.5% 13.2%	19.7% 15.7% 51.4% 13.2%	19.9% 15.8% 53.4% 10.9%	⁴ (for the year 1970)
Rate of ageing in an older risk group or exiting the model at age 50	$Age_0 \\ Age_1 \\ Age_2 \\ Age_3$	$Age_0 = \frac{1}{5}$; $Age_1 = \frac{1}{5}$; $Age_2 = \frac{1}{25}$; $Age_2 = \frac{1}{25}$; $Age_3 = \frac{1}{25}$; $Age_4 = \frac{1}{5}$; $Age_5 $	$Age_3 = \frac{1}{10}$	Based on the pre-defined modelled age groups (15-19, 20-24, 25-49, 50-59 years old)

Proportion of sexually naïve	$Vir_{g=0}(t)$	Start = 27.4%	Start = 27.4%	Start = 64.8%	DHS surveys in Côte d'Ivoire ¹⁰⁻¹³ , Mali ¹⁴⁻¹⁸ ,
among 15-19 years old females	5	1994 = 27.4%	1995.5 = 27.4%	1992.5 = 64.8%	and Senegal ¹⁹⁻²⁸ . Proportion is assumed to be
		1999 = 35.9%	2001 = 36.5%	1997 = 66.0%	constant from the last data point.
		2004.5 = 34.2%	2006 = 45.2%	2005 = 71.2%	*
		2012 = 35.3%	2012.5 = 35.3%	2011 = 72.1%	
		End = 35.3%	2018 = 32.2%	2013 = 74.8%	
			End = 32.2%	2014 = 72.9%	
				2015 = 74.8%	
				2016 = 74.4% 2017 = 74.1%	
				2017 = 74.1% 2018 = 75.8%	
				2018 = 73.8% 2019 = 77.2%	
				End = 77.2%	
Proportion of sexually naïve	Vir (t)	Start = 44.3%	Start = 63.3%	Start = 69.0%	As above
among 15-19 years old males	$Vir_{g=1}(t)$	1994 = 44.3%	1995.5 = 63.3%	1992.5 = 69.0%	As above
among 13-19 years old males		1999 = 44.3%	2001 = 66.1%	1992.5 = 69.0%	
		2004.5 = 48.9%	2001 = 00.170 2006 = 75.8%	2005 = 69.0%	
		2001.0 = 10.9% 2012 = 57.3%	2012.5 = 81.3%	2000 = 00.0% 2011 = 80.9%	
		End = 57.3%	2018 = 77.5%	2013 = 89.0%	
			End = 77.5%	2014 = 89.0%	
				2015 = 86.5%	
				2016 = 87.8%	
				2017 = 84.6%	
				2018 = 89.3%	
				2019 = 92.4%	
				End = 92.4%	
Fraction of FSW among females	PR _{FSW}	U(0.8, 2.1%)	U(0.4, 1.1%)	U(0.5, 0.9%)	Côte d'Ivoire: ^{5,6,29-31}
					Mali: ^{6,32}
					Senegal: ^{6,33,34}
Fraction of MSM among males	PR _{MSM}	U(0.8, 1.7%)	U(0.2, 0.5%)	U(0.3, 1.2%)	Côte d'Ivoire: ³⁵⁻³⁸
C	MSM				Mali: ^{6,32}
					Senegal: ^{6,39}
Fraction of MSMW among all	PR _{Bi}	U(54.0, 75.5%)	U(53.5, 86.0%)	U(62.0, 85.0%)	Côte d'Ivoire: ^{38,40-46}
MSM w among an	I N _{Bi}	0(07.0, 70.070)	0(00.0,00.070)	0(02.0, 05.070)	Mali: ^{45,47-49}
WISINI					Senegal: ⁵⁰⁻⁵⁶
Turnover of sex work (year ⁻¹)	tur	U(0.067, 0.2)	U(0.067, 0.2)	U(0.067, 0.2)	Assumed as in ^{1,3}
Fraction of intermediate-risk	PR _{IRF}	U(5, 10%)	U(1, 5%)	U(1, 5%)	Côte d'Ivoire: ^{10-12,31,57}
females (>1 partner/yr) among all non-KP females					Mali: ^{15-17,58} Senegal: ^{21,22,24-27,59}
					a 1 21 22 24 27 50

Fraction of intermediate-risk males (>2 partner/yr) among all non-KP males	PR _{IRM}	U(5, 10%)	U(1, 5%)	U(1, 5%)	Côte d'Ivoire: ^{10-12,31,57} Mali: ^{15-17,58} Senegal: ^{21,22,24-27,59}	
HIV epidemic seeding						
Year of epidemic start	<i>HIV_{Start}</i>	U(1975, 1979)	U(1975, 1979)	U(1975, 1979)	Assumption	
HIV prevalence among FSW at epidemic start	Prev _{FSW}	U(0.1, 2%)	U(0.1, 2%)	U(0.1, 2%)	Assumption	
HIV prevalence among FSW clients at epidemic start	Prev _{Cli}	U(0.1, 1%)	U(0.1, 1%)	U(0.1, 1%)	Assumption	
HIV prevalence among MSM clients at epidemic start	Prev _{MSM}	U(0.1, 2%)	U(0.1, 2%)	U(0.1, 2%)	Assumption	

FSW: female sex workers; MSM: men who have sex with men; MSMW: men who have sex with men and women; U: uniform distribution (min, max)

Turnover in sex-work $J_{i,u,s}^{r,a}$

Female sex-workers (r=2) are assumed to start and cease sex work over their life course (see Figure S1a and Table S1a).

$$J_{i,u,s}^{r,a}(t) = 0 \text{ if } r \neq 1 \text{ and } r \neq 2$$

$$J_{i,u,s}^{r=1,a}(t) = tur X_{i,u,s}^{r=2,a}(t) - tur'(t) X_{i,u,s}^{r=1,a}(t)$$

$$J_{i,u,s}^{r=2,a}(t) = tur'(t) X_{i,u,s}^{r=1,a}(t) - tur X_{i,u,s}^{r=2,a}(t)$$

Where tur is the rate at which FSW (r=2) cease forming commercial partnership and transition to the risk group of intermediate-risk females (r=1). This parameter varies across simulations but is fixed over time. Conversely, the parameter tur'(t) represent the rate at which intermediate-risk females initiate sex work and transit into the compartment of FSW. This parameter is calculated at each time step so that the number of women initiating sex work is always equal to the number of women ceasing sex work.

$$tur'(t) = \frac{tur \sum_{r=2,a,i,u,s} X_{i,u,s}^{r,a}(t)}{\sum_{r=1,a,i,u,s} X_{i,u,s}^{r,a}(t)}$$

Non-HIV mortality $Y_{i,u,s}^{r,a}$

The rates of non-HIV mortality (μ_a) vary by age group *a* and are sourced from the United Nations Population Division (2019 revision of World Population Prospects)⁴.

$$Y_{i,u,s}^{r,a}(t) = -\mu_a X_{i,u,s}^{r,a}(t)$$

Non-HIV mortality rates also apply to the sexually naïve population, with $Y'_r(t) = -\mu_0 V_r(t)$

Population ageing $G_{i,u,s}^{r,a}$

The rates of ageing of sexually active populations into older age groups (or to exit the model when reaching 60 years old) ($G_{i,u,s}^{r,a}$), are obtained as the inverse of the number of years covered by the age groups: $Age_0 = \frac{1}{5}$; $Age_1 = \frac{1}{5}$; $Age_2 = \frac{1}{25}$; $Age_3 = \frac{1}{10}$.

The term G'_r correspond to the ageing of sexually naïve populations (all assumed to be 15-19 years old) age into a compartment of 20-24 years of sexually active.

$$G'_r(t) = Age_0 V_r(t)$$

Whereas,

$$G_{i,u,s}^{r,0}(t) = -Age_0 X_{i,u,s}^{r,0}(t)$$

$$G_{i,u,s}^{r,1}(t) = Age_0 X_{i,u,s}^{r,0}(t) - Age_1 X_{i,u,s}^{r,0} + Age_0 V_r(t) \text{ if } (i+u+s)=0 \text{ , and } G_{i,u,s}^{r,1}(t) = Age_0 X_{i,u,s}^{r,0}(t) - Age_1 X_{i,u,s}^{r,0}(t) \text{ otherwise}$$

$$G_{i,u,s}^{r,2}(t) = Age_1 X_{i,u,s}^{r,1}(t) - Age_2 X_{i,u,s}^{r,2}(t)$$

$$G_{i,u,s}^{r,3}(t) = Age_2 X_{i,u,s}^{r,2}(t) - Age_3 X_{i,u,s}^{r,3}(t)$$




Figure S1b: modelled population age structure, migration, ageing and mortality, adapted from Maheu-Giroux et al.¹

HIV infection $D_{i,u,s}^{r,a}$

The force of HIV infection, or rate at which people acquire HIV, vary over time and depend on individual and partner risk factors. We first describe how sexual mixing is represented in the model, then how the force of infection is derived.

Overall sexual mixing

As in ¹, sexual mixing was modelled as a function of the gender, age, and risk group of individuals, and informed with data whenever possible. We define $p_{rar'a'}$ as the probability of a sexual contact between someone of risk group r and age i with someone of risk group r' and age i', and estimated this quantity using the following equation:

$p_{rir'i} = WMW_{rr'}(M_{rr'})\Lambda_{rad}$	h = WMV	$V_{rr'}(M_r)$	r') Λ_{raal}
---	---------	----------------	----------------------

	/	F_{LR}	F_{IR}	F_{FSW}	M_{LR}	M_{IR}	M _{Cli}	M_{MSMW}	M_{MSME}
	F_{LR}	0	0	0	1	1	1	1	0
	F_{IR}	0	0	0	1	1	1	1	0
	F _{FSW}	0	0	0	0	0	1	0	0
$WMW_{rr'} =$	M_{LR}	1	1	0	0	0	0	0	0
	M _{IR}	1	1	0	0	0	0	0	0
	M _{Cli}	1	1	1	0	0	0	0	0
	M _{MSMW}	1	1	0	0	0	0	1	1
	$\setminus M_{MSME}$	0	0	0	0	0	0	1	1 /

The binary matrix WMW_{rrr} represent the types of partnerships allowed in the model for the risk groups of lower-risk females (F_{LR}), intermediate-risk female (F_{IR}), and female sex worker (F_{FSW}), as well as lower-risk males (M_{LR}), intermediate-risk males (M_{IR}), clients of female sex workers (M_{Cli}), men who have sex with men and women (M_{MSMW}), and men who have sex with men exclusively (M_{MSME}).

As in ¹, the sizes of the low- and intermediate-risk groups were based on the number of sexual partners during the last 12 months in the countries DHS surveys (F_{IR} defined as >1 partner per year; M_{IR} defined as >2 partners per year; excluding those that reported selling or buying sex).

Risk-mixing

Sexual mixing by risk group was calculated using sexual behaviour data for low and intermediate-risk individuals. Due to data limitation, mixing by risk group was only available for couples living in the same household who both agreed to be interviewed and reported complete data on their sexual partners in Côte d'Ivoire, and was analysed from the female perspective. A DHS-reported matrix M was expanded to include the other risk groups and their associated parameters: Bi_{Pref} being the fraction of partnerships that are with females for men having sex with men and women (MSMW), Pr_{MSMW} the fraction of MSM also having sex with women (assuming proportional mixing between MSMW and MSME), and Cli_{Mix} the fraction of partnerships that are with FSW for clients of FSW $Cli_{Mix} = \frac{c_5}{c_5+c_{5b}}$, where c_5 and c_{5b} are the clients reported number of commercial partners and non-commercial

partners, respectively.

$M_{rr'} =$								
(F_{LR}	F_{IR}	F_{FSW}	M_{LR}	M_{IR}	M_{Cli}	M_{MSMW}	M _{MSME}
F_{LR}	0	0	0	0.91	0.09*M _{IR}	0.09*M _{Cli}	0.09*M _{MSMW}	0
	0	0	0	0.88	$\frac{M_{IR}+M_{Cli}+M_{MSMW}}{0.12*M_{IR}}$	$\frac{M_{IR}+M_{Cli}+M_{MSMW}}{0.12*M_{Cli}}$	$\frac{M_{IR}+M_{Cli}+M_{MSMW}}{0.12*M_{MSMW}}$	0
F _{FSW}	0	0	0	0	$M_{IR} + M_{Cli} + M_{MSMW}$	M _{IR} +M _{Cli} +M _{MSMW} 1	$M_{IR}+M_{Cli}+M_{MSMW}$	0
M_{LR}	0.91	0.09	Õ	0	ů 0	0	0	ů l
M _{IR}	0.88	0.12	1	0	0	0	0	0
M _{Cli}	$0.88(1 - Cli_{Mix})$	$0.12(1 - Cli_{Mix})$	Cli _{Mix}	0	0	0	0	0
M _{MSMW}	$0.88(Bi_{Pref})$	$0.12(Bi_{Pref})$	0	0	0	0	$Pr_{MSMW}(1 - Bi_{Pref})$	$(1 - Pr_{MSMW})(1 - Bi_{Pref})$
M_{MSME}	0	0	0	0	0	0	Pr _{MSMW}	$1 - Pr_{MSMW}$

Mixing between risk groups was calculated using data from the 2011-2012 DHS in Côte d'Ivoire. See ¹ for further details.

Age-mixing

Mixing patterns by age (Λ) were informed using data from the latest DHS surveys available for each country. This survey data reports the age of the most recent sexual partner among the population that was sexually active in the 12 months preceding the survey interview. The age-mixing matrices differ for males and females. As in ¹, we assumed that age-mixing between FSW and their clients would correspond to that reported by males in the DHSs. For MSM, it was assumed that age mixing could range between completely assortative and proportional using the tuning parameter MSM_{AgeMix} , which was given a uniform distribution between 0 and 1.

For Côte d'Ivoire:

$$\begin{split} \Lambda_{raa'} &= \begin{pmatrix} 0.130 & 0.130 & 0.719 & 0.021 \\ 0.130 & 0.130 & 0.719 & 0.021 \\ 0.003 & 0.003 & 0.753 & 0.241 \\ 0 & 0 & 0.187 & 0.813 \end{pmatrix} \text{for } r=0,1 \\ \Lambda_{raa'} &= \begin{pmatrix} 0.483 & 0.483 & 0.035 & 0 \\ 0.483 & 0.483 & 0.035 & 0 \\ 0.194 & 0.194 & 0.609 & 0.004 \\ 0.125 & 0.125 & 0.187 & 0.167 \end{pmatrix} \text{for } r=2:6 \\ \Lambda_{raa'} &= \begin{pmatrix} 1 - MSM_{AgeMix} \end{pmatrix} \begin{pmatrix} 1 & 0 & 0 & 0 \\ 0 & 1 & 0 & 0 \\ 0 & 0 & 1 & 0 \\ 0 & 0 & 0 & 1 \end{pmatrix} + MSM_{AgeMix} \begin{pmatrix} 0.182 & 0.147 & 0.565 & 0.106 \\ 0.182 & 0.147 & 0.565 & 0.106 \\ 0.182 & 0.147 & 0.565 & 0.106 \\ 0.182 & 0.147 & 0.565 & 0.106 \\ 0.182 & 0.147 & 0.565 & 0.106 \\ 0.182 & 0.147 & 0.565 & 0.106 \end{pmatrix} \text{for } r=7:8 \end{split}$$

For Mali:

$$\Lambda_{raar} = \begin{pmatrix} 0.076 & 0.076 & 0.820 & 0.028 \\ 0.076 & 0.076 & 0.820 & 0.028 \\ 0.001 & 0.001 & 0.674 & 0.324 \\ 0 & 0 & 0.112 & 0.888 \end{pmatrix}$$
for r=0,1

$$\Lambda_{raa'} = \begin{pmatrix} 0.496 & 0.496 & 0.008 & 0 \\ 0.496 & 0.496 & 0.008 & 0 \\ 0.175 & 0.175 & 0.645 & 0.004 \\ 0.024 & 0.024 & 0.876 & 0.077 \end{pmatrix} \text{for } r=2:6$$

$$\Lambda_{raa'} = \begin{pmatrix} 1 - MSM_{AgeMix} \end{pmatrix} \begin{pmatrix} 1 & 0 & 0 & 0 \\ 0 & 1 & 0 & 0 \\ 0 & 0 & 1 & 0 \\ 0 & 0 & 0 & 1 \end{pmatrix} + MSM_{AgeMix} \begin{pmatrix} 0.197 & 0.157 & 0.514 & 0.132 \\ 0.197 & 0.157 & 0.514 & 0.132 \\ 0.197 & 0.157 & 0.514 & 0.132 \\ 0.197 & 0.157 & 0.514 & 0.132 \end{pmatrix} \text{for } r=7:8$$

For Senegal:

$$\begin{split} \Lambda_{raa'} &= \begin{pmatrix} 0.043 & 0.043 & 0.886 & 0.028 \\ 0.043 & 0.043 & 0.886 & 0.028 \\ 0.001 & 0.001 & 0.638 & 0.361 \\ 0 & 0 & 0.088 & 0.912 \end{pmatrix} \text{for } r=0,1 \\ \Lambda_{raa'} &= \begin{pmatrix} 0.494 & 0.494 & 0.012 & 0 \\ 0.494 & 0.494 & 0.012 & 0 \\ 0.182 & 0.182 & 0.632 & 0.003 \\ 0.026 & 0.026 & 0.865 & 0.103 \end{pmatrix} \text{for } r=2:6 \\ \Lambda_{raa'} &= \begin{pmatrix} 1 - MSM_{AgeMix} \end{pmatrix} \begin{pmatrix} 1 & 0 & 0 & 0 \\ 0 & 1 & 0 & 0 \\ 0 & 0 & 1 & 0 \\ 0 & 0 & 0 & 1 \end{pmatrix} + MSM_{AgeMix} \begin{pmatrix} 0.199 & 0.158 & 0.534 & 0.109 \\ 0.199 & 0.158 & 0.534 & 0.109 \\ 0.199 & 0.158 & 0.534 & 0.109 \\ 0.199 & 0.158 & 0.534 & 0.109 \\ 0.199 & 0.158 & 0.534 & 0.109 \end{pmatrix} \text{for } r=7:8 \end{split}$$

As in ¹, probabilities of sexual contacts are calculated separately for each partnership type (*rar'a'*). Imbalances between sexual partnerships demand and offer of the groups are likely (e.g. males typically reporting higher number of partners than females). The balance between supply of and demand for sexual partnership was obtained using a modified partner change rate $(c_{rar'a'}^*)$ using the method described by Garnett and Anderson ⁶⁰, and below:

$$\Delta_{rar'a'} = \frac{c_{r'a'} p_{r'a'ra} N_{r'a}}{c_{ra} p_{rar'a'} N_{ra}}$$
$$c^*_{rar'a'} = c_{ra} \Delta^{\eta_k}_{rar'a'}$$
$$c^*_{r'a'ra} = c_{r'a'} \Delta^{-(1-\eta_k)}_{rar'a'}$$

Here, the parameter $\Delta_{rar'a'}$ measures the degree of imbalance between supply and demand for sexual partnerships of type *rar'a'*, while η_k is the balance parameter which determines the degree to which partners alter their demand/offer of sexual partnerships. We assumed that clients of FSW would drive demand, whereas the balance parameter was assumed to be equal to 0.5 for MSM.

HIV force of infection

As in ¹, we defined the force of infection (i.e. annual probability of HIV transmission) from an individual of risk group r and age class a to an individual of risk group r and age class a ⁶¹. This probability partly depends on a "base" per-sex-act probability of transmission β which has different

values depending on the sex of both partners, with 1) female-to-male transmission probabilities (= β_{fm}) being lower than 2) male-to-female (= $\beta_{fm}RR_{\beta mf}$) and 3) male-to-male (= $\beta_{fm}RR_{\beta mm}$) transmission probabilities. Per-act transmission probabilities are further altered by a term of cofactors $Cof_{gg'a'}^{iu}$ (see next page and **Table S1c**). Since male circumcision is nearly ubiquitous in Western Africa, its protective effect was implicitly taken into account in the per-sex act transmission probabilities⁶².

The matrix $\lambda_{rar'a'}(t)$ reflects the transmission probabilities for each partnership combination of category r/r' and age a/a', where the susceptible partner is the one indexed by ra. The terms g' and g refers to the susceptible partner and infectious partner sex (=0 if female, =1 if male)

$$\begin{split} \lambda_{rar'a'}(t) &= c_{rar'a'}^* p_{rar'a'} \left[\sum_{i,t} \left(\left(\frac{I_{r'a'}^{iu}(t)}{\sum_{i,t} I_{r'a'}^{iu}(t) + S_{r'a'}(t)} \right) \left(1 - \left(\left(1 - \beta Cof_{gg'a'}^{iu}(t) \right)^{\alpha_{rar'a'}(1 - \nu_{ra}(t))} \left(1 - \beta Cof_{gg'a'}^{iu}(t)(1 - \varsigma) \right)^{\alpha_{rar'a'}(\nu_{ra}(t))} \right) \right) \right) \end{split}$$

Where $Cof_{gg'a'}^{iu}(t)$ represent a combination of cofactors for HIV acquisition (related to the susceptible individual gender g' and age a') and transmissions (related to the infectious individual disease stage *i* and treatment status *u*). Here, the model accounts for the elevated risk of acquisition among young women $(RR_{\beta YF})$ (compared to older women) ^{63,64}, the elevated risk of HIV transmission of individuals in the acute stage of HIV infection $(RR_{\beta Acute})$ ⁶⁵. We also assume that an increasing fraction of PLHIV on ART $(VLS_g(t))$ have a suppressed viral load and can't transmit HIV ⁶⁶. Estimates of this fraction are available over time and by sex from UNAIDS⁶⁷. PLHIV on ART that don't have a suppressed viral load $(1 - (VLS_g(t) VLSPtl))$ are assumed to transmit HIV at the same rate as those not on ART.

The cofactor term $Cof_{gg'a'}^{iu}(t)$ is described below under three specific cases:

1) when both susceptible and infected partners don't have any specific risk factor for HIV acquisition/transmission (if (g' = 1 or a' > 1) and i > 1 and $u \neq 5$):

1.1.:
$$Cof_{gg'a'}^{iu}(t) = 1$$

2) when the susceptible individual is not a young woman (i.e. if g' = 1 or a' > 1) and the infected partner has a modified risk of HIV transmission because he/she is in the acute stage of infection or in on ART (i.e. if i = 1 or u = 5):

2.1.:
$$Cof_{gg'a'}^{iu}(t) = RR_{\beta Acute}$$
 if $i = 1$ and $u \neq 5$
2.2.: $Cof_{gg'a'}^{iu}(t) = \left(1 - \left(VLS_g(t) VLSPtl\right)\right)$ if $i \neq 1$ and $u = 5$
2.3.: $Cof_{gg'a'}^{iu}(t) = RR_{\beta Acute}\left(1 - \left((VLS_g(t) VLSPtl\right)\right)$ if $i = 1$ and $u = 5$

3) when the susceptible individual is a young woman (i.e. if g' = 0 and $a' \le 1$) and the infected partner has a modified risk of HIV transmission because it is in the acute stage of infection or in on ART (if i = 1 or u = 5):

2.1.: $Cof_{gg'a'}^{iu}(t) = RR_{\beta Acute}RR_{\beta YF}$ if i = 1 and $u \neq 5$ 2.2.: $Cof_{gg'a'}^{iu}(t) = \left(1 - \left(VLS_g(t) VLSPtl\right)\right)RR_{\beta YF}$ if $i \neq 1$ and u = 52.3.: $Cof_{gg'a'}^{iu}(t) = RR_{\beta Acute}\left(1 - \left(VLS_g(t) VLSPtl\right)\right)RR_{\beta YF}$ if i = 1 and u = 5

Parameter	Symbol		References		
		Côte d'Ivoire	Mali	Senegal	
Number of sexual partners of se	exually active r	isk groups			
Lower-risk females	C ₀	U(0.8, 0.9)	U(0.79, 0.84)	U(0.63, 0.66)	Range selected as minimum and maximum values across DHS surveys in Côte d'Ivoir ¹⁰⁻¹³ , Mali ¹⁴⁻¹⁸ , and Senegal ¹⁹⁻²⁸
Intermediate-risk females	<i>C</i> ₁	U(2.4, 9.4)	U(2.0, 2.8)	U(2.0, 2.2)	As above
Lower-risk males	<i>C</i> ₃	U(1.0, 1.2)	U(0.86, 0.92)	U(0.61, 0.73)	As above
Intermediate-risk males	C_4	U(4.7, 6.8)	U(4.2, 8.2)	U(3.2, 7.0)	As above
FSW	<i>C</i> ₂	U(216.0, 360.0)	U(200.0, 1007.0)	U(182.0, 273.0)	Studies among FSW in Côte d'Ivoire ⁶⁸⁻⁷¹ ,
Clients of FSW with FSW	<i>C</i> ₅	U(23.0, 37.0)	U(23.0, 37.0)	U(23.0, 42.0)	Mali ⁷² , and Senegal ⁷³⁻⁷⁶ Surveys in Côte d'Ivoire ⁷⁷ and Senegal (personal communication of estimated from an unpublished IBBS client survey ⁷⁸). No
Clients of FSW with non-KP females	<i>c</i> _{5<i>b</i>}	U(1.0, 6.8)	U(1.0, 6.8)	U(2.5, 4.5)	 data for Mali (used Côte d'Ivoire data) Surveys in Côte d'Ivoire⁶⁸⁻⁷¹ and Senegal⁷⁸ No data for Mali (used Côte d'Ivoire data)
MSMW	<i>C</i> ₆	U(1.0, 10.0)	U(1.0, 10.0)	U(1.0, 10.0)	Assumption
MSME	<i>C</i> ₇	U(1.0, 10.0)	U(1.0, 10.0)	U(1.0, 10.0)	Assumption
Number of sex acts per partner-	-year				
Lower-risk partners (r=0,3)	$\alpha_{rir'i'}$	U(40.0, 48.0)	U(40.0, 48.0)	U(40.0, 48.0)	10
Intermediate-risk partners (r=1,4)	$\alpha_{rir'i'}$	U(33.0, 66.0)	U(33.0, 66.0)	U(33.0, 66.0)	10
Clients-FSW partners (r=3,5)	$\alpha_{rir'i'}$	U(1.0, 4.0)	U(1.0, 4.0)	U(1.0, 4.0)	10
MSM partners (r=6,7)	$\alpha_{rir'i'}$	U(33.0, 66.0)	U(33.0, 66.0)	U(26.4, 39.6)	Data from MSM survey in Senegal ⁷⁹ . Assumption for Côte d'Ivoire and Mali
Increase in numbers of sex acts of MSM from 2016 compared to before 2007	$RR\alpha_{MSM2016}$	No increase assumed	No increase assumed	U(1.5, 2.0)	Assuming a linear trend between 2007 ⁵² a 2016 ⁵⁵
Sexual balance parameter as per Garnett et al. 1994 ⁶⁰	η	U(0, 1)	U(0, 1)	U(0, 1)	Assumption

Proportion of partnerships that are with females for MSMW	Bi _{Pref}	U(32.0, 44.3%)	U(30.0, 45.0%)	U(34.7, 42.0%)	Surveys among MSM in Côte d'Ivoire ³⁶ and Senegal ⁷⁹ . Range for Mali expanded from Côte d'Ivoire and Senegal estimates (as no Mali data available)
Tuning parameter between assortative and proportional mixing by age among MSM	MSM _{AgeMix}	U(0, 1)	U(0, 1)	U(0, 1)	Assumption

FSW: female sex workers; MSM: men who have sex with men; MSMW: men who have sex with men and women; MSME: men who have sex with men exclusively; U: uniform distribution (min, max)

Table S1c: Model parameters related to H			
Parameter	Symbol	Prior distribution	References
Natural history progression (PLHIV no	t on ART)		
Average duration of acute infection (years)	$1/\gamma_0$	U(0.11, 0.18)	65
Average time from seroconversion to 350 CD4 cells/µL	$\frac{1/\gamma_0 + 1/\gamma_1}{+ 1/\gamma_2}$	U(2.2, 4.6)	80
Average time from 350 CD4 to 200 CD4 cells/µL	$1/\gamma_3$	U(3.9, 5.0)	80
Average time from 200 CD4 cells/ μ L to death	$1/\gamma_4$	U(1.9, 3.9)	80
HIV transmission			
	P	U(0.001, 0.017)	81,82
Female-to-male transmission probability per sex act	β_{fm}		81
RR of HIV transmission from male to female compared to from female to male	$RR_{\beta mf}$	U(1, 3)	
RR of HIV transmission between males compared to from female to male	$RR_{\beta mm}$	U(2, 6)	83
RR of HIV acquisition of females aged <25 years compared to females aged ≥ 25 years	$RR_{\beta YF}$	U(1.25, 2.5)	63,64
Excess hazard-months of HIV transmission attributable to the acute stage	$EHM_{\beta Acute}$	U(4.2, 16.8)	⁶⁵ . This parameter is used to calculate the RR of HIV transmission during acute HIV infection <i>RR</i> _{βAcute} using the formula $RR_{βAcute} = \left(\frac{EHM_{βAcute}}{12/\gamma_0}\right) + 1$
RR of HIV transmission among when a condom is used during a sex act (vs during a condomless sex act)	ς	U(0.75, 0.942)	βλαιτέ (12/γ ₀) ⁻ 84
ART and viral suppression			
ART initiation rate in the AIDS stage (<200 CD4 cells/µL)	$ ho_4$	U(0.5, 4.0)	Assumption
Slope cofactor shaping linear relation between CD4 stages and ART initiation	ω	U(0, 1.0)	Assumption
RR of ART initiation among diagnosed PLHIV in 2000 compared to 2020	$RR_{\rho 2000}$	U(0, 1.0)	Assumption
RR of ART initiation among KP compared to non-KP	$RR_{\rho KP}$	U(0.2, 5.0)	Assumption
RR survival extension cofactor by HIV diagnosis/treatment status	$RR\omega_u$	U(2.2, 6.3) if <i>u</i> =5, and 0 otherwise (only PLHIV on ART experience a reduced HIV mortality)	8
ART drop-out rate prior to 2015	arphi	U(0.15, 0.27)	85-91
RR of ART drop-out for FSW and MSM (vs non-KP or clients)	$RR_{\varphi KP}$	U(1.25, 1.75)	⁹² (FSW data)
RR of ART drop-out after 2015 compared to before 2015	$RR_{\varphi 2015p}$	U(0.75, 1.00)	Assumption

FSW: female sex workers; MSM: men who have sex with men; MSMW: men who have sex with men and women; MSME: men who have sex with men exclusively; RR: relative risk; U: uniform distribution (min, max)

Parameter	Symbol		Prior distribution		References
	Ľ	Côte d'Ivoire	Mali	Senegal	
During sex acts between no	on-KP groups				
Among 15-24 years old	$Condom_{0:1}(t)$	$Start = (0-5\%)$ $YrCond_{NonKP} = (3-5\%)$ $1995 = (9.9-47.2\%)$ $1999 = (11.5-55.7\%)$ $2006 = (20.9-53.5\%)$ $2012 = (20.7-59.5\%)$ End = (20.7-59.5\%)	$Start = (0-1\%)$ $YrCond_{NonKP} = (1-2\%)$ $2001 = (2.8-20.5\%)$ $2006 = (20.6-30.5\%)$ $2012 = (4.1-26.4\%)$ $2018 = (2.5-20.7\%)$ End = (2.5-20.7\%)	$Start = (0-1\%)$ $YrCond_{NonKP} = (1-2\%)$ $2005 = (1.2-5.6\%)$ $2011 = (0.0-1.8\%)$ $2014 = (2.8-4.8\%)$ $2016 = (1.7-3.8\%)$ $2018 = (1.3-2.4\%)$ End = (1.3-2.4\%)	 ^{93,94} For estimates in the early 1980's. Range from DHS surveys in Côte d'Ivoire ¹⁰⁻¹³, Mali¹⁴⁻¹⁸, and Senegal¹⁹⁻²⁸, using levels reported by females as minimum, and reported by males as maximum
Among 25-49 years old	Condom ₂ (t)	$Start = (0-2.5\%)$ $YrCond_{NonKP} = (1-2.5\%)$ $1995 = (2.5-21.7\%)$ $1999 = (3.1-21.8\%)$ $2006 = (4.7-23.8\%)$ $2012 = (7.3-24.2\%)$ End = (7.3-24.2\%)	$\begin{array}{l} \text{Start} = (0-1\%) \\ \text{YrCond}_{NonKP} = (0.5-1\%) \\ 2001 = (0.1-4.1\%) \\ 2006 = (1.0-4.4\%) \\ 2012 = (1.4-4.5\%) \\ 2018 = (0.9-5.4\%) \\ \text{End} = (0.9-5.4\%) \end{array}$	$Start = (0-1\%)$ $YrCond_{NonKP} = (0.5-1\%)$ $2005 = (1.2-4.6\%)$ $2011 = (1.6-3.3\%)$ $2014 = (1.5-2.0\%)$ $2016 = (1.8-2.8\%)$ $2018 = (0.5-1.5\%)$ End = (0.5-1.5\%)	As above
Among 50-59 years old	Condom ₃ (t)	$Start = (0-2\%)$ $YrCond_{NonKP} = (0.2-2\%)$ $1995 = (0.2-9.7\%)$ $1999 = (0.6-9.7\%)$ $2006 = (0.6-10.0\%)$ $2012 = (1.8-11.5\%)$ End = (1.8-11.5\%)	$Start = (0-1\%)$ $YrCond_{NonKP} = (0.5-1\%)$ $2001 = (0.1-4.1\%)$ $2006 = (1.0-4.4\%)$ $2012 = (1.4-4.5\%)$ $2018 = (0.9-5.4\%)$ End = (0.9-5.4\%)	$Start = (0.5 - 1.5 \%)$ $Start = (0-1\%)$ $YrCond_{NonKP} = (0.5 - 1.5\%)$ $2005 = (1.2 - 4.6\%)$ $2011 = (1.6 - 3.3\%)$ $2014 = (1.5 - 2.0\%)$ $2016 = (1.8 - 2.8\%)$ $2018 = (0.5 - 1.5\%)$ End = (0.5 - 1.5\%)	As above

All FSW with clients	CondomSW(t)	Start = (0-5%)	Start = (0-5%)	Start = (0-5%)	Surveys among FSW in Côte
		$YrCond_{SW} = (5-15\%)$	$YrCond_{SW} = (5-15\%)$	$YrCond_{SW} = (5-15\%)$	d'Ivoire ^{68,69,71,95} , Mali ^{72,96-101} and
		1991 = (57-68%)	1997 = (74-83%)	1990 = (79-89%)	Senegal ^{73-76,102}
		1993 = (74-81%)	2000 = (90-98%)	2006 = (93-99%)	Stingar
		1995 = (73-88%)	2003 = (94-98%)	2010 = (90-98%)	
		1997 = (88-93%)	2009 = (94-98%)	2015 = (95-99%)	
		1998 = (88-98%)	2018 = (95 - 98%)	2019 = (88-96%)	
		2002 = (91-99%)	End = (95-98%)	End = (88-96%)	
		2007 = (90-99%)			
		2012 = (90-95%) 2014 = (85, 02%)			
		2014 = (85-93%) End = (85-93%)			
All MSM	CondomMSM(t)	Start = (0-0%)	Start = (0-0%)	Start = (0-0%)	Surveys among MSM in Côte
		$YrCond_{MSM} = (5-15\%)$	$YrCond_{MSM} = (5-15\%)$	$YrCond_{MSM} = (5-15\%)$	d'Ivoire ^{36,40,50} , Mali ^{32,103} and
		2004 = (35-50%)	2014 = (70-82%)	2005 = (76-77%)	Senegal ^{52,55,78,104} . Estimates in Côte
		2012 = (57-69%)	2018 = (70-82%)	2014 = (73-76%)	d'Ivoire and Senegal similar to levels
		2015 = (63-81%)	End = (70-82%)	2016 = (70-84%)	of condom use reported by CohMSM
		2017 = (68-82%)		End = (70-84%)	participants ($\sim 75\%$) ⁴⁵ .
Year of increase in condom u	as in the 1000's	End = (68-82%)			
				11/1001 1000	
Non-KP groups (r=0,1,3,4)	$YrCond_{NonKP}$	U(1981, 1990)	U(1981, 1990)	U(1981, 1990)	Assumption
FSW with clients (r=2,5)	$YrCond_{SW}$	U(1981, 1990)	U(1981, 1990)	U(1981, 1990)	Assumption
MSM (r=6,7)	$YrCond_{MSM}$	U(1981, 1990)	U(1981, 1990)	U(1981, 1990)	Assumption
Scaling factors for the propo	rtion of sex acts pro	tected by condoms			
Among non-KP aged 15-24 years	$CondPtl_{0:1}$	U(0, 1)	U(0, 1)	U(0, 1)	Assumption
Among non-KP aged 25-49	$CondPtl_2$	U(0, 1)	U(0, 1)	U(0, 1)	Assumption
years	contai ti ₂	O(0, 1)	O(0, 1)	O(0, 1)	Assumption
Among non-KP aged 50-59	$CondPtl_3$	U(0, 1)	U(0, 1)	U(0, 1)	Assumption
years	5				1
All FSW with clients	CondSWPtl	U(0, 1)	U(0, 1)	U(0, 1)	Assumption
All MSM	CondMSMPtl	U(0, 1)	U(0, 1)	U(0, 1)	Assumption
RR actual condom use during	RR _{condSW}	U(0.7,1.0)	U(0.7,1.0)	U(0.7,1.0)	Conservative assumption based on
sex work (vs reported)	CondSW	- (,,-)	- (,)	- (,)	studies among clients of FSW, or using biomarkers, pooling booth surveys or list randomisation 105-107

list randomisation¹⁰⁵⁻¹⁰⁷

FSW: female sex workers; MSM: men who have sex with men; MSMW: men who have sex with men and women; MSME: men who have sex with men exclusively; RR: relative risk; U: uniform distribution (min, max)

HIV disease progression and mortality $Q_{i,u,s}^{r,a}$

At each time step, newly infected PLHIV progress through different stages of infections according to their CD4 cell counts, expressed by the superscript "*i*", (with *i*=0 corresponding to HIV-uninfected people, **Figure S1c**). The first stage of HIV infection (*i*=1) corresponds to acute infection, the second (*i*=2) to CD4>500 cells/ μ L, the third (*i*=3) for CD4 between 350 and 500 cells/ μ L, the fourth (*i*=4) for CD4 between 200 and 350 cells/ μ L, and the last one (*i*=5) for CD4 <200 cells/ μ L, the latter stage being associated with HIV-related mortality. Transitions rates between infection stages (γ_i) were sourced from the literature and shown in **Table S1c**. As in ¹, the reduced HIV-mortality among PLHIV on ART was obtained by reducing the transition rates γ_3 and γ_4 by a factor $RR\omega_u$ (informed by mortality data) which is > 1 only when *u*=5.

For HIV-uninfected people: $Q_{i=0,u,s}^{r,a}(t) = 0$

For PLHIV:

 $\begin{aligned} Q_{i=1,u,s}^{r,a}(t) &= -\gamma_0 X_{i=1,u,s}^{r,a}(t), \text{ if in the acute infection stage} \\ Q_{i=2,u,s}^{r,a}(t) &= \gamma_0 X_{i=1,u,s}^{r,a}(t) - \gamma_1 X_{i=2,u,s}^{r,a}(t), \text{ if CD4} > 500 \text{ cells/}\mu L \\ Q_{i=3,u,s}^{r,a}(t) &= \gamma_1 X_{i=2,u,s}^{r,a}(t) - \gamma_2 X_{i=3,u,s}^{r,a}(t), \text{ if CD4 between 350 and 500 cells/}\mu L \\ Q_{i=4,u,s}^{r,a}(t) &= \gamma_2 X_{i=3,u,s}^{r,a}(t) - (\frac{\gamma_3}{RR\omega_u}) X_{i=4,u,s}^{r,a}(t), \text{ if CD4 between 200 and 350 cells/}\mu L \\ Q_{i=5,u,s}^{r,a}(t) &= (\frac{\gamma_3}{RR\omega_u}) X_{i=4,u,s}^{r,a}(t) - (\frac{\gamma_4}{RR\omega_u}) X_{i=5,u,s}^{r,a}(t), \text{ if CD4} < 200 \text{ cells/}\mu L \end{aligned}$




Figure S1c: modelled HIV infection stages among people not on ART.

HIV conventional testing, and diagnosis $T_{i,u,s}^{r,a}$

The rates of conventional HIV testing and diagnosis in the modelled populations vary over time and are informed by the trends in proportions of people having tested for HIV in the last year (parameter $\tau^{g,a}(t)$) (see **Table S2e**). This data was available by sex and age group from countries successive DHS surveys. As in¹, in order to replicate the trends in testing rates and maintain temporal consistency despite uncertainties in exact levels of testing, the parameter *TestPtl* is used to represent the percentile of each data uncertainty range, and is sampled between 0 and 1 within each simulation. The variable *Year*_{τ} is the time where people start testing for HIV in each country, and is sampled in each simulation.

$$T_{i,u,s}^{r,a}(t) = 0$$
 if time $\leq Year_{t}$

When time > $Year_{\tau}$, population flows will depend on population HIV and diagnosis/treatment status.

Among HIV-uninfected populations (*i*=0):

$$T_{i,u=0,s}^{r,a}(t) = -X_{i,u=0,s}^{r,a}(t) \tau^{g,a}(t) RRTest_{i,u=0}^{r}(t) K_{g,a}^{r}(t) RRTest_{i,u=0}^{r}(t) K_{g,a}^{r}(t) K_{g,a}^{r}(t) RRTest_{i,u=0}^{r}(t) K_{g,a}^{r}(t) RRTest_{i,u=0}^{r}(t) K_{g,a}^{r}(t) K_{g,a}^{r}(t) RRTest_{i,u=0}^{r}(t) RRTest_{i,u=0}^$$

 $T_{i,u=1,s=0}^{r,a}(t) = 0$ (conventional HIV tests by this population are accounted for, but do not correspond to a flow into another population group)

 $T_{i,u=1,s=1}^{r,a}(t) = X_{i,u=2,s=1}^{r,a}(t) \tau^{g,a}(t) RRTest_{i,u=2}^{r}(t) K_g$ (conventional HIV tests following false-reactive self-tests)

$$T_{i,u=2,s=1}^{r,a}(t) = -X_{i,u=2,s=1}^{r,a}(t) \tau^{g,a}(t) RRTest_{i,u=2}^{r}(t) K_g \text{ (as above)}$$

Among PLHIV (i >0):

$$T_{i,u=0,s}^{r,a}(t) = -X_{i,u=0,s}^{r,a}(t) \tau^{g,a}(t) RRTest_{i,u=0}^{r}(t) K_{g}$$

$$T_{i,u=1,s=0}^{r,a}(t) = -X_{i,u=1,s=0}^{r,a}(t) \tau^{g,a}(t) RRTest_{i,u=1}^{r}(t) K_{g}$$

$$T_{i,u=1,s=1}^{r,a}(t) = -X_{i,u=1,s=1}^{r,a}(t) \tau^{g,a}(t) RRTest_{i,u=1}^{r}(t) K_{g}$$

$$T_{i,u=2,s=1}^{r,a}(t) = -X_{i,u,s}^{r,a}(t) \tau_{ST} \text{ (confirmation of reactive HIV self-tests)}$$

$$T_{i,u=2,s=1}^{r,a}(t) = -X_{i,u,s}^{r,a}(t) \tau_{ST} \text{ (confirmation of reactive HIV self-tests)}$$

$$T_{i,u=3,s=0}^{r,a}(t) = \left(\left(X_{i,u=0,s}^{r,a}(t) \tau^{g,a}(t) RRTest_{i,u=0}^{r}(t) \right) + \left(X_{i,u=1,s=0}^{r,a}(t) \tau^{g,a}(t) RRTest_{i,u=1}^{r}(t) \right) \right) K_{g}$$

 $T_{i,u=3,s=1}^{r,a}(t) = X_{i,u=1,s=1}^{r,a}(t) \tau^{g,a}(t) RRTest_{i,u=1}^{r}(t) K_g$ $T_{i,u=4,s}^{r,a}(t) = X_{i,u=2,s=1}^{r,a}(t) \tau^{g,a}(t) RRTest_{i,u=2}^{r}(t) K_g$

 $T_{i,u\geq 5,s}^{r,a}(t) = 0$ (conventional HIV tests by PLHIV on ART or that have dropped-out from ART are accounted for, but do not correspond to a flow into another population group)

Where the parameter $RRTest_{i,u}^{r}(t)$ is a product of cofactors (relative risks) defined using wide uncertainty ranges which aimed at reproducing empirical heterogeneities in HIV testing coverage by risk group, HIV status and HIV testing history status (see **Table S1e**):

- The parameter $RR_{\tau AIDS}$ reflects the increase in HIV conventional testing among PLHIV in the AIDS stage of infection (compared to PLHIV not in the AIDS stage).
- The parameters $RR_{\tau FSWStart}$ and $RR_{\tau FSW2020}$ represent the elevated HIV conventional testing rates among FSW compared to non-FSW females at the time points $Year_{\tau}$ and 2020, with the RR for a specific time being calculated assuming a linear trend between $RR_{\tau FSWStart}$ and $RR_{\tau FSW2020}$ over the period [$Year_{\tau} 2020$]. A similar assumption is made for the HIV testing rates of MSM (compared to non-MSM males), using the parameters $RR_{\tau MSMStart}$ and $RR_{\tau MSMStart}$ and $RR_{\tau MSM2020}$.
- Heterogeneities in HIV conventional testing rates among PLHIV vs HIV-uninfected populations are represented using one parameter for KPs $(RR_{\tau PLHIV_KP})$ and one for non-KPs $(RR_{\tau PLHIV_NKP})$, and similarly for populations never having tested for HIV (vs ever testing, including HIV self-tests) (using the parameters $RR_{\tau NTest_KP}$ and $RR_{\tau NTest_NKP}$).
- Possible heterogeneities in HIV conventional testing among diagnosed PLHIV (compared to undiagnosed PLHIV) are captured using the parameter $RR_{\tau Diagn}$.

An overall K_g parameter is used as an overall fudge factor to fit the model to history of HIV testing (by risk group, and HIV status when available) as well as number of conventional HIV tests done in the countries.




Figure S1d: modelled stages of HIV testing, diagnosis and treatment.

Parameter	Symbol		Prior distribution		References	
		Côte d'Ivoire	Mali	Senegal		
HIV conventional testing probabilitie	es (last 12 mont	ths) $ au^{g,a}(t)$				
Start year of HIV testing	$Year_{\tau}$	U(1996, 1999)	U(1996, 1999)	U(1996, 1999)	Assumed	
Non-FSW females aged 15-24 years	$\tau^{0,0:1}(t)$	Start = (0, 0%)	Start = (0, 0%)	Start = (, 0%)	DHS surveys in Côte d'Ivoire 10-13, Mali ¹	
ç .		<i>Year</i> _{τ} = (0, 0%)	<i>Year</i> _{τ} = (0, 0%)	<i>Year</i> _{τ} = (0, 0%)	¹⁸ , and Senegal ^{19-22,28}	
		2005 = (1, 6%)	2006 = (2, 7%)	2005 = (0, 2%)	ý 8	
		2011 = (7, 26%)	2013 = (3, 12%)	2011 = (5, 25%)		
		2017 = (8, 33%)	2018 = (4, 15%)	2014 = (7, 28%)		
		End = (8, 33%)	End = (4, 15%)	End = (7, 28%)		
Non-FSW females aged 25-49 years	$\tau^{0,2}(t)$	Start = (0, 0%)	Start = (0, 0%)	Start = (0, 0%)	As above	
6 7		<i>Year</i> _{τ} = (0, 0%)	<i>Year</i> _{τ} = (0, 0%)	<i>Year</i> _{τ} = (0, 0%)		
		2005 = (2, 9%)	2006 = (1, 5%)	2005 = (0, 1%)		
		2011 = (7, 26%)	2013 = (3, 12%)	2011 = (7, 28%)		
		2017 = (11, 45%)	2018 = (5, 18%)	2014 = (8, 33%)		
		End = (11, 45%)	End = (5, 18%)	End = (8, 33%)		
Non-FSW females aged 50-59 years	$\tau^{0,3}(t)$	Start = (0, 0%)	Start = (0, 0%)	Start = (0, 0%)	As above	
6 7		<i>Year</i> _{τ} = (0, 0%)	<i>Year</i> _{τ} = (0, 0%)	<i>Year</i> _{τ} = (0, 0%)		
		2005 = (2, 9%)	2006 = (1, 3%)	2005 = (0, 2%)		
		2011 = (7, 26%)	2013 = (2, 4%)	2011 = (4, 17%)		
		2017 = (11, 45%)	2018 = (3, 12%)	2014 = (6, 25%)		
		End = (11, 45%)	End = (3, 12%)	End = (6, 25%)		
Non-MSM males aged 15-24 years	$\tau^{1,0:1}(t)$	Start = (0, 0%)	Start = (0, 0%)	Start = (0, 0%)	As above	
Ç ,	(0)	<i>Year</i> _{τ} = (0, 0%)	<i>Year</i> _{τ} = (0, 0%)	<i>Year</i> _{τ} = (0, 0%)		
		2005 = (1, 4%)	2006 = (1, 4%)	2005 = (0, 2%)		
		2011 = (4, 15%)	2013 = (2, 7%)	2011 = (3, 15%)		
		2017 = (3, 11%)	2018 = (1, 4%)	2014 = (3, 15%)		
		End = (3, 11%)	End = (1, 4%)	End = (3, 15%)		
Non-MSM males aged 25-49 years	$\tau^{1,2}(t)$	Start = (0, 0%)	Start = (0, 0%)	Start = (0, 0%)	As above	
C jana		<i>Year</i> _{τ} = (0, 0%)	<i>Year</i> _{τ} = (0, 0%)	<i>Year</i> _{τ} = (0, 0%)		
		2005 = (2, 8%)	2006 = (2, 10%)	2005 = (1, 4%)		
		2011 = (5, 22%)	2013 = (4, 15%)	2011 = (5, 20%)		
		2017 = (7, 28%)	2018 = (3, 12%)	2014 = (5, 20%)		
		End = (7, 28%)	End = (3, 12%)	End = (5, 20%)		

Non-MSM males aged 50-59 years	$\tau^{1,3}(t)$	Start = (0, 0%)	Start = (0, 0%)	Start = (0, 0%)	As above
		<i>Year</i> _{τ} = (0, 0%)	<i>Year</i> _{τ} = (0, 0%)	<i>Year</i> _{τ} = (0, 0%)	
		2005 = (1, 3%)	2006 = (2, 10%)	2005 = (1, 4%)	
		2011 = (5, 22%)	2013 = (4, 15%)	2011 = (4, 17%)	
		2017 = (4, 16%)	2018 = (3, 12%)	2014 = (3, 15%)	
		End = (4, 16%)	End = (3, 12%)	End = (3, 15%)	
Scaling factor for HIV testing among	TestPtl	U(0, 1)	U(0, 1)	U(0, 1)	Assumed
non-FSW and non-MSM					
Overall HIV testing scaling factor	K_{g}	U(0.2, 5)	U(0.2, 5)	U(0.2, 5)	Assumed
(by gender)					
Relative change in conventional test		· · · · · · · · · · · · · · · · · · ·			
RR HIV testing among PLHIV in	$RR_{\tau AIDS}$	U(1, 8)	U(1, 8)	U(1, 8)	Assumption similar to ¹
AIDS stage (vs PLHIV not in the					
AIDS stage)					
RR HIV testing among FSW (vs	$RR_{\tau FSWStart}$	U(1, 10)	U(1, 10)	U(1, 10)	Assumption based on higher reported
non-KP females) at Year _{τ}	ti Siv Start				history of testing among FSW compared to
, t					non-FSW women
RR HIV testing among FSW (vs	$RR_{ au FSW2020}$	U(1, 10)	U(1, 10)	U(1, 10)	As above
non-KP females) from 2020	1117FSW 2020	- () - /	- () - /	- () - /	
RR HIV testing among MSM (vs	$RR_{\tau MSMStart}$	U(1, 10)	U(1, 10)	U(1, 10)	Assumption based on higher reported
non-MSM males) at Year _{τ}	πη _τ MSMStart	0(1, 10)	0(1, 10)	0(1, 10)	history of testing among MSM compared
non-ivisivi mates) at $T \in u_{\tau}$					to non-MSM men
DD IIIV testing an an a MCM (as	מת	U(1, 10)	U(1, 10)	U(1, 10)	
RR HIV testing among MSM (vs	$RR_{ au MSM2020}$	U(1, 10)	U(1, 10)	U(1, 10)	As above
non-MSM males) from 2020					
RR HIV testing among KP PLHIV	$RR_{\tau PLHIV_{KP}}$	U(0.2, 5)	U(0.2, 5)	U(0.2, 5)	Assumed
(vs HIV-uninfected KP)					
RR HIV testing among non-KP	$RR_{\tau PLHIV_NKP}$	U(0.2, 5)	U(0.2, 5)	U(0.2, 5)	Assumed
PLHIV (vs HIV-uninfected non-KP)					
RR HIV testing among KP never	$RR_{\tau NTest_KP}$	U(0.2, 5)	U(0.2, 5)	U(0.2, 5)	Assumed
having tested (vs KP ever tested)					
RR HIV testing among non-KP	$RR_{\tau NTest_NKP}$	U(0.2, 5)	U(0.2, 5)	U(0.2, 5)	Assumed
never having tested (vs non-KP ever					
tested)					
RR HIV testing among diagnosed	$RR_{\tau Diagn}$	U(0.2, 3)	U(0.2, 3)	U(0.2, 3)	Assumed
PLHIV (vs undiagnosed)	i Diugn				
HIV self-testing					
Rate of HIV self-testing	$v_{i,u,s}^{r,a}(t)$				Calculated from the number of kits
Strict Son Costing	i,u,s(v)				distributed and used, see specific section
					and a set a una abea, see speemie section

Fraction of HIV self-tests replacing conventional tests	Repl	20%	30%	40%	From an analysis of ATLAS and subnational programmatic data in Côte d'Ivoire and Senegal ¹⁰⁸ . Mali assumed as the average between the estimates for Côte d'Ivoire and Senegal
HIV self-test sensitivity and specificity	STSe _i and STSp		$STSe_i = 0.92$ if i>1 $STSe_i = 0$ if i=1 STSp = 0.99		d'Ivoire and Senegal Assumptions of the base-case scenario, based on manufacturer data ¹⁰⁹ . We assumed that tests cannot detect HIV when the individual is in the acute stage of
			515p = 0.99		infection
Fraction of HIV self-tests which are followed by a confirmation test and linkage to care	STLnk		STLnk = 0.5		ATLAS phone survey data (2 nd stage) ¹¹⁰
Rate of HIV confirmatory testing among having had a reactive test and linked to care	$ au_{ST}$		$ au_{ST} = 6$	As above	
Rate of ART initiation among those diagnosed via a confirmed reactive test	$ ho_{ST}$		$ \rho_{ST} = 12 $		As above
Viral suppression among PLHIV					
Fraction of female PLHIV on ART that have a suppressed viral load	$VLS_{g=0}(t)$	Start = (40-60%) 2000 = (40-60%) 2018 = (70-89%) 2020 = (73-93%) 2030 = (85-95%) End = (85-95%)	Start = (40-60%) 2000 = (40-60%) 2020 = (63-83%) 2030 = (85-95%) End = (85-95%)	Start = (40-60%) 2000 = (40-60%) 2016 = (73-91%) 2020 = (77-97%) 2030 = (85-97%) End = (85-97%)	From ⁶⁷ for 2016 and 2020, assumptions otherwise
Fraction of male PLHIV on ART that have a suppressed viral load	$VLS_{g=1}(t)$	Start = (40-60%) 2000 = (40-60%) 2018 = (69-91%) 2020 = (75-97%) 2030 = (85-97%) End = (85-97%)	Start = (40-60%) 2000 = (40-60%) 2020 = (65-87%) 2030 = (85-95%) End = (85-97%)	Start = (40-60%) 2000 = (40-60%) 2016 = (66-83%) 2020 = (76-96%) 2030 = (85-96%) End = (85-96%)	As above
Scaling factor for viral suppression among PLHIV on ART	VLSPtl	U(0, 1)	U(0, 1)	U(0, 1)	Assumption

FSW: female sex workers; MSM: men who have sex with men; MSMW: men who have sex with men and women; MSME: men who have sex with men exclusively; RR: Relative risk; U: uniform distribution (min, max)

HIV treatment initiation and drop-out $U_{i,u,s}^{r,a}$

Our model reused the approach from^{1,3} to represent ART initiation, which accounts for changes in ART eligibility, while reflecting the fact that CD4 cell counts may have been widely available in the region⁹⁰. Our model assumes that individuals could only initiate ART after being diagnosed, hence no treatment was given until the period 1980-*Year*_{τ}, with *Year*_{τ} being sampled over 1996-1999. PLHIV diagnosed through a confirmed reactive self-test initiate ART at a rate ρ_{ST} , informed by ATLAS survey data (see **Figure S1d**).

$$\begin{split} U_{i,u,s}^{r,a}(t) &= 0 \text{ if } u \leq 2 \\ U_{i,u=3,s}^{r,a}(t) &= -UStart_{i} \, RRUStart_{r}(t) \, X_{i,u=3,s}^{r,a}(t) \\ U_{i,u=4,s}^{r,a}(t) &= -\rho_{ST} \, X_{i,u=4,s}^{r,a}(t) \\ U_{i,u=5,s=0}^{r,a}(t) &= UStart_{i} \, RRUStart_{r}(t) \, X_{i,u=3,s=0}^{r,a}(t) \\ &+ \left(\left(UStart_{i} \, RRUStart_{r}(t) \right) - \left(UStop \, RRUStop(t) \right) \right) \, X_{i,u=6,s=0}^{r,a}(t) \\ U_{i,u=5,s=1}^{r,a}(t) &= UStart_{i} \, RRUStart_{r}(t) \, X_{i,u=3,s=1}^{r,a}(t) + \rho_{ST} \, X_{i,u=4,s}^{r,a}(t) \\ &+ \left(\left(UStart_{i} \, RRUStart_{r}(t) \right) - \left(UStop \, RRUStop(t) \right) \right) \, X_{i,u=6,s=1}^{r,a}(t) \\ U_{i,u=6,s}^{r,a}(t) &= UStop \, RRUStop(t) \, X_{i,u=6,s}^{r,a}(t) \end{split}$$

The parameter *UStart_i* is the "base" rate of ART initiation and depend on PLHIV HIV stage of infection, whereas *UStop* is the "base" rate of ceasing ART. As in ^{1,3}, we assumed that PLHIV with a diagnosed infection and a CD4 count <200 cells/µL were more likely to show clinical symptoms and initiate ART. A linear relation was assumed between CD4 count stage and initiation rate using parameter ϖ . This parameter was given a uniform prior over [0-1] so that PLHIV with lower CD4 cell counts always had higher initiation rates. ART initiation rates were first sampled among PLHIV with a CD4 count <200 cells/µL (*UStart*₄ = ρ_4), and the rates among the other infection stages were calculated using the formula described in ¹, where $m = ((0 - \rho_4)/9.25) \varpi$, *UStart*₃ = $\rho_3 = 3m - \rho_4$, *UStart*₂ = $\rho_2 = 6m - \rho_4$, and *UStart*₁ = $\rho_1 = 9m - \rho_4$.

The parameter $RRUStart_r(t)$ is a product of cofactors for initiating ART (see **Table S1c**): the parameter $RR_{\rho 2000}$ is the relative risk of ART initiation among PLHIV with a diagnosed infection at the time $Year_{\tau}$ compared to 2020, and we assumed that ART initiation rates would linearly increase between $Year_{\tau}$ and 2020, then stay constant at the 2020 levels after this period. Our model allowed the ART initiation rates to differ between KP and non-KP, using a wide prior range for a parameter $RR_{\rho KP}$. Similarly, the parameter $RRUStop_r(t)$ is a product of cofactors for ceasing ART: our model assumed that ART drop-out rates could slightly decrease over time and be different between FSW and MSM compared to non-KP and FSW clients.

Our model used a specific ART initiation rate among people that had confirmed a reactive HIV reactive self-test (ρ_{ST}), which could be directly informed by ATLAS data (see specific section).

A fraction of PLHIV on ART have a suppressed viral load and are assumed not to be able to transmit HIV. This fraction increases over time and vary by sex $(VLS_g(t))$, using estimates from UNAIDS⁶⁷. The scaling factor *VLSPtl* sampled between 0 and 1 was used to reflect uncertainties in estimates as well as overall time trends.

HIV self-testing $S_{i,u,s}^{r,a}$

We calculated the number of HIV self-test kits used by each modelled population at each timestep $(v_{i,u}^{r,a})$. For the period 2019-2021, this number was based on the ATLAS programmatic data (available for each quarter over 2019-2021) and survey data described in the "HIVST scenarios" of this supplement. From January 2022, the number of kits used was calculated by assuming that 95% of KP HIV-uninfected or living with HIV but not on ART should receive two HIV tests each year (see specific section on HIV self-testing). The parameters $STSe_i$ and STSp represent the sensitivity and specificity of the self-tests, whereas STLnk is the fraction of reactive self-tests which are followed by conventional tests (informed by ATLAS survey data). False-reactive self-tests among people not living with HIV were contradicted by subsequent non-reactive tests or negative conventional tests (see Figure S1d), whereas false non-reactive self-tests among PLHIV would prevent them to undertake confirmatory tests in facilities.

Transitions between model states $S_{i,u,s}^{r,a}$ are shown in **Figure S1d** and only apply to:

1) people who have never tested for HIV (u=0), or ever had a conventional test but never a self-test (u=1, s=0):

$$S_{i,u=0-1,s=0}^{r,a} = -v_{i,u=0-1,s=0}^{r,a}$$

2) people not living with HIV (i=0) who have ever had a conventional HIV test but never had a self-test (u=1, s=0), and that can have a first self-test that is a false reactive:

$$S_{i=0,u=1,s=0}^{r,a} = -v_{i=0,u=1,s=0}^{r,a} (1 - STSp)$$

33

3) people not living with HIV (i=0) who have ever had a conventional HIV test, ever had a self-test, and their last self-test was not reactive (u=1, s=1):

$$S_{i=0,u=1,s=1}^{r,a} = \left[\left(v_{i=0,u=0,s=0}^{r,a} + v_{i=0,u=1,s=0}^{r,a} + v_{i=0,u=2,s=1}^{r,a} \right) STSp \right] - v_{i=0,u=1,s=1}^{r,a} (1 - STSp)$$

4) people not living with HIV (*i*=0) who have ever had a conventional HIV test and a self-test, but their last self-test was reactive and they haven't had a conventional test since (u=2, s=1):

$$S_{i=0,u=2,s=1}^{r,a} = \left[\left(v_{i=0,u=0,s=0}^{r,a} + v_{i=0,u=1,s=0}^{r,a} + v_{i=0,u=1,s=1}^{r,a} \right) (1 - STSp) \right] - v_{i=0,u=2,s=1}^{r,a} STSp$$

5) PLHIV (*i* >0) who are currently undiagnosed (*u*=1) and have never tested for HIV (*s*=0): $S_{i>0,u=1,s=0}^{r,a} = -v_{i>0,u=1,s=0}^{r,a}$

6) PLHIV (*i* >0) who are currently undiagnosed (*u*=1) and have ever tested for HIV (*s*=1), some of which may have had a reactive self-test, but not followed by a confirmation test (fraction (1 - STLnk)).

$$S_{i>0,u=1,s=1}^{r,a} = \sum_{u=0-1} v_{i>0,u,s=0}^{r,a} \left((1 - STSe_i) + (STSe_i \times (1 - STLnk)) \right) - v_{i>0,u=1,s=1}^{r,a} STSe_i$$

7) PLHIV who have had a reactive self-test, are undiagnosed but can do a confirmation test (*u*=2). $S_{i>0,u=2,s=1}^{r,a} = \left[v_{i>0,u=0,s=0}^{r,a} + v_{i>0,u=1,s=0}^{r,a} + v_{i>0,u=1,s=1}^{r,a}\right] STSe_i$

8) PLHIV who have never used a self-test (s=0) but that have a diagnosed infection (u=3,5,6). Our base case scenario assumes that PLHIV in ART (u=5) do not receive self-tests.

$$S_{i>0,u>2,s=0}^{r,a} = -v_{i>0,u>2,s=0}^{r,a}$$

7) PLHIV who have ever used a self-test (s=1) but that have a diagnosed infection (u=3,5,6).

$$S_{i>0,u>2,s=1}^{r,a} = v_{i>0,u>2,s=0}^{r,a}$$

Model fitting overview

Each model was fitted under a Bayesian framework in three steps. In the first step, a Latin hypercube of model parameters was used to simulate 50M simulations from prior distributions of the parameters describe above. In the second step, we only retained the simulations which agreed with all the widen confidence intervals of the fitting outcomes described in **Tables S2a-c** (between 579 and 1550 simulations were retained across models). In the third step, the 100 fitted simulations with the highest overall likelihood (calculated on all outcomes except on HIV incidence rate, number of conventional tests and fraction of positive tests, for which there were no sample size) were identified for each country. The resulting posterior parameter sets were used to simulate all our model scenarios.

Model fitting data

Fitting data (Côte d'Ivoire)

Population or age group	Year	Point estimate	Original 95%CI	Prior constraint	Reference
Population size	e		207002		
Total number	1970	2.58 million	N.A.	Initial value	From ⁴
of 15-59	1980	4.05 million		for 1970 and	
years-old	1990	6.02 million		direct	
-	2000	8.51 million		calibration	
	2010	10.64 million		using growth	
	2020	14.19 million		rate between	
				1970 and	
				2020	
				estimates	
Age distribution	on among 1	15–59-year-old females			
	1970	15-24 years: 33.5%	N.A.	Used for	From ⁴
		25-49 years: 55.5%		comparison	
		50-59 years: 10.9%			
	1980	15-24 years: 37.1%	N.A.	Used for	As above
		25-49 years: 52.7%		comparison	
		50-59 years: 10.4%		-	
	1990	15-24 years: 38.1%	N.A.	Used for	As above
		25-49 years: 51.7%		comparison	
		50-59 years: 10.2%		Ĩ	
	2000	15-24 years: 40.0%	N.A.	Used for	As above
		25-49 years: 51.1%		comparison	
		50-59 years: 9.0%		L	

	2010	15.24			
	2010	15-24 years: 39.6%	N.A.	Used for	As above
		25-49 years: 51.0%		comparison	
	2020	50-59 years: 9.3%	N.A.	35.2-42.6%	Fitted from ⁴
	2020	15-24 years: 38.7% 25-49 years: 52.3%	N.A.	33.2-42.6% 47.5-57.5%	Filled from
		50-59 years: 9.0%		6.9-11.7%	
A go distribut	tion among 1	15–59-year-old males		0.9-11.770	
Age uisti ibut	1970	15-24 years: 32,2%	N.A.	Used for	From ⁴
	1970	25-49 years: 57.5%	N.A.	comparison	FIOIII
		50-59 years: 10.3%		comparison	
	1980	15-24 years: 33.4%	N.A.	Used for	As above
	1700	25-49 years: 56.1%	14.7 4.	comparison	
		50-59 years: 10.5%		comparison	
	1990	15-24 years: 33.9%	N.A.	Used for	As above
	1770	25-49 years: 54.9%	10.21	comparison	
		50-59 years: 11.3%		· · · · · · · · · · · · · · · ·	
-	2000	15-24 years: 36.6%	N.A.	Used for	As above
		25-49 years: 52.7%		comparison	
		50-59 years: 10.7%		1	
	2010	15-24 years: 37.6%	N.A.	Used for	As above
		25-49 years: 51.7%		comparison	
		50-59 years: 10.7%		-	
	2020	15-24 years: 38.0%	N.A.	34.5-41.8%	Fitted from ⁴
		25-49 years: 52.1%		47.4-57.3%	
		50-59 years: 9.9%		7.6-12.9%	
HIV prevaler	nce among a	ll adult females (except	female sex worke	ers)	
15-24	1989	2.5%	(0.9-4.4%)	0.1-18.0%	111
15-24	2005	2.4%	(1.6-3.0%)	1.0-10.0%	11
15-24	2012	2.2%	(1.5-3.0%)	1.0-10.0%	10
15-24	2017	0.9%	(0.5-1.4%)	0.2-6.0%	31
15-24	2018	0.4%	(0.0-0.8%)	Only used for	112
				comparison	
25-49	1989	2.5%	(1.0-4.3%)	0.8-20.0%	111
25-49	2005	9.9%	(8.4-12.0%)	4.0-18.0%	11
25-49	2012	6.3%	(5.2-8.0%)	3.0-15.0%	10
25-49	2017	5.5%	(4.5-6.8%)	3.0-8.0%	31
50-59	1989	1.9%	(0.4-4.4%)	0.1-10.0%	111 11
50-59	2005	10.2%	(6.2-16.0%)	4.0-20.0%	10
50-59 50-59	2012 2017	9.5%	(5.7-15.0%) (5.0-13.1%)	4.0-20.0%	31
		8.2% Il adult males	(3.0-13.1%)	4.0-20.0%	
15-24	1989	2.4%	(0.8-4.3%)	0.5-15.0%	111
15-24	2005	0.3%	(0.1-1.0%)	0.1-4.0%	11
15-24	2003	0.3%	(0.1-1.0%) (0.1-1.0%)	0.1-4.0%	10
15-24	2012	0.3%	(0.1 - 0.9%)	0.1-4.0%	31
15-24	2018	0.3%	(0.0-0.6%)	Only used	112
			(0.0 0.0,0)	for	
				comparison	
25-49	1989	7.7%	(5.5-10.0%)	2.0-40.0%	111
25 40	2005	4.8%	(3.6-6.0%)	2.0-15.0%	11
25-49	2012	4.3%	(3.3-5.0%)	2.0-15.0%	10
25-49			$(1 \ 4 \ 2 \ 00/)$	1.0-4.0%	31
25-49 25-49	2017	2.1%	(1.4-2.9%)		
25-49 25-49 50-59	<u>2017</u> 1989	1.7%	(0.4-3.9%)	1.0-25.0%	111
25-49 25-49 50-59 50-59	2017 1989 2005	1.7% 4.9%	(0.4-3.9%) (2.4-10.0%)	1.0-25.0% 2.0-20.0%	11
25-49 25-49 50-59 50-59 50-59	2017 1989 2005 2012	1.7% 4.9% 8.7%	(0.4-3.9%) (2.4-10.0%) (5.4-14.0%)	1.0-25.0% 2.0-20.0% 4.0-30.0%	11 10
25-49 25-49 50-59 50-59 50-59 50-59	2017 1989 2005 2012 2017	1.7% 4.9%	(0.4-3.9%) (2.4-10.0%)	1.0-25.0% 2.0-20.0%	11

15-59	1987	36.9%	(30.1-48.2%)	10.0-85.0%	113
15-59	1989	47.6%	(38.4-56.7%)	10.0-85.0%	113
15-59	1990	68.4%	(57.0-78.6%)	10.0-85.0%	113
15-59	1994	67.0%	(63.2-70.8%)	10.0-85.0%	68
15-59	1995	54.0%	(50.5-57.4%)	10.0-85.0%	68
15-59	1996	52.0%	(48.7-55.2%)	10.0-85.0%	68
15-59	1990	52.0%	(48.7-55.4%)	10.0-85.0%	68
					114
15-59	1998	32.0%	(28.9-35.3%)	10.0-65.0%	114
15-59	1999	32.0%	(28.7-35.5%)	10.0-65.0%	114
15-59	2000	28.0%	(24.8-31.4%)	10.0-55.0%	
15-59	2001	31.0%	(27.7-34.4%)	10.0-55.0%	114
15-59	2002	27.0%	(23.8-30.3%)	10.0-55.0%	114
15-59	2003	33.0%	(28.0-38.0%)	10.0-55.0%	115
15-59	2004	27.0%	(22.4-31.9%)	10.0-55.0%	115
15-59	2005	18.0%	(14.1-22.4%)	8.0-40.0%	115
15-59	2006	19.0%	(15.1-23.6%)	8.0-40.0%	115
15-59	2007	21.0%	(16.9-25.7%)	8.0-40.0%	115
15-59	2007	22.9%	(13.7-35.6%)	8.0-40.0%	116
15-59	2008	19.0%	(15.1-23.6%)	8.0-40.0%	115
15-59	2000	20.0%	(15.9-22.5%)	8.0-40.0%	115
15-59	2009	11.2%	(13.9-22.5%) (6.4-18.9%)	8.0-40.0%	116
15-59	2009	21.0%	(0.4-18.9%) (10.0-35.0%)	8.0-40.0% 8.0-40.0%	115
			· · · · ·		95
15-59	2014	11.0%	(8.3-14.3%)	5.0-25.0%	117
15-59	2016	11.4%	(8.8-14.8%)	5.0-25.0%	118
15-59	2020	4.9%	(3.8-6.3%)	2.0-15.0%	116
_	0	lients of sex workers			
15-59	1999	13.4%	(10.5-17.0%)	5.0-30.0%	77
HIV Prevalence					10
All 15-59	2015	11.2%	(9.6-13.1%)	5.0-25.0%	42
All 15-59	2016	19.6%	N.A.	10.0-40.0%	119
All 15-59	2017	12.3%	(9.3-16.1%)	5.0-25.0%	117
All 15-59	2020	6.4%	(5.2-7.5%)	4.0-20.0%	46
All 15-24	2012	12.5%	(6.8-18.2%)	3.0-35.0%	40
All 15-24	2015	11.4%	(6.6-19.0%)	3.0-25.0%	42
All 15-24	2020	5.1%	(3.4-6.8%)	2.0-15.0%	46
All 25-49	2012	24.8%	(16.7-34.9%)	10.0-60.0%	40
All 25-49	2015	16.3%	(7.5-32.0%)	5.0-40.0%	42
All 25-49	2020	11.2%	(7.3-14.9%)	3.0-22.0%	46
All MSMW	2012	12.3%	(9.2-16.3%)	5.0-25.0%	40
All MSMW	2012	6.2%	(4.1-8.3%)	3.0-15.0%	46
All MSME	2012	25.7%	(20.8-31.3%)	10.0-45.0%	40
	2012	6.2%	· · · · ·	3.0-15.0%	46
All MSME			(4.0-8.2%)	5.0-15.0%	
		100 susceptible-year)	(0.000.0.204)	0.02.0.75	120
15-59	2005	0.161	(0.069-0.304)	0.03-0.75	
15-59	2010	0.152	(0.065-0.286)	0.03-0.75	As above
<u>15-59</u>	2017	0.129	(0.055-0.243)	0.05-0.24	As above
Number of new					100
15-59	2005	18100	(7900-34000)	3000-65000	120
15-59	2010	22000	(9700-41000)	4000-80000	As above
15-59	2017	26000	(11400-49000)	11400-	As above
				49000	
Number of HI	V-related	deaths			
15-59	2005	48000	(29000-72000)	1000- 100000	120
15-59	2010	29000	(17500-45000)	5000-70000	As above
15-59	2010	29000	(17300-43000) (12700-32000)	12700-	As above
15-57	2017	21700	(12700-52000)	32000	110 00000
Fraction of all	famelos	ver tested for HIV		52000	
15-49			(67770)	1.0.25.00/	121
10-49	2000	7.2%	(6.7-7.7%)	1.0-25.0%	

15-49	2005	10.9%	(8.2-14.5%)	5.0-35.0%	11	
15-49	2011	35.4%	(33.1-37.8%)	20.0-50.0%	10	
15-49	2016	56.0%	(53.9-58.0%)	35.0-75.0%	122	
15-24	2009	25.3%	(23.6-27.1)	10.0-50.0%	123	
Fraction of all	females no	ot living with HIV ever	tested for HIV			
15-49	2005	10.0%	(7.2-13.7%)	4.0-25.0%	11	
15-49	2011	34.5%	(31.8-37.2%)	15.0-55.0%	10	
15-49	2017	56.3%	(54.3-58.2%)	35.0-75.0%	31	
		ving with HIV ever test				
15-49	2005	13.6%	(7.9-22.5%)	5.0-40.0%	11	
15-49	2011	42.0%	(34.2-50.2%)	20.0-70.0%	10	
15-49	2017	74.7%	(67.5-82.0%)	50.0-95.0%	31	
		r tested for HIV	(1111)			
15-49	2005	7.9%	(6.2-9.9%)	3.0-25.0%	11	
15-49	2011	23.1%	(20.7-25.7%)	10.0-40.0%	10	
15-49	2016	34.6%	(32.1-37.1%)	20.0-55.0%	122	
15-24 males	2009	18.1%	(16.7-19.6%)	5.0-40.0%	123	
		living with HIV ever to	· · · · · · · · · · · · · · · · · · ·	2.0 10.070		
15-49	2005	7.4%	(6.2-9.9%)	3.0-20.0%	11	
15-49	2003	23.0%	(0.2-9.9%) (20.7-25.7%)	10.0-40.0%	10	
15-49	2011	32.2%	(30.1-34.4%)	20.0-45.0%	31	
		ng with HIV ever tested		20.0-43.070		
15-49	2005	23.7%	(10.9-44.1%)	8.0-50.0%	11	
15-49	2003	39.0%	(10.9-44.1%) (28.4-50.7%)	25.0-65.0%	10	
15-49	2011	53.4%	(28.4-30.7%) (39.1-67.6%)	30.0-75.0%	31	
Fraction of FS			(39.1-07.0%)	30.0-73.0%		
15-59	2007	54.0%	(52.0-56.0%)	30.0-85.0%	124	
15-59	2007	82.0%	· · · · · ·		118	
			(79.0-83.0%)	65.0-92.0%	95	
15-24	2014	75.3%	(68.5-81.0%)	50.0-95.0%	95	
25-49	2014	85.7%	(81.1-89.3%)	65.0-99.0%	,,,	
Fraction of M				40.0.05.00/	40	
15-59	2011	62.6%	(56.5-68.2%)	40.0-95.0%	125	
15-59	2015 2020	92.4%	(85.7-96.1%)	70.0-99.0%	46	
15-59		70.0%	(67.0-72.0%)	60.0-90.0%	40	
		ving with HIV which an	0	10.0.05.00/	126	
15-59	2015	68.0%	(61.0-77.0%)	40.0-85.0%	126	
15-59	2016	71.0%	(64.0-81.0%)	40.0-90.0%	126	
15-59	2017	75.0%	(67.0-85.0%)	45.0-95.0%	120	
15-59	2018	78.0%	(70.0-89.0%)	50.0-99.0%	126	
15-59	2019	81.0%	(72.0-92.0%)	55.0-99.0%	126	
15-59	2020	84.0%	(75.0-95.0%)	70.0-99.0%	120	
		ng with HIV which are		20.0.55.00/	126	
15-59	2015	49.0%	(43.0-58.0%)	30.0-75.0%	126	
15-59	2016	52.0%	(46.0-62.0%)	30.0-75.0%	120	
15-59	2017	56.0%	(50.0-66.0%)	30.0-80.0%	126	
15-59	2018	60.0%	(54.0-71.0%)	40.0-80.0%	126	
15-59	2019	64.0%	(58.0-75.0%)	45.0-85.0%	126	
15-59	2020	68.0%	(61.0-79.0%)	54.0-85.0%	120	
		ng with HIV with a diag		FO FO F	05	
15-59	2014	26.7%	(15.9-41.0%)	5.0-70.0%	95	
15-59	2020	81.0%	(69.0-89.0%)	50.0-95.0%	118	
		ng with HIV with a dia	Q		40	
15-59	2011	15.9%	(10.3-23.8%)	30.0-50.0%	40	
15-59	2015	37.0%	(29.6-45.1%)	15.0-65.0%	36	
15-59	2017	26.7%	(16.0-41.0%)	10.0-60.0%	44	
15-59	2020	32.7%	(34.1-42.4%)	15.0-60.0%	46	
		ving with HIV with a tr				
15-59	2015	44.0%	(40.0-50.0%)	25.0-60.0%	67	
15-59		A A A A	(= 1 0 0 1 0 0 1)	(0 0 00 00/	67	
13-39	2020	83.0%	(74.0-94.0%)	69.0-99.0%	07	

Fraction of all	males living	with HIV with a tro	eated infection		
15-59	2015	29.0%	(25.0-34.0%)	15.0-50.0%	67
15-59	2013	61.0%	(55.0-71.0%)	49.0-78.0%	67
		with HIV with a tre		49.0-78.070	
15-59	2012	45.6%	(42.2-49.1%)	20.0-70.0%	115
15-59	2012	65.0%	(52.0-76.0%)	52.0-76.0%	118
		suppressed viral loa	· · · · · · · · · · · · · · · · · · ·	52.0-70.070	
15-49	2017	38.4%	(29.2-47.7%)	20.0-55.0%	31
females	2017	50.470	(29.2-47.770)	20.0-33.070	
15-49 males	2017	20.1%	(11.9-28.3%)	5.0-40.0%	31
15-49 MSM	2017	19.4%	(9.8-35.2%)	10.0-45.0%	44
		IV tests done by fen	(/	10.0-43.070	
15-59	2015	1,601,691	N.A.	(800,846-	Programmatic data reported by
15-59	2015	1,001,091	IN.A.	3,203,382)	countries to UNAIDS's
				5,205,582)	Shyny90 ¹²⁶
15-59	2016	1,826,826	N.A.	(913,413-	As above
15-57	2010	1,020,020	11.71.	3,653,652)	As above
15-59	2017	1,631,236	N.A.	(815,718-	As above
15 57	2017	1,051,250	14.71.	3,262,672)	113 00000
15-59	2018	1,809,731	N.A.	(904,866-	As above
15 57	2010	1,009,751	11.11	3,619,462)	115 00000
Number of cor	ventional H	IV tests done by ma	les each vear	5,017,102)	
15-59	2015	492,691	N.A.	(246,346-	126
		.,_,.,_		985,382)	
15-59	2016	553,680	N.A.	(276,840-	As above
		,		1,107,360)	
15-59	2017	437,692	N.A.	(218,846-	As above
		,		975,384)	
15-59	2018	902,838	N.A.	(451,419-	As above
				1,805,676)	
Fraction of con	nventional H	IV tests done by fer	nales which are pos	sitive	
15-59	2015	3.2%	N.A.	(1.6-6.5%)	Programmatic data reported by countries to UNAIDS's Shyny90 ¹²⁶
15-59	2016	2.6%	N.A.	(1.3-5.2%)	As above
15-59	2017	2.2%	N.A.	(1.1-4.4%)	As above
15-59	2018	1.8%	N.A.	(0.9-3.5%)	As above
		IV tests done by ma			
15-59	2015	3.6%	N.A.	(1.8-7.1%)	Programmatic data reported by countries to UNAIDS's Shyny90 ¹²⁶
15-59	2016	3.0%	N.A.	(1.5-6.0%)	As above
15-59	2017	3.0%	N.A.	(1.5-6.0%)	As above
15-59	2018	3.5%	N.A.	(1.8-7.0%)	As above

MSMW: men who have sex with men as well as female partners; MSME: men who have sex with men exclusively. N.A.: Not available

Fitting data (Mali)

		raphic, epidemiological, ar			
Population	Year	Point estimate	Original	Prior	Reference
or age group			95%CI	constraint	
Population siz	æ				
Total number	1970	3.15 million	N.A.	Initial value	From ⁴
of 15-59	1980	3.57 million		for 1970 and	
years-old	1990	4.00 million		direct	
	2000	5.30 million		calibration	
	2010	7.27 million		using growth	
	2020	9.95 million		rate between	
				1970 and	
				2020	
				estimates	
Age distributi	on among 1	15–59-year-old females			
	1970	15-24 years: 35.0%	N.A.	Used for	From ⁴
		25-49 years: 51.6%		comparison	
		50-59 years: 13.4%			
	1980	15-24 years: 36.3%	N.A.	Used for	As above
		25-49 years: 51.5%		comparison	
		50-59 years: 12.2%		-	
	1990	15-24 years: 39.0%	N.A.	Used for	As above
		25-49 years: 49.8%		comparison	
		50-59 years: 11.2%		1	
	2000	15-24 years: 40.5%	N.A.	Used for	As above
		25-49 years: 49.3%		comparison	
		50-59 years: 10.2%		· · · · · · · · · · · · · · · · · · ·	
	2010	15-24 years: 39.0%	N.A.	Used for	As above
		25-49 years: 51.7%		comparison	
		50-59 years: 9.3%		· · · · · · · · · · · · · · · · · · ·	
	2020	15-24 years: 39.9%	N.A.	30.7-51.9%	Fitted from ⁴
	2020	25-49 years: 51.1%	1 1.1 1.	39.3-66.4%	
		50-59 years: 9.0%		6.0-13.5%	
Age distribution	on among 1	15–59-year-old males		010 1010 /0	
nge uistributi	1970	15-24 years: 35.8%	N.A.	Initial value	From ⁴
	1770	25-49 years: 51.2%	14.74.	from data	Tom
		50-59 years: 13.0%		nom autu	
	1980	15-24 years: 38.0%	N.A.	Used for	As above
	1900	25-49 years: 50.2%	1 1. / 1 .	comparison	
		50-59 years: 11.8%		comparison	
	1990	15-24 years: 42.0%	N.A.	Used for	As above
	1990	15-24 years: 42.0% 25-49 years: 47.9%	IN.A.	Used for	As above
				comparison	
	2000	50-59 years: 10.1%	ΝΤ Α	II. I C.	Acchova
	2000	15-24 years: 43.3%	N.A.	Used for	As above
		25-49 years: 48.1%		comparison	
	2010	50-59 years: 8.6%	NT 4	TT 10	
	2010	15-24 years: 40.5%	N.A.	Used for	As above
		25-49 years: 51.5%		comparison	
	2000	50-59 years: 8.0%		24	7
	2020	15-24 years: 41.1%	N.A.	31.6-53.4%	Fitted from ⁴
		25-49 years: 50.9%		39.2-66.2%	
		50-59 years: 8.0%		5.3-12.0%	
		ll adult females (except f			12
15-24	2001	1.3%	(0.7-2.0%)	0.1-5.0%	17
15-24	2006	0.9%	(0.4 - 1.5%)	0.1-4.0%	16

					15
15-24	2013	1.1%	(0.6-1.7%)	0.3-2.3%	15
25-49	2001	2.6%	(1.0-4.3%)	0.5-10.0%	17
25-49	2006	1.7%	(1.0-2.4%)	0.2-7.0%	16
25-49	2013	1.5%	(1.0-1.9%)	0.4-2.9%	15
HIV prevalen	ce among all a	adult males	· · · · · · · · · · · · · · · · · · ·		
15-24	2001	0.3%	(0.0-0.7%)	0.0-3.0%	17
15-24	2006	0.5%	(0.0-0.9%)	0.0-4.0%	16
15-24	2013	0.3%	(0.0-0.7%)	0.0-1.0%	15
25-49	2001	2.0%	(1.0-4.3%)	0.5-8.0%	17
25-49	2006	1.1%	(0.5-1.8%)	0.2-5.0%	16
25-49	2013	1.1%	(0.6-1.6%)	0.2-2.5%	15
50-59	2006	1.2%	(0.0-2.4%)	0.0-7.0%	16
50-59	2013	1.2%	(0.0-2.3%)	0.0-3.5%	15
		emale sex workers			
15-59	1987	36.0%	N.A.	5.0-85.0%	96
15-59	1995	46.0%	(38.8-53.4%)	20.0-85.0%	127
15-59	1997	30.4%	(24.3-37.2%)	15.0-80.0%	97
15-59	2000	28.9%	(2 HS 571270) N.A.	13.0-70.0%	72
15-59	2003	31.9%	N.A.	15.0-60.0%	72
15-59	2005	35.3%	N.A.	15.0-70.0%	72
15-59	2009	24.2%	(21.4-27.2%)	12.0-60.0%	72
15-59	2013	18.3%	(14.8-22.5%)	10.0-50.0%	72
15-59	2017	20.8%	(16.6-25.7%)	10.0-40.0%	128
15-59	2018	20.4%	(16.3-25.0%)	10.0-40.0%	101
15-59	2019	8.7%	(7.3-10.4%)	4.0-30.0%	14
		nts of sex workers	(7.5 10.170)	1.0 50.070	
	ce among ene	nes of sear wormens			
15-59		2.7%	(1.8-4.2%)	N.A.	⁷² Only used for comparison
15-59	2009	2.7%	(1.8-4.2%)	N.A.	⁷² Only used for comparison (truck drivers)
	2009		, , , , , , , , , , , , , , , , , , ,		(truck drivers)
15-59 15-59		2.7% 1.9%	(1.8-4.2%) (1.2-2.9%)	N.A. N.A.	(truck drivers) ¹⁴ Only used for comparison
15-59	2009 2019	1.9%	, , , , , , , , , , , , , , , , , , ,		(truck drivers)
15-59 HIV Prevalen All 15-59	2009 2019 <u>ce among MS</u> 2011	1.9% M 20.1%	(1.2-2.9%)	N.A.	(truck drivers) ¹⁴ Only used for comparison (truck drivers) ⁶ (original source not found)
15-59 HIV Prevalen All 15-59 All 15-59	2009 2019 ce among MS 2011 2015	1.9% M 20.1% 18.1%	(1.2-2.9%) N.A. (15.1-21.5%)	N.A. 5.0-70.0% 3.0-32.0%	(truck drivers) ¹⁴ Only used for comparison (truck drivers) ⁶ (original source not found) ¹²⁹
15-59 HIV Prevalen All 15-59 All 15-59 All 15-59 All 15-59	2009 2019 ce among MS 2011 2015 2015	1.9% M 20.1% 18.1% 9.5%	(1.2-2.9%) N.A. (15.1-21.5%) (5.6-13.5%)	N.A. 5.0-70.0% 3.0-32.0% 3.0-32.0%	(truck drivers) ¹⁴ Only used for comparison (truck drivers) ⁶ (original source not found)
15-59 HIV Prevalent All 15-59 All 15-59 All 15-59 All 15-24	2009 2019 ce among MS 2011 2015	1.9% M 20.1% 18.1%	(1.2-2.9%) N.A. (15.1-21.5%)	N.A. 5.0-70.0% 3.0-32.0%	(truck drivers) ¹⁴ Only used for comparison (truck drivers) ⁶ (original source not found) ¹²⁹
15-59 HIV Prevalen All 15-59 All 15-59 All 15-59 All 15-59	2009 2019 ce among MS 2011 2015 2015	1.9% M 20.1% 18.1% 9.5%	(1.2-2.9%) N.A. (15.1-21.5%) (5.6-13.5%)	N.A. 5.0-70.0% 3.0-32.0% 3.0-32.0%	(truck drivers) ¹⁴ Only used for comparison (truck drivers) ⁶ (original source not found) ¹²⁹ 47
15-59 HIV Prevalent All 15-59 All 15-59 All 15-59 All 15-24 All 25-49	2009 2019 ce among MS 2011 2015 2015 2020 2020	1.9% M 20.1% 18.1% 9.5% 8.5%	(1.2-2.9%) N.A. (15.1-21.5%) (5.6-13.5%) (6.5-11.0%) (15.6-23.1%)	N.A. 5.0-70.0% 3.0-32.0% 3.0-32.0% 4.0-15.0%	(truck drivers) ¹⁴ Only used for comparison (truck drivers) ⁶ (original source not found) ¹²⁹ 47 32 32
15-59 HIV Prevalent All 15-59 All 15-59 All 15-59 All 15-24 All 25-49	2009 2019 ce among MS 2011 2015 2015 2020 2020	1.9% M 20.1% 18.1% 9.5% 8.5% 19.1%	(1.2-2.9%) N.A. (15.1-21.5%) (5.6-13.5%) (6.5-11.0%)	N.A. 5.0-70.0% 3.0-32.0% 3.0-32.0% 4.0-15.0%	(truck drivers) ¹⁴ Only used for comparison (truck drivers) ⁶ (original source not found) ¹²⁹ ⁴⁷ ³²
15-59 HIV Prevalen All 15-59 All 15-59 All 15-59 All 15-24 All 25-49 HIV incidence	2009 2019 ce among MS 2011 2015 2015 2020 2020 e rate (per 100	1.9% M 20.1% 18.1% 9.5% 8.5% 19.1% Susceptible-year)	(1.2-2.9%) N.A. (15.1-21.5%) (5.6-13.5%) (6.5-11.0%) (15.6-23.1%)	N.A. 5.0-70.0% 3.0-32.0% 3.0-32.0% 4.0-15.0% 10.0-28.0%	(truck drivers) ¹⁴ Only used for comparison (truck drivers) ⁶ (original source not found) ¹²⁹ 47 32 32
15-59 HIV Prevalen All 15-59 All 15-59 All 15-24 All 25-49 HIV incidence 15-59 15-59 15-59 15-59	2009 2019 ce among MS 2011 2015 2015 2020 2020 e rate (per 100 1990 1995 2000	1.9% M 20.1% 18.1% 9.5% 8.5% 19.1% 9 susceptible-year) 0.255	(1.2-2.9%) N.A. (15.1-21.5%) (5.6-13.5%) (6.5-11.0%) (15.6-23.1%) (0.128-0.398) (0.179-0.310) (0.105-0.167)	N.A. 5.0-70.0% 3.0-32.0% 3.0-32.0% 4.0-15.0% 10.0-28.0% 0.03-1.40	(truck drivers) ¹⁴ Only used for comparison (truck drivers) ⁶ (original source not found) ¹²⁹ 47 32 32 67
15-59 HIV Prevalen All 15-59 All 15-59 All 15-59 All 25-49 HIV incidence 15-59 15-59 15-59 15-59 15-59	2009 2019 ce among MS 2011 2015 2015 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2	1.9% M 20.1% 18.1% 9.5% 8.5% 19.1% 0.255 0.232 0.133 0.092	(1.2-2.9%) N.A. (15.1-21.5%) (5.6-13.5%) (6.5-11.0%) (15.6-23.1%) (0.128-0.398) (0.179-0.310)	N.A. 5.0-70.0% 3.0-32.0% 3.0-32.0% 4.0-15.0% 10.0-28.0% 0.03-1.40 0.06-0.36	(truck drivers) ¹⁴ Only used for comparison (truck drivers) ⁶ (original source not found) ¹²⁹ ⁴⁷ ³² ³² ⁶⁷ As above
15-59 HIV Prevalen All 15-59 All 15-59 All 15-24 All 25-49 HIV incidence 15-59 15-59 15-59 15-59 15-59 15-59 15-59	2009 2019 ce among MS 2011 2015 2015 2020 2020 2020 rate (per 100 1990 1995 2000 2005 2010	1.9% M 20.1% 18.1% 9.5% 8.5% 19.1% 9usceptible-year) 0.255 0.232 0.133	(1.2-2.9%) N.A. (15.1-21.5%) (5.6-13.5%) (6.5-11.0%) (15.6-23.1%) (0.128-0.398) (0.179-0.310) (0.105-0.167)	N.A. 5.0-70.0% 3.0-32.0% 3.0-32.0% 4.0-15.0% 10.0-28.0% 0.03-1.40 0.06-0.36 0.05-0.30 0.03-0.21 0.03-0.19	(truck drivers) ¹⁴ Only used for comparison (truck drivers) ⁶ (original source not found) ¹²⁹ ⁴⁷ ³² ³² ⁶⁷ As above As above
15-59 HIV Prevalen All 15-59 All 15-59 All 15-59 All 25-49 HIV incidence 15-59 15-59 15-59 15-59 15-59 15-59 15-59 15-59	2009 2019 ce among MS 2011 2015 2015 2020 2020 e rate (per 100 1995 2000 2005 2000 2005 2010 2015	1.9% M 20.1% 18.1% 9.5% 8.5% 19.1% 0.255 0.232 0.133 0.092 0.066 0.048	(1.2-2.9%) N.A. (15.1-21.5%) (5.6-13.5%) (6.5-11.0%) (15.6-23.1%) (0.128-0.398) (0.179-0.310) (0.105-0.167) (0.071-0.115) (0.049-0.086) (0.032-0.067)	N.A. 5.0-70.0% 3.0-32.0% 3.0-32.0% 4.0-15.0% 10.0-28.0% 0.03-1.40 0.06-0.36 0.05-0.30 0.03-0.21 0.03-0.19 0.01-0.17	(truck drivers) ¹⁴ Only used for comparison (truck drivers) ⁶ (original source not found) ¹²⁹ ⁴⁷ ³² ³² ⁶⁷ As above As above As above
15-59 HIV Prevalen All 15-59 All 15-59 All 15-24 All 25-49 HIV incidence 15-59 15	2009 2019 ce among MS 2011 2015 2015 2020 2020 e rate (per 100 1990 1995 2000 2005 2010 2015 2010 2015 2020	1.9% M 20.1% 18.1% 9.5% 8.5% 19.1% 0 susceptible-year) 0.255 0.232 0.133 0.092 0.066 0.048 0.030	(1.2-2.9%) N.A. (15.1-21.5%) (5.6-13.5%) (6.5-11.0%) (15.6-23.1%) (0.128-0.398) (0.179-0.310) (0.105-0.167) (0.071-0.115) (0.049-0.086)	N.A. 5.0-70.0% 3.0-32.0% 3.0-32.0% 4.0-15.0% 10.0-28.0% 0.03-1.40 0.06-0.36 0.05-0.30 0.03-0.21 0.03-0.19	(truck drivers) ¹⁴ Only used for comparison (truck drivers) ⁶ (original source not found) ¹²⁹ ⁴⁷ ³² ³² ⁶⁷ As above As above As above As above As above
15-59 HIV Prevalen All 15-59 All 15-59 All 15-24 All 25-49 HIV incidence 15-59 15	2009 2019 ce among MS 2011 2015 2015 2020 2020 e rate (per 100 1990 1995 2000 2005 2010 2015 2010 2015 2020	1.9% M 20.1% 18.1% 9.5% 8.5% 19.1% 0 susceptible-year) 0.255 0.232 0.133 0.092 0.066 0.048 0.030 ons	(1.2-2.9%) N.A. (15.1-21.5%) (5.6-13.5%) (6.5-11.0%) (15.6-23.1%) (0.128-0.398) (0.179-0.310) (0.105-0.167) (0.071-0.115) (0.049-0.086) (0.032-0.067) (0.018-0.052)	N.A. 5.0-70.0% 3.0-32.0% 3.0-32.0% 4.0-15.0% 10.0-28.0% 0.03-1.40 0.06-0.36 0.05-0.30 0.03-0.19 0.01-0.17 0.01-0.06	(truck drivers) ¹⁴ Only used for comparison (truck drivers) ⁶ (original source not found) ¹²⁹ 47 32 32 ⁶⁷ As above As above As above As above As above As above As above As above As above
15-59 HIV Prevalen All 15-59 All 15-59 All 15-59 All 25-49 HIV incidence 15-59 15	2009 2019 2011 2015 2015 2020 2020 2020 2020 2020	1.9% M 20.1% 18.1% 9.5% 8.5% 19.1% 0 susceptible-year) 0.255 0.232 0.133 0.092 0.066 0.048 0.030 ons 11000	(1.2-2.9%) N.A. (15.1-21.5%) (5.6-13.5%) (6.5-11.0%) (15.6-23.1%) (0.128-0.398) (0.179-0.310) (0.105-0.167) (0.071-0.115) (0.049-0.086) (0.032-0.067) (0.018-0.052) (5600-17000)	N.A. 5.0-70.0% 3.0-32.0% 3.0-32.0% 4.0-15.0% 10.0-28.0% 0.03-1.40 0.06-0.36 0.05-0.30 0.03-0.19 0.01-0.17 0.01-0.06 2600-37000	(truck drivers) ¹⁴ Only used for comparison (truck drivers) ⁶ (original source not found) ¹²⁹ 47 32 32 67 As above As above As above As above As above As above As above
15-59 HIV Prevalem All 15-59 All 15-59 All 15-59 All 25-49 HIV incidence 15-59 15	2009 2019 2011 2015 2015 2020 2020 2020 2020 2020	1.9% M 20.1% 18.1% 9.5% 8.5% 19.1% 0 susceptible-year) 0.255 0.232 0.133 0.092 0.066 0.048 0.030 ons 11000 11000	(1.2-2.9%) N.A. (15.1-21.5%) (5.6-13.5%) (6.5-11.0%) (15.6-23.1%) (0.128-0.398) (0.179-0.310) (0.105-0.167) (0.071-0.115) (0.049-0.086) (0.032-0.067) (0.018-0.052) (5600-17000) (8700-15000)	N.A. 5.0-70.0% 3.0-32.0% 3.0-32.0% 4.0-15.0% 10.0-28.0% 0.03-1.40 0.06-0.36 0.05-0.30 0.03-0.21 0.03-0.19 0.01-0.17 0.01-0.06 2600-37000 2700-35000	(truck drivers) ¹⁴ Only used for comparison (truck drivers) ⁶ (original source not found) ¹²⁹ ⁴⁷ ³² ³² ⁶⁷ As above As above
15-59 HIV Prevalen All 15-59 All 15-59 All 15-59 All 25-49 HIV incidence 15-59 15	2009 2019 2011 2015 2015 2020 2020 2020 2020 2020	1.9% M 20.1% 18.1% 9.5% 8.5% 19.1% 0 susceptible-year) 0.255 0.232 0.133 0.092 0.066 0.048 0.030 ons 11000 11000 7400	(1.2-2.9%) N.A. (15.1-21.5%) (5.6-13.5%) (6.5-11.0%) (15.6-23.1%) (0.128-0.398) (0.179-0.310) (0.105-0.167) (0.071-0.115) (0.049-0.086) (0.032-0.067) (0.018-0.052) (5600-17000) (8700-15000) (5800-9300)	N.A. 5.0-70.0% 3.0-32.0% 3.0-32.0% 4.0-15.0% 10.0-28.0% 0.03-1.40 0.06-0.36 0.05-0.30 0.03-0.21 0.03-0.19 0.01-0.17 0.01-0.06 2600-37000 2700-35000 1800-25300	(truck drivers) ¹⁴ Only used for comparison (truck drivers) ⁶ (original source not found) ¹²⁹ ⁴⁷ ³² ³² ⁶⁷ As above As above
15-59 HIV Prevalen All 15-59 All 15-59 All 15-59 All 25-49 HIV incidence 15-59 15	2009 2019 2019 2011 2015 2015 2020 2020 2020 2020 2020	1.9% M 20.1% 18.1% 9.5% 8.5% 19.1% 0 susceptible-year) 0.255 0.232 0.133 0.092 0.066 0.048 0.030 ons 11000 11000 7400 5900	(1.2-2.9%) N.A. (15.1-21.5%) (5.6-13.5%) (6.5-11.0%) (15.6-23.1%) (0.128-0.398) (0.179-0.310) (0.105-0.167) (0.071-0.115) (0.049-0.086) (0.032-0.067) (0.018-0.052) (5600-17000) (8700-15000) (5800-9300) (4500-7400)	N.A. 5.0-70.0% 3.0-32.0% 3.0-32.0% 4.0-15.0% 10.0-28.0% 0.03-1.40 0.06-0.36 0.05-0.30 0.03-0.21 0.03-0.19 0.01-0.17 0.01-0.06 2600-37000 2700-35000 1800-25300 1200-14000	(truck drivers) ¹⁴ Only used for comparison (truck drivers) ⁶ (original source not found) ¹²⁹ ⁴⁷ ³² ³² ⁶⁷ As above As above
15-59 HIV Prevalen All 15-59 All 15-59 All 15-59 All 25-49 HIV incidence 15-59 15	2009 2019 2019 2011 2015 2015 2020 2020 2020 2020 2020	1.9% M 20.1% 18.1% 9.5% 8.5% 19.1% 9.susceptible-year) 0.255 0.232 0.133 0.092 0.066 0.048 0.030 0ns 11000 7400 5900 4900	(1.2-2.9%) N.A. (15.1-21.5%) (5.6-13.5%) (6.5-11.0%) (15.6-23.1%) (0.128-0.398) (0.179-0.310) (0.105-0.167) (0.071-0.115) (0.049-0.086) (0.032-0.067) (0.018-0.052) (5600-17000) (8700-15000) (5800-9300) (4500-7400) (3600-6400)	N.A. 5.0-70.0% 3.0-32.0% 3.0-32.0% 4.0-15.0% 10.0-28.0% 0.03-1.40 0.06-0.36 0.05-0.30 0.03-0.21 0.03-0.19 0.01-0.17 0.01-0.06 2600-37000 2700-35000 1800-25300 1200-14000 1000-9000	(truck drivers) ¹⁴ Only used for comparison (truck drivers) ⁶ (original source not found) ¹²⁹ ⁴⁷ ³² ³² ⁶⁷ As above As above
15-59 HIV Prevalen All 15-59 All 15-59 All 15-59 All 25-49 HIV incidence 15-59 15	2009 2019 2019 ce among MS 2011 2015 2015 2020 2000 2015 2020 W HIV infecti 1995 2000 2005 2010 2020 W HIV infecti 1995 2000 2005 2010 2020 W HIV infecti 1995 2000 2005 2010 2020 W HIV infecti 1995 2000 2005 2010 2020 W HIV infecti 2020 2005 2000 2005 2000 2005 2000 2005 2000 2005 2000 2005 2000 2005 2000 2005 2000 2005 2000 2005 2000 2005 2010 2005 2010 2005 2010 2015 2010 2015 2010 2015 2000 2015 2015 2015	1.9% M 20.1% 18.1% 9.5% 8.5% 19.1% 0 susceptible-year) 0.255 0.232 0.133 0.092 0.066 0.048 0.030 0ns 11000 7400 5900 4900 4100	(1.2-2.9%) N.A. (15.1-21.5%) (5.6-13.5%) (6.5-11.0%) (15.6-23.1%) (0.128-0.398) (0.179-0.310) (0.105-0.167) (0.071-0.115) (0.049-0.086) (0.032-0.067) (0.018-0.052) (5600-17000) (8700-15000) (5800-9300) (4500-7400) (3600-6400) (2800-5800)	N.A. 5.0-70.0% 3.0-32.0% 3.0-32.0% 4.0-15.0% 10.0-28.0% 0.03-1.40 0.06-0.36 0.05-0.30 0.03-0.21 0.03-0.19 0.01-0.17 0.01-0.06 2600-37000 2700-35000 1800-25300 1200-14000 1000-9000 800-8000	(truck drivers) ¹⁴ Only used for comparison (truck drivers) ⁶ (original source not found) ¹²⁹ ⁴⁷ ³² ³² ⁶⁷ ⁶⁷ ⁶⁷ ⁶³ ⁶³ ⁶³ ⁶³ ⁶⁴ ⁶⁵ ⁶⁵ ⁶⁵ ⁶⁵ ⁶⁵ ⁶⁵ ⁶⁵ ⁶⁵ ⁶⁷ ⁶⁷ ⁶⁷ ⁶⁸ ⁸ above ⁶⁷ ⁶⁷ ⁶⁸ above ⁶⁸ ⁶⁷ ⁶⁸ above ⁶⁷ ⁶⁸ above ⁶⁷ ⁶⁷ ⁶⁷ ⁶⁸ above ⁶⁷ ⁶⁷ ⁶⁷ ⁶⁷ ⁶⁷ ⁶⁷ ⁶⁷ ⁶⁷ ⁶⁷ ⁶⁷ ⁶⁷ ⁶⁸ above ⁶⁷ ⁶⁷ ⁶⁸ above ⁶⁷ ⁶⁷ ⁶⁷ ⁶⁷ ⁶⁷ ⁶⁸ above ⁶⁷ ⁶⁸ above ⁶⁷ ⁶⁸ above ⁶⁷ ⁶⁸ above ⁶⁷ ⁶⁸ above ⁶⁸ above ⁶⁷ ⁶⁸ above ⁶⁸ above ⁶⁸ above ⁶⁸ above ⁶⁸ above ⁶⁸ above ⁶⁸ above ⁶⁹ As above ⁶⁸ above ⁶⁹ above ⁶⁰ abov
15-59 HIV Prevalen All 15-59 All 15-59 All 15-59 All 25-49 HIV incidence 15-59 15	2009 2019 2019 2011 2015 2015 2020 2020 2020 2020 2020	1.9% M 20.1% 18.1% 9.5% 8.5% 19.1% 0 susceptible-year) 0.255 0.232 0.133 0.092 0.066 0.048 0.030 0ns 11000 11000 7400 5900 4900 4100 3100	(1.2-2.9%) N.A. (15.1-21.5%) (5.6-13.5%) (6.5-11.0%) (15.6-23.1%) (0.128-0.398) (0.179-0.310) (0.105-0.167) (0.071-0.115) (0.049-0.086) (0.032-0.067) (0.018-0.052) (5600-17000) (8700-15000) (5800-9300) (4500-7400) (3600-6400)	N.A. 5.0-70.0% 3.0-32.0% 3.0-32.0% 4.0-15.0% 10.0-28.0% 0.03-1.40 0.06-0.36 0.05-0.30 0.03-0.21 0.03-0.19 0.01-0.17 0.01-0.06 2600-37000 2700-35000 1800-25300 1200-14000 1000-9000	(truck drivers) ¹⁴ Only used for comparison (truck drivers) ⁶ (original source not found) ¹²⁹ ⁴⁷ ³² ³² ⁶⁷ ⁶⁷ ⁶⁷ ⁶³ As above ⁶³ As above ⁶³ As above ⁶⁷ ⁶⁷ ⁶⁷ ⁶⁷ ⁶⁷ ⁶⁷ ⁶⁷ ⁶⁷ ⁶⁸ above ⁶⁷ ⁶⁷ ⁶⁸ above ⁶⁷ ⁶⁸ above ⁶⁷ ⁶⁷ ⁶⁸ above ⁶⁷ ⁶⁷ ⁶⁷ ⁶⁷ ⁶⁷ ⁶⁷ ⁶⁷ ⁶⁷ ⁶⁸ above ⁶⁷ ⁶⁸ above ⁶⁷ ⁶⁷ ⁶⁷ ⁶⁷ ⁶⁷ ⁶⁷ ⁶⁷ ⁶⁷ ⁶⁸ above ⁶⁷ ⁶⁷ ⁶⁷ ⁶⁷ ⁶⁷ ⁶⁸ above ⁶⁸ above ⁶⁷ ⁶⁸ above ⁶⁷ ⁶⁷ ⁶⁸ above ⁶⁷ ⁶⁷ ⁶⁸ above ⁶⁸ above ⁶⁸ above ⁶⁷ ⁶⁸ above ⁶⁷ ⁶⁷ ⁶⁸ above ⁶⁸ above ⁶⁷ ⁶⁸ above ⁶⁸ above ⁶⁹ above ⁶⁹ above ⁶⁹ above ⁶⁹ above ⁶⁹ above ⁶⁹ above ⁶⁹ above ⁶⁹ above ⁶⁰ above ⁶⁰ above ⁶⁰ above ⁶⁰ above ⁶⁰ above ⁶¹ above ⁶
15-59 HIV Prevalen All 15-59 All 15-59 All 15-59 All 25-49 HIV incidence 15-59 15	2009 2019 2019 2011 2015 2015 2020 2020 2020 2020 2020	1.9% M 20.1% 18.1% 9.5% 8.5% 19.1% 0 susceptible-year) 0.255 0.232 0.133 0.092 0.066 0.048 0.030 ons 11000 11000 7400 5900 4900 4100 3100 oths	(1.2-2.9%) $(1.2-2.9%)$ $(1.5.1-21.5%)$ $(5.6-13.5%)$ $(6.5-11.0%)$ $(15.6-23.1%)$ $(0.128-0.398)$ $(0.179-0.310)$ $(0.105-0.167)$ $(0.071-0.115)$ $(0.049-0.086)$ $(0.032-0.067)$ $(0.018-0.052)$ $(5600-17000)$ $(8700-15000)$ $(5800-9300)$ $(4500-7400)$ $(3600-6400)$ $(2800-5800)$ $(1800-5200)$	N.A. 5.0-70.0% 3.0-32.0% 3.0-32.0% 4.0-15.0% 10.0-28.0% 0.03-1.40 0.06-0.36 0.05-0.30 0.03-0.19 0.01-0.17 0.01-0.17 0.01-0.06 2600-37000 2700-35000 1800-25300 1200-14000 1000-9000 800-8000 1800-7000	(truck drivers) ¹⁴ Only used for comparison (truck drivers) ⁶ (original source not found) ¹²⁹ ⁴⁷ ³² ³² ⁶⁷ As above As above
15-59 HIV Prevalem All 15-59 All 15-59 All 15-59 All 25-49 HIV incidence 15-59	2009 2019 2019 2011 2015 2015 2020 2020 2020 2020 2020 2020 2020 2020 2020 2015 2000 2005 2010 2015 2020 w HIV infecti 1990 1995 2000 2005 2010 2015 2020 W HIV infecti 1990 1995 2000 2015 2020 W HIV infecti 1990 1995 2000 2015 2020 W HIV infecti 1990 1995 2000 2015 2020 W HIV infecti 1990 1995 2000 2015 2020 W HIV infecti 1990 1995 2000 2015 2020 W HIV infecti 1990 2015 2020 2015 2020 W HIV infecti 1990 2015 2020 2015 2020 2015 2020 2015 2020 W HIV infecti 1995 2000 2005 2010 2015 2020 W HIV infecti 1990 1995 2000 2015 2020 W HIV infecti 1990 2015 2020 2010 2015 2020 W HIV infecti 1990 2015 2020 2015 2020 2010 2015 2020 2010 2015 2020 2010 2015 2020 2010 2015 2020 2015 2020	1.9% M 20.1% 18.1% 9.5% 8.5% 19.1% 0 susceptible-year) 0.255 0.232 0.133 0.092 0.066 0.048 0.030 008 11000 11000 7400 5900 4900 4100 3100 ths 1100	(1.2-2.9%) N.A. (15.1-21.5%) (5.6-13.5%) (6.5-11.0%) (15.6-23.1%) (0.128-0.398) (0.179-0.310) (0.105-0.167) (0.071-0.115) (0.049-0.086) (0.032-0.067) (0.018-0.052) (5600-17000) (8700-15000) (8700-15000) (5800-9300) (4500-7400) (3600-6400) (2800-5800) (1800-5200) (0-3200)	N.A. 5.0-70.0% 3.0-32.0% 3.0-32.0% 4.0-15.0% 10.0-28.0% 0.03-1.40 0.06-0.36 0.05-0.30 0.03-0.21 0.03-0.19 0.01-0.17 0.01-0.17 0.01-0.06 2600-37000 2700-35000 1800-25300 1200-14000 1000-9000 800-8000 1800-7000 0-8200	(truck drivers) ¹⁴ Only used for comparison (truck drivers) ⁶ (original source not found) ¹²⁹ ⁴⁷ ³² ³² ⁶⁷ ⁶⁷ ⁶⁷ ⁶³ As above ⁶³ As above ⁶⁷ ⁶⁸ ⁶⁹ ⁶⁷ ⁶⁷ ⁶⁷ ⁶⁷ ⁶⁷ ⁶⁸ ⁶⁹ ⁶⁷ ⁶⁷ ⁶⁷ ⁶⁸ ⁶⁹ ⁶⁷ ⁶⁷ ⁶⁸ ⁶⁹ ⁶⁷ ⁶⁸ ⁶⁹ ⁶⁷ ⁶⁸ ⁶⁹ ⁶⁷ ⁶⁸ ⁶⁹ ⁶⁷ ⁶⁸ ⁶⁹ ⁶⁷ ⁶⁸ ⁶⁹ ⁶⁸ ⁶⁸ ⁶⁹ ⁶⁸ ⁶⁹ ⁶⁸ ⁶⁹ ⁶⁹ ⁶⁹ ⁶⁹ ⁶⁹ ⁶⁹ ⁶⁹ ⁶⁹ ⁶⁹ ⁶⁹ ⁶⁰ ⁶⁷ ⁶⁷ ⁶⁸ ⁶⁸ ⁶⁹ ⁶⁷ ⁶⁸ ⁶⁹ ⁶⁹ ⁶⁹ ⁶⁹ ⁶⁹ ⁶⁹ ⁶⁹ ⁶⁹ ⁶⁹ ⁶⁹
15-59 HIV Prevalem All 15-59 All 15-59 All 15-59 All 25-49 HIV incidence 15-59 15	2009 2019 2019 2011 2015 2015 2020 2020 2020 2020 2020	1.9% M 20.1% 18.1% 9.5% 8.5% 19.1% D susceptible-year) 0.255 0.232 0.133 0.092 0.066 0.048 0.030 ons 11000 1400 3100 tths 1100 3400	(1.2-2.9%) N.A. (15.1-21.5%) (5.6-13.5%) (6.5-11.0%) (15.6-23.1%) (0.128-0.398) (0.179-0.310) (0.105-0.167) (0.071-0.115) (0.049-0.086) (0.032-0.067) (0.018-0.052) (5600-17000) (8700-15000) (5800-9300) (4500-7400) (3600-6400) (2800-5800) (1800-5200) (0-3200) (1600-6700)	N.A. 5.0-70.0% 3.0-32.0% 3.0-32.0% 4.0-15.0% 10.0-28.0% 0.03-1.40 0.06-0.36 0.05-0.30 0.03-0.21 0.03-0.19 0.01-0.17 0.01-0.17 0.01-0.06 2600-37000 2700-35000 1800-25300 1200-14000 1000-9000 800-8000 1800-7000 0-8200 500-12300	(truck drivers) ¹⁴ Only used for comparison (truck drivers) ⁶ (original source not found) ¹²⁹ ⁴⁷ ³² ³² ⁶⁷ ⁶⁸ ⁶⁰ ⁶⁷ ⁶⁷ ⁶⁷ ⁶⁷ ⁶⁷ ⁶⁷ ⁶⁸ ⁶⁹ ⁶⁷ ⁶⁷ ⁶⁷ ⁶⁸ ⁶⁷ ⁶⁷ ⁶⁸ ⁶⁹ ⁶⁷ ⁶⁸ ⁶⁹ ⁶⁷ ⁶⁷ ⁶⁸ ⁶⁹ ⁶⁷ ⁶⁸ ⁶⁹ ⁶⁷ ⁶⁷ ⁶⁸ ⁶⁹ ⁶⁷
15-59 HIV Prevalem All 15-59 All 15-59 All 15-59 All 25-49 HIV incidence 15-59	2009 2019 2019 2011 2015 2015 2020 2000 2005 2010 2020 2020 2015 2020 2020 2020 2020 2005 2010 2020 2020 2020 2015 2020 2020 2015 2020 2015 2020 VHIV infecti 1990 1995 2000 2005 2010 2020 V-related dea 1990 1995 2000 2015 2020 2010 2015 2020 2010 2020 2010 2020 2015 2020 2010 2015 2020 2000 2005 2010 2015 2020 2000 2005 2010 2015 2020 2010 2015 2020 2010 2015 2020 2010 2015 2020 2010 2015 2020 2010 2015 2020 2010 2015 2020 2010 2015 2020 V-related dea 1995 2000	1.9% M 20.1% 18.1% 9.5% 8.5% 19.1% D susceptible-year) 0.255 0.232 0.133 0.092 0.066 0.048 0.030 ons 11000 1400 3100 oths 1100 3400 6000	(1.2-2.9%) N.A. (15.1-21.5%) (5.6-13.5%) (6.5-11.0%) (15.6-23.1%) (0.128-0.398) (0.179-0.310) (0.105-0.167) (0.071-0.115) (0.049-0.086) (0.032-0.067) (0.018-0.052) (0.018-0.052) (5600-17000) (8700-15000) (5800-9300) (4500-7400) (3600-6400) (2800-5800) (1800-5200) (0-3200) (1600-6700) (4100-8500)	N.A. 5.0-70.0% 3.0-32.0% 3.0-32.0% 4.0-15.0% 10.0-28.0% 0.03-1.40 0.06-0.36 0.05-0.30 0.03-0.21 0.03-0.19 0.01-0.17 0.01-0.17 0.01-0.06 2600-37000 2700-35000 1800-25300 1200-14000 1000-9000 800-8000 1800-7000 0-8200 500-12300 2100-15500	(truck drivers) ¹⁴ Only used for comparison (truck drivers) ⁶ (original source not found) ¹²⁹ ⁴⁷ ³² ³² ⁶⁷ ⁶⁷ ⁶⁷ ⁶³ As above ⁶³ As above ⁶⁷ ⁶⁸ ⁶⁹ ⁶⁷ ⁶⁷ ⁶⁷ ⁶⁷ ⁶⁷ ⁶⁸ ⁶⁹ ⁶⁷ ⁶⁷ ⁶⁷ ⁶⁸ ⁶⁹ ⁶⁷ ⁶⁷ ⁶⁸ ⁶⁹ ⁶⁷ ⁶⁸ ⁶⁹ ⁶⁷ ⁶⁸ ⁶⁹ ⁶⁷ ⁶⁸ ⁶⁹ ⁶⁷ ⁶⁸ ⁶⁹ ⁶⁷ ⁶⁸ ⁶⁹ ⁶⁸ ⁶⁸ ⁶⁹ ⁶⁸ ⁶⁹ ⁶⁸ ⁶⁹ ⁶⁹ ⁶⁹ ⁶⁹ ⁶⁹ ⁶⁹ ⁶⁹ ⁶⁹ ⁶⁹ ⁶⁹ ⁶⁰ ⁶⁷ ⁶⁷ ⁶⁸ ⁶⁸ ⁶⁹ ⁶⁷ ⁶⁸ ⁶⁹ ⁶⁹ ⁶⁹ ⁶⁹ ⁶⁹ ⁶⁹ ⁶⁹ ⁶⁹ ⁶⁹ ⁶⁹
15-59 HIV Prevalem All 15-59 All 15-59 All 15-59 All 25-49 HIV incidence 15-59	2009 2019 2019 2011 2015 2015 2020 2000 2005 2010 2020 2020 2015 2020 2020 2020 2020 2005 2010 2020 2020 2015 2020 2020 2015 2020 2020 2015 2020 2015 2020 2020 2015 2020 2020 W HIV infecti 1990 1995 2000 2005 2010 2015 2020 W HIV infecti 1995 2000 2015 2020 W HIV infecti 1995 2000 2015 2020 2010 2020 2020 W HIV infecti 1995 2000 2015 2020 2010 2015 2020 2010 2015 2020 2010 2015 2020 2010 2015 2020 2010 2015 2020 2010 2015 2020 W -related dea 1995 2000 2005 2020 W -related dea 1995 2000 2005 2000 2015 2020 W -related dea 1995 2000 2005 2000 2005 2000 2020 W -related dea 1995 2000 2005 200	1.9% M 20.1% 18.1% 9.5% 8.5% 19.1% 9.ssceptible-year) 0.255 0.232 0.133 0.092 0.066 0.048 0.030 001 11000 11000 11000 7400 5900 4900 4100 3100 01 1100 3400 6000 6400	(1.2-2.9%) N.A. (15.1-21.5%) (5.6-13.5%) (6.5-11.0%) (15.6-23.1%) (0.128-0.398) (0.179-0.310) (0.105-0.167) (0.071-0.115) (0.049-0.086) (0.032-0.067) (0.018-0.052) (5600-17000) (8700-15000) (5800-9300) (4500-7400) (3600-6400) (2800-5800) (1800-5200) (0-3200) (1600-6700)	N.A. 5.0-70.0% 3.0-32.0% 3.0-32.0% 4.0-15.0% 10.0-28.0% 0.03-1.40 0.06-0.36 0.05-0.30 0.03-0.21 0.03-0.19 0.01-0.17 0.01-0.17 0.01-0.06 2600-37000 2700-35000 1800-25300 1200-14000 1000-9000 800-8000 1800-7000 0-8200 500-12300 2100-15500 2100-16000	(truck drivers) ¹⁴ Only used for comparison (truck drivers) ⁶ (original source not found) ¹²⁹ ⁴⁷ ³² ³² ⁶⁷ ⁶⁸ ⁶⁰ ⁶⁷ ⁶⁷ ⁶⁷ ⁶⁷ ⁶⁷ ⁶⁷ ⁶⁸ ⁶⁹ ⁶⁷ ⁶⁷ ⁶⁷ ⁶⁸ ⁶⁷ ⁶⁷ ⁶⁸ ⁶⁹ ⁶⁷ ⁶⁸ ⁶⁹ ⁶⁷ ⁶⁷ ⁶⁸ ⁶⁹ ⁶⁷ ⁶⁸ ⁶⁹ ⁶⁷ ⁶⁷ ⁶⁸ ⁶⁹ ⁶⁷
15-59 HIV Prevalem All 15-59 All 15-59 All 15-59 All 25-49 HIV incidence 15-59 15	2009 2019 2019 2011 2015 2015 2020 2000 2005 2010 2020 2020 2015 2020 2020 2020 2020 2005 2010 2020 2020 2020 2015 2020 2020 2015 2020 2015 2020 VHIV infecti 1990 1995 2000 2005 2010 2020 V-related dea 1990 1995 2000 2015 2020 2010 2015 2020 2010 2020 2010 2020 2015 2020 2010 2015 2020 2000 2005 2010 2015 2020 2000 2005 2010 2015 2020 2010 2015 2020 2010 2015 2020 2010 2015 2020 2010 2015 2020 2010 2015 2020 2010 2015 2020 2010 2015 2020 V-related dea 1995 2000	1.9% M 20.1% 18.1% 9.5% 8.5% 19.1% D susceptible-year) 0.255 0.232 0.133 0.092 0.066 0.048 0.030 ons 11000 1400 3100 oths 1100 3400 6000	(1.2-2.9%) N.A. (15.1-21.5%) (5.6-13.5%) (6.5-11.0%) (15.6-23.1%) (0.128-0.398) (0.179-0.310) (0.105-0.167) (0.071-0.115) (0.049-0.086) (0.032-0.067) (0.018-0.052) (0.018-0.052) (5600-17000) (8700-15000) (5800-9300) (4500-7400) (3600-6400) (2800-5800) (1800-5200) (0-3200) (1600-6700) (4100-8500)	N.A. 5.0-70.0% 3.0-32.0% 3.0-32.0% 4.0-15.0% 10.0-28.0% 0.03-1.40 0.06-0.36 0.05-0.30 0.03-0.21 0.03-0.19 0.01-0.17 0.01-0.17 0.01-0.06 2600-37000 2700-35000 1800-25300 1200-14000 1000-9000 800-8000 1800-7000 0-8200 500-12300 2100-15500	(truck drivers) ¹⁴ Only used for comparison (truck drivers) ⁶ (original source not found) ¹²⁹ ⁴⁷ ³² ³² ⁶⁷ As above As above

15 50	2020	2100	(2200, 1200)	1500 5500	4 1
15-59	2020	3100	(2200-4300)	1500-5500	As above
		tested for HIV	(2		17
15-49	2001	4.2%	(3.5-5.0%)	1.0-20.0%	
15-49	2009	14.4%	(13.3-15.6%)	5.0-50.0%	130
15-49	2015	19.9%	(18.0-21.9%)	8.0-50.0%	131
15-49	2018	17.9%	(15.8-20.1%)	10.0-50.0%	58
		iving with HIV eve			
15-49	2006	6.2%	(5.2-7.5%)	2.0-25.0%	16
15-49	2013	12.4%	(10.6-14.3%)	5.0-45.0%	15
Fraction of a		g with HIV ever te			
15-49	2006	16.9%	N.A.	5.0-50.0%	126
15-49	2013	36.5%	N.A.	20.0-60.0%	As above
15-49	2020	54.7%	N.A.	40.0-70.0%	As above
Fraction of a	ll males ever te	ested for HIV			
15-49	2001	9.0%	(7.3-10.9%)	1.0-40.0%	17
15-49	2015	17.3%	(15.7-19.0%)	5.0-45.0%	131
15-49	2018	14.7%	(32.1-37.1%)	8.0-30.0%	58
Fraction of a	ll males not livi	ing with HIV ever	tested for HIV		
15-49	2006	6.4%	(5.3-7.8%)	2.0-30.0%	16
15-49	2013	10.7%	(9.1-12.6%)	4.0-30.0%	15
		with HIV ever test			
15-49	2006	16.4%	N.A.	8.0-45.0%	126
15-49	2013	33.7%	N.A.	15.0-60.0%	As above
15-49	2019	49.8%	N.A.	35.0-65.0%	As above
	SW ever tested		11.71.	35.0 05.070	
15-59	2000	36.0%	N.A.	2.0-70.0%	98
15-59	2000	31.0%	N.A.	10.0-60.0%	As above
15-59	2005	51.0%	N.A.	25.0-80.0%	As above
15-59	2000	67.0%	N.A.	30.0-90.0%	As above
15-59	2009	45.8%			101 (All are living with HIV)
			(34.8-57.3%)	20.0-85.0%	(All are living with III v)
Fraction of M	ISM ever teste	d for HIV	· · · · ·		
Fraction of M 15-59	ISM ever teste 2015	d for HIV 72.0%	N.A.	50.0-95.0%	129
Fraction of M 15-59 15-59	ISM ever teste 2015 2019	d for HIV 72.0% 83.0%	N.A. (80.8-85.4%)		
Fraction of N 15-59 15-59 Fraction of a	ISM ever tester 2015 2019 Il females living	d for HIV 72.0% 83.0% g with HIV which	N.A. (80.8-85.4%) are diagnosed	50.0-95.0% 60.0-90.0%	129 32
Fraction of M 15-59 15-59 Fraction of al 15-59	ISM ever teste 2015 2019 Il females livin 2015	d for HIV 72.0% 83.0% g with HIV which 47.0%	N.A. (80.8-85.4%) are diagnosed (39.0-56.0%)	50.0-95.0% 60.0-90.0% 20.0-80.0%	129 32 126
Fraction of M 15-59 15-59 Fraction of al 15-59 15-59	ISM ever tester 2015 2019 Il females livin 2015 2016	d for HIV 72.0% 83.0% g with HIV which 47.0% 50.0%	N.A. (80.8-85.4%) are diagnosed (39.0-56.0%) (42.0-60.0%)	50.0-95.0% 60.0-90.0% 20.0-80.0% 30.0-85.0%	129 32 126 As above
Fraction of M 15-59 15-59 Fraction of al 15-59 15-59 15-59	ISM ever tester 2015 2019 Il females living 2015 2016 2017	d for HIV 72.0% 83.0% g with HIV which 47.0% 50.0% 53.0%	N.A. (80.8-85.4%) are diagnosed (39.0-56.0%) (42.0-60.0%) (44.0-64.0%)	50.0-95.0% 60.0-90.0% 20.0-80.0% 30.0-85.0% 30.0-85.0%	129 32 126 As above As above
Fraction of M 15-59 15-59 Fraction of al 15-59 15-59 15-59 15-59	ISM ever tester 2015 2019 Il females living 2015 2016 2017 2018	d for HIV 72.0% 83.0% g with HIV which 47.0% 50.0% 53.0% 56.0%	N.A. (80.8-85.4%) are diagnosed (39.0-56.0%) (42.0-60.0%) (44.0-64.0%) (47.0-68.0%)	50.0-95.0% 60.0-90.0% 20.0-80.0% 30.0-85.0% 30.0-85.0% 35.0-90.0%	129 32 126 As above As above As above
Fraction of M 15-59 15-59 Fraction of al 15-59 15-59 15-59 15-59 15-59	ISM ever tester 2015 2019 Il females living 2015 2016 2017 2018 2019	d for HIV 72.0% 83.0% g with HIV which 47.0% 50.0% 53.0% 56.0% 60.0%	N.A. (80.8-85.4%) are diagnosed (39.0-56.0%) (42.0-60.0%) (44.0-64.0%) (47.0-68.0%) (49.0-73.0%)	50.0-95.0% 60.0-90.0% 20.0-80.0% 30.0-85.0% 30.0-85.0% 35.0-90.0% 40.0-90.0%	129 32 126 As above As above As above As above As above
Fraction of M 15-59 15-59 Fraction of al 15-59 15-59 15-59 15-59 15-59 15-59	ISM ever tester 2015 2019 Il females living 2015 2016 2017 2018 2019 2020	d for HIV 72.0% 83.0% g with HIV which 47.0% 50.0% 53.0% 56.0% 60.0% 64.0%	N.A. (80.8-85.4%) are diagnosed (39.0-56.0%) (42.0-60.0%) (44.0-64.0%) (47.0-68.0%) (49.0-73.0%) (53.0-78.0%)	50.0-95.0% 60.0-90.0% 20.0-80.0% 30.0-85.0% 30.0-85.0% 35.0-90.0%	129 32 126 As above As above As above
Fraction of M 15-59 15-59 Fraction of al 15-59 15-59 15-59 15-59 15-59 15-59 15-59 15-59 15-59 15-59 15-59 15-59 15-59 15-59 15-59 15-59 15-59 15-59 15-59 Fraction of al	ISM ever tester 2015 2019 Il females living 2015 2016 2017 2018 2019 2020 Il males living v	d for HIV 72.0% 83.0% g with HIV which 47.0% 50.0% 53.0% 56.0% 60.0% 64.0% with HIV which ar	N.A. (80.8-85.4%) are diagnosed (39.0-56.0%) (42.0-60.0%) (44.0-64.0%) (47.0-68.0%) (47.0-68.0%) (49.0-73.0%) (53.0-78.0%) re diagnosed	50.0-95.0% 60.0-90.0% 20.0-80.0% 30.0-85.0% 30.0-85.0% 35.0-90.0% 40.0-90.0% 53.0-78.0%	129 32 126 As above As above As above As above As above As above
Fraction of M 15-59 Fraction of al 15-59 15-59 15-59 15-59 15-59 15-59 Fraction of al 15-59	ISM ever tester 2015 2019 Il females living 2015 2016 2017 2018 2019 2020 Il males living 2015	d for HIV 72.0% 83.0% g with HIV which 47.0% 50.0% 53.0% 56.0% 60.0% 64.0% with HIV which ar 36.0%	N.A. (80.8-85.4%) are diagnosed (39.0-56.0%) (42.0-60.0%) (44.0-64.0%) (47.0-68.0%) (49.0-73.0%) (53.0-78.0%) re diagnosed (30.0-43.0%)	50.0-95.0% 60.0-90.0% 20.0-80.0% 30.0-85.0% 30.0-85.0% 35.0-90.0% 40.0-90.0% 53.0-78.0%	129 32 126 As above As above As above As above As above 126
Fraction of M 15-59 15-59 Fraction of al 15-59 15-59 15-59 15-59 15-59 15-59 Fraction of al 15-59 15-59	ISM ever tester 2015 2019 Il females living 2015 2016 2017 2018 2019 2020 Il males living v 2015 2015 2015	d for HIV 72.0% 83.0% g with HIV which 47.0% 50.0% 53.0% 56.0% 60.0% 64.0% with HIV which ar 36.0% 38.0%	N.A. (80.8-85.4%) are diagnosed (39.0-56.0%) (42.0-60.0%) (44.0-64.0%) (47.0-68.0%) (49.0-73.0%) (53.0-78.0%) (53.0-78.0%) (30.0-43.0%) (32.0-45.0%)	50.0-95.0% 60.0-90.0% 20.0-80.0% 30.0-85.0% 30.0-85.0% 35.0-90.0% 40.0-90.0% 53.0-78.0% 15.0-55.0% 15.0-60.0%	129 32 126 As above As above As above As above As above 126 As above
Fraction of M 15-59 15-59 Fraction of al 15-59 15-59 15-59 15-59 15-59 15-59 Fraction of al 15-59 15-59 15-59 15-59	ISM ever tester 2015 2019 Il females living 2015 2016 2017 2018 2019 2020 Il males living 2015 2016 2015 2016 2017	d for HIV 72.0% 83.0% g with HIV which 47.0% 50.0% 53.0% 56.0% 60.0% 64.0% with HIV which ar 36.0% 38.0% 40.0%	N.A. (80.8-85.4%) are diagnosed (39.0-56.0%) (42.0-60.0%) (44.0-64.0%) (47.0-68.0%) (49.0-73.0%) (53.0-78.0%) (53.0-78.0%) (30.0-43.0%) (32.0-45.0%) (33.0-48.0%)	50.0-95.0% 60.0-90.0% 20.0-80.0% 30.0-85.0% 30.0-85.0% 35.0-90.0% 40.0-90.0% 53.0-78.0% 15.0-55.0% 15.0-60.0% 20.0-60.0%	129 32 126 As above As above As above As above As above 126 As above
Fraction of M 15-59 15-59 Fraction of al 15-59 15-59 15-59 15-59 15-59 15-59 Fraction of al 15-59 15-59 15-59 15-59 15-59 15-59 15-59	ISM ever tester 2015 2019 Il females living 2015 2016 2017 2018 2019 2020 Il males living v 2015 2016 2015 2016 2017 2018	d for HIV 72.0% 83.0% g with HIV which 47.0% 50.0% 53.0% 56.0% 60.0% 64.0% with HIV which ar 36.0% 38.0% 40.0% 43.0%	N.A. (80.8-85.4%) are diagnosed (39.0-56.0%) (42.0-60.0%) (44.0-64.0%) (47.0-68.0%) (49.0-73.0%) (53.0-78.0%) (53.0-78.0%) (30.0-43.0%) (32.0-45.0%) (33.0-48.0%) (35.0-51.0%)	50.0-95.0% 60.0-90.0% 20.0-80.0% 30.0-85.0% 30.0-85.0% 35.0-90.0% 40.0-90.0% 53.0-78.0% 15.0-55.0% 15.0-60.0% 20.0-60.0%	129 32 126 As above As above As above As above As above 126 As above As above As above As above As above
Fraction of M 15-59 15-59 Fraction of al 15-59 15-59 15-59 15-59 15-59 15-59 15-59 15-59 15-59 15-59 15-59 15-59 15-59 15-59	ISM ever tester 2015 2019 Il females living 2015 2016 2017 2018 2019 2020 Il males living 2015 2016 2017 2015 2016 2017 2018 2019	d for HIV 72.0% 83.0% g with HIV which 47.0% 50.0% 53.0% 56.0% 60.0% 64.0% with HIV which ar 36.0% 38.0% 40.0% 43.0% 45.0%	N.A. (80.8-85.4%) are diagnosed (39.0-56.0%) (42.0-60.0%) (44.0-64.0%) (47.0-68.0%) (49.0-73.0%) (53.0-78.0%) (53.0-78.0%) (32.0-45.0%) (32.0-45.0%) (35.0-51.0%) (37.0-55.0%)	50.0-95.0% 60.0-90.0% 20.0-80.0% 30.0-85.0% 30.0-85.0% 35.0-90.0% 40.0-90.0% 53.0-78.0% 15.0-55.0% 15.0-60.0% 20.0-60.0% 25.0-65.0%	129 32 126 As above As above As above As above As above 126 As above 127 126 As above
Fraction of M 15-59 15-59 Fraction of al 15-59	ISM ever tester 2015 2019 Il females living 2015 2016 2017 2018 2019 2020 Il males living v 2015 2016 2017 2015 2016 2017 2018 2019 2020	d for HIV 72.0% 83.0% g with HIV which 1 47.0% 50.0% 53.0% 56.0% 60.0% 64.0% with HIV which ar 36.0% 38.0% 40.0% 43.0% 45.0% 49.0%	N.A. (80.8-85.4%) are diagnosed (39.0-56.0%) (42.0-60.0%) (44.0-64.0%) (47.0-68.0%) (47.0-68.0%) (49.0-73.0%) (53.0-78.0%) (53.0-78.0%) (32.0-45.0%) (33.0-48.0%) (35.0-51.0%) (37.0-55.0%) (39.0-59.0%)	50.0-95.0% 60.0-90.0% 20.0-80.0% 30.0-85.0% 30.0-85.0% 35.0-90.0% 40.0-90.0% 53.0-78.0% 15.0-55.0% 15.0-60.0% 20.0-60.0%	129 32 126 As above As above As above As above As above 126 As above As above As above As above As above
Fraction of M 15-59 15-59 Fraction of al 15-59	ISM ever tester 2015 2019 Il females living 2015 2016 2017 2018 2019 2020 Il males living v 2015 2016 2017 2015 2016 2017 2018 2019 2020 Il fSW living v	d for HIV 72.0% 83.0% g with HIV which 47.0% 50.0% 53.0% 56.0% 60.0% 64.0% with HIV which ar 36.0% 38.0% 40.0% 43.0% 45.0% 49.0% with HIV with a dia	N.A. (80.8-85.4%) are diagnosed (39.0-56.0%) (42.0-60.0%) (44.0-64.0%) (47.0-68.0%) (49.0-73.0%) (53.0-78.0%) (53.0-78.0%) (30.0-43.0%) (32.0-45.0%) (33.0-48.0%) (35.0-51.0%) (37.0-55.0%) (39.0-59.0%) agnosed infection	50.0-95.0% 60.0-90.0% 20.0-80.0% 30.0-85.0% 30.0-85.0% 35.0-90.0% 40.0-90.0% 53.0-78.0% 15.0-55.0% 15.0-60.0% 20.0-60.0% 25.0-65.0%	129 32 126 As above As above As above As above As above 126 As above 127 128 As above As above
Fraction of M 15-59 15-59 Fraction of al 15-59	ISM ever tester 2015 2019 Il females living 2015 2016 2017 2018 2019 2020 Il males living v 2015 2016 2017 2018 2017 2018 2019 2020 Il fSW living v 2018	d for HIV 72.0% 83.0% g with HIV which 47.0% 50.0% 53.0% 56.0% 60.0% 64.0% with HIV which ar 36.0% 38.0% 40.0% 43.0% 45.0% 49.0% vith HIV with a dia 45.8%	N.A. (80.8-85.4%) are diagnosed (39.0-56.0%) (42.0-60.0%) (44.0-64.0%) (47.0-68.0%) (49.0-73.0%) (53.0-78.0%) (53.0-78.0%) (30.0-43.0%) (32.0-45.0%) (32.0-45.0%) (35.0-51.0%) (37.0-55.0%) (39.0-59.0%) agnosed infection (34.8-57.3%)	50.0-95.0% 60.0-90.0% 20.0-80.0% 30.0-85.0% 30.0-85.0% 35.0-90.0% 40.0-90.0% 53.0-78.0% 15.0-55.0% 15.0-60.0% 20.0-60.0% 25.0-65.0%	129 32 126 As above As above As above As above As above 126 As above 127 126 As above
Fraction of M 15-59 15-59 Fraction of al 15-59 Fraction of al 15-59	ISM ever tester 2015 2019 Il females living 2015 2016 2017 2018 2019 2020 Il males living v 2015 2016 2017 2015 2016 2017 2018 2019 2020 Il FSW living v 2018 Il MSM living v	d for HIV 72.0% 83.0% g with HIV which 47.0% 50.0% 53.0% 56.0% 60.0% 64.0% with HIV which ar 36.0% 38.0% 40.0% 43.0% 45.0% 49.0% vith HIV with a dia 45.8% with HIV with a dia	N.A. (80.8-85.4%) are diagnosed (39.0-56.0%) (42.0-60.0%) (44.0-64.0%) (47.0-68.0%) (49.0-73.0%) (53.0-78.0%) (53.0-78.0%) (30.0-43.0%) (32.0-45.0%) (32.0-45.0%) (35.0-51.0%) (37.0-55.0%) (39.0-59.0%) agnosed infection (34.8-57.3%)	50.0-95.0% 60.0-90.0% 20.0-80.0% 30.0-85.0% 30.0-85.0% 35.0-90.0% 40.0-90.0% 53.0-78.0% 15.0-55.0% 15.0-60.0% 20.0-60.0% 25.0-65.0% 30.0-59.0%	129 32 126 As above As above As above As above As above 126 As above 127 128 As above 129 120 121 122 101
Fraction of M 15-59 15-59 Fraction of al 15-59	ISM ever tester 2015 2019 Il females living 2015 2016 2017 2018 2019 2020 Il males living v 2015 2016 2017 2018 2017 2018 2019 2020 Il fSW living v 2018	d for HIV 72.0% 83.0% g with HIV which 47.0% 50.0% 53.0% 56.0% 60.0% 64.0% with HIV which ar 36.0% 38.0% 40.0% 43.0% 45.0% 49.0% vith HIV with a dia 45.8%	N.A. (80.8-85.4%) are diagnosed (39.0-56.0%) (42.0-60.0%) (44.0-64.0%) (47.0-68.0%) (49.0-73.0%) (53.0-78.0%) (53.0-78.0%) (30.0-43.0%) (32.0-45.0%) (32.0-45.0%) (35.0-51.0%) (37.0-55.0%) (39.0-59.0%) agnosed infection (34.8-57.3%)	50.0-95.0% 60.0-90.0% 20.0-80.0% 30.0-85.0% 30.0-85.0% 35.0-90.0% 40.0-90.0% 53.0-78.0% 15.0-55.0% 15.0-60.0% 20.0-60.0% 25.0-65.0% 30.0-59.0%	129 32 126 As above As above As above As above As above 126 As above 127 128 As above As above
Fraction of M 15-59 15-59 Fraction of al 15-59 Fraction of al 15-59 Fraction of al 15-59	ISM ever tester 2015 2019 Il females living 2015 2016 2017 2018 2019 2020 Il males living v 2015 2016 2017 2018 2017 2018 2019 2020 Il FSW living v 2018 Il MSM living v 2014	d for HIV 72.0% 83.0% g with HIV which 47.0% 50.0% 53.0% 56.0% 60.0% 64.0% with HIV which ar 36.0% 38.0% 40.0% 43.0% 45.0% 49.0% vith HIV with a dia 45.8% with HIV with a dia	N.A. (80.8-85.4%) are diagnosed (39.0-56.0%) (42.0-60.0%) (44.0-64.0%) (47.0-68.0%) (49.0-73.0%) (53.0-78.0%) (53.0-78.0%) (32.0-45.0%) (32.0-45.0%) (33.0-48.0%) (35.0-51.0%) (37.0-55.0%) (39.0-59.0%) agnosed infection (34.8-57.3%) agnosed infection (15.6-52.5%)	50.0-95.0% 60.0-90.0% 20.0-80.0% 30.0-85.0% 30.0-85.0% 35.0-90.0% 40.0-90.0% 53.0-78.0% 15.0-55.0% 15.0-60.0% 20.0-60.0% 20.0-60.0% 25.0-65.0% 30.0-59.0%	129 32 126 As above As above As above As above As above 126 As above 126 As above 126 As above As above 126 As above As above As above As above As above As above 47
Fraction of M 15-59 15-59 Fraction of al 15-59 Fraction of al 15-59 Fraction of al 15-59	ISM ever tester 2015 2019 Il females living 2015 2016 2017 2018 2019 2020 Il males living v 2015 2016 2017 2018 2017 2018 2019 2020 Il FSW living v 2018 Il MSM living v 2014	d for HIV 72.0% 83.0% g with HIV which 47.0% 50.0% 53.0% 56.0% 60.0% 64.0% with HIV which ar 36.0% 38.0% 40.0% 43.0% 45.0% 49.0% vith HIV with a dia 45.8% with HIV with a dia 34.1%	N.A. (80.8-85.4%) are diagnosed (39.0-56.0%) (42.0-60.0%) (44.0-64.0%) (47.0-68.0%) (49.0-73.0%) (53.0-78.0%) (53.0-78.0%) (32.0-45.0%) (32.0-45.0%) (33.0-48.0%) (35.0-51.0%) (37.0-55.0%) (39.0-59.0%) agnosed infection (34.8-57.3%) agnosed infection (15.6-52.5%)	50.0-95.0% 60.0-90.0% 20.0-80.0% 30.0-85.0% 30.0-85.0% 35.0-90.0% 40.0-90.0% 53.0-78.0% 15.0-55.0% 15.0-60.0% 20.0-60.0% 20.0-60.0% 25.0-65.0% 30.0-59.0%	129 32 126 As above As above As above As above As above 126 As above 127 128 As above 129 120 121 122 101
Fraction of M 15-59 15-59 Fraction of al 15-59 Fraction of al 15-59 Fraction of al 15-59 Fraction of al 15-59	ISM ever tester 2015 2019 Il females living 2015 2016 2017 2018 2019 2020 Il males living v 2015 2016 2017 2018 2019 2020 Il FSW living v 2018 Il FSW living v 2018 Il females living v	d for HIV 72.0% 83.0% g with HIV which 47.0% 50.0% 53.0% 56.0% 60.0% 64.0% with HIV which ar 36.0% 38.0% 40.0% 43.0% 45.0% 49.0% vith HIV with a dia 45.8% with HIV with a dia 34.1% g with HIV with a	N.A. (80.8-85.4%) are diagnosed (39.0-56.0%) (42.0-60.0%) (44.0-64.0%) (47.0-68.0%) (49.0-73.0%) (53.0-78.0%) (53.0-78.0%) (30.0-43.0%) (32.0-45.0%) (32.0-45.0%) (33.0-48.0%) (35.0-51.0%) (37.0-55.0%) (39.0-59.0%) agnosed infection (34.8-57.3%) agnosed infection (15.6-52.5%) treated infection	50.0-95.0% 60.0-90.0% 20.0-80.0% 30.0-85.0% 30.0-85.0% 35.0-90.0% 40.0-90.0% 53.0-78.0% 15.0-55.0% 15.0-60.0% 20.0-60.0% 25.0-65.0% 30.0-59.0% 28.0-70.0%	129 32 126 As above As above As above As above As above As above 126 As above 126 As above 126 As above As above 126 As above As above As above As above As above 47
Fraction of M 15-59 15-59 Fraction of al 15-59 Fraction of al 15-59 Fraction of al 15-59 Fraction of al 15-49 15-49 15-49	ISM ever tester 2015 2019 Il females living 2015 2016 2017 2018 2019 2020 Il males living v 2015 2016 2017 2018 2017 2018 2019 2020 Il FSW living v 2018 Il MSM living v 2014 Il females living 2014	d for HIV 72.0% 83.0% g with HIV which 47.0% 50.0% 53.0% 56.0% 60.0% 64.0% with HIV which ar 36.0% 38.0% 40.0% 43.0% 45.0% 49.0% vith HIV with a dia 45.8% with HIV with a dia 34.1% g with HIV with a dia 39.0% 62.0%	N.A. (80.8-85.4%) are diagnosed (39.0-56.0%) (42.0-60.0%) (44.0-64.0%) (47.0-68.0%) (49.0-73.0%) (53.0-78.0%) (53.0-78.0%) (30.0-43.0%) (32.0-45.0%) (32.0-45.0%) (35.0-51.0%) (35.0-51.0%) (35.0-55.0%) (39.0-59.0%) agnosed infection (34.8-57.3%) treated infection (33.0-47.0%) (51.0-76.0%)	50.0-95.0% 60.0-90.0% 20.0-80.0% 30.0-85.0% 30.0-85.0% 35.0-90.0% 40.0-90.0% 53.0-78.0% 15.0-65.0% 20.0-60.0% 28.0-70.0% 15.0-65.0% 20.0-60.0%	129 32 126 As above As above As above As above As above 126 As above 126 As above 126 As above 126 As above As above 126 As above As above 126 As above As above As above 43 101 47 67
Fraction of M 15-59 15-59 Fraction of al 15-59 Fraction of al 15-59 Fraction of al 15-59 Fraction of al 15-49 15-49 15-49	ISM ever tester 2015 2019 Il females living 2015 2016 2017 2018 2019 2020 Il males living v 2015 2016 2017 2018 2017 2018 2019 2020 Il FSW living v 2018 Il MSM living v 2014 Il females living 2015 2020 Il males living v 2018	d for HIV 72.0% 83.0% g with HIV which 47.0% 50.0% 53.0% 56.0% 60.0% 64.0% with HIV which ar 36.0% 38.0% 40.0% 43.0% 45.0% 49.0% vith HIV with a dia 45.8% with HIV with a dia 34.1% g with HIV with a dia 39.0% 62.0% with HIV with a tr	N.A. (80.8-85.4%) are diagnosed (39.0-56.0%) (42.0-60.0%) (44.0-64.0%) (47.0-68.0%) (49.0-73.0%) (53.0-78.0%) (53.0-78.0%) (32.0-45.0%) (32.0-45.0%) (32.0-45.0%) (33.0-48.0%) (35.0-51.0%) (37.0-55.0%) (39.0-59.0%) agnosed infection (34.8-57.3%) treated infection (33.0-47.0%) (51.0-76.0%) eated infection	50.0-95.0% 60.0-90.0% 20.0-80.0% 30.0-85.0% 30.0-85.0% 35.0-90.0% 40.0-90.0% 53.0-78.0% 15.0-60.0% 20.0-60.0% 20.0-60.0% 25.0-65.0% 28.0-70.0% 28.0-70.0% 20.0-60.0% 45.0-82.0%	129 32 126 As above As above As above As above As above 126 As above 126 As above 126 As above 126 As above As above 126 As above As above 126 As above As above As above 43 101 47 67
Fraction of M 15-59 15-59 Fraction of al 15-59 Fraction of al 15-59 Fraction of al 15-49 15-49 15-49 Fraction of al 15-49 15-49 15-49 15-49 15-49 15-49 15-49	ISM ever tester 2015 2019 Il females living 2015 2016 2017 2018 2019 2020 Il males living v 2015 2016 2017 2018 2017 2018 2019 2020 Il FSW living v 2018 Il MSM living v 2014 Il females living 2015 2020	d for HIV 72.0% 83.0% g with HIV which 47.0% 50.0% 53.0% 56.0% 60.0% 64.0% with HIV which ar 36.0% 38.0% 40.0% 43.0% 45.0% 49.0% vith HIV with a dia 45.8% with HIV with a dia 34.1% g with HIV with a dia 39.0% 62.0% with HIV with a tr 25.0%	N.A. (80.8-85.4%) are diagnosed (39.0-56.0%) (42.0-60.0%) (44.0-64.0%) (47.0-68.0%) (49.0-73.0%) (53.0-78.0%) (53.0-78.0%) (32.0-45.0%) (32.0-45.0%) (33.0-43.0%) (35.0-51.0%) (35.0-51.0%) (37.0-55.0%) (39.0-59.0%) agnosed infection (34.8-57.3%) treated infection (15.6-52.5%) treated infection (33.0-47.0%) (51.0-76.0%) eated infection (21.0-30.0%)	50.0-95.0% 60.0-90.0% 20.0-80.0% 30.0-85.0% 30.0-85.0% 35.0-90.0% 40.0-90.0% 53.0-78.0% 15.0-60.0% 20.0-60.0% 20.0-60.0% 25.0-65.0% 30.0-59.0% 28.0-70.0% 20.0-60.0% 45.0-82.0%	129 32 126 As above As above As above As above As above 126 As above As above As above As above As above 126 As above As above As above As above As above 43 101 47 67 67 67 67
Fraction of M 15-59 15-59 Fraction of al 15-59 Fraction of al 15-59 Fraction of al 15-49 15-49 15-49 15-49 15-49 15-49 15-49 15-49 15-49 15-49 15-49 15-49 15-49 15-49 15-49 15-49 15-49	ISM ever tester 2015 2019 Il females living 2015 2016 2017 2018 2019 2020 Il males living v 2015 2016 2017 2018 2017 2018 2019 2020 Il FSW living v 2018 Il MSM living v 2014 Il females living v 2014 Il females living v 2015 2020	d for HIV 72.0% 83.0% g with HIV which 47.0% 50.0% 53.0% 56.0% 60.0% 64.0% with HIV which ar 36.0% 38.0% 40.0% 43.0% 45.0% 49.0% vith HIV with a dia 45.8% with HIV with a dia 34.1% g with HIV with a dia 39.0% 62.0% with HIV with a tr 25.0% 44.0%	N.A. (80.8-85.4%) are diagnosed (39.0-56.0%) (42.0-60.0%) (44.0-64.0%) (47.0-68.0%) (49.0-73.0%) (53.0-78.0%) (30.0-43.0%) (32.0-45.0%) (32.0-45.0%) (33.0-48.0%) (35.0-51.0%) (37.0-55.0%) (39.0-59.0%) agnosed infection (34.8-57.3%) iagnosed infection (15.6-52.5%) treated infection (33.0-47.0%) (51.0-76.0%) eated infection (21.0-30.0%) (35.0-53.0%)	50.0-95.0% 60.0-90.0% 20.0-80.0% 30.0-85.0% 30.0-85.0% 35.0-90.0% 40.0-90.0% 53.0-78.0% 15.0-60.0% 20.0-60.0% 20.0-60.0% 25.0-65.0% 28.0-70.0% 28.0-70.0% 20.0-60.0% 45.0-82.0%	129 32 126 As above As above As above As above As above 126 As above 127 128 As above 129 126 As above As above As above As above 101 47 67 67 67 67 67 67
Fraction of M 15-59 15-59 Fraction of al 15-59 Fraction of al 15-59 Fraction of al 15-49 15-49 15-49 15-49 15-49 15-49 15-49 15-49 15-49 15-49 15-49 15-49 15-49 15-49 15-49	ISM ever tester 2015 2019 Il females living 2015 2016 2017 2018 2019 2020 Il males living v 2015 2016 2017 2018 2017 2018 2019 2020 Il FSW living v 2018 Il MSM living v 2014 Il females living v 2014 Il females living v 2015 2020	d for HIV 72.0% 83.0% g with HIV which 47.0% 50.0% 53.0% 56.0% 60.0% 64.0% with HIV which ar 36.0% 38.0% 40.0% 43.0% 45.0% 49.0% vith HIV with a dia 45.8% with HIV with a dia 34.1% g with HIV with a dia 39.0% 62.0% with HIV with a tr 25.0%	N.A. (80.8-85.4%) are diagnosed (39.0-56.0%) (42.0-60.0%) (44.0-64.0%) (47.0-68.0%) (49.0-73.0%) (53.0-78.0%) (30.0-43.0%) (32.0-45.0%) (32.0-45.0%) (33.0-48.0%) (35.0-51.0%) (37.0-55.0%) (39.0-59.0%) agnosed infection (34.8-57.3%) iagnosed infection (15.6-52.5%) treated infection (33.0-47.0%) (51.0-76.0%) eated infection (21.0-30.0%) (35.0-53.0%)	50.0-95.0% 60.0-90.0% 20.0-80.0% 30.0-85.0% 30.0-85.0% 35.0-90.0% 40.0-90.0% 53.0-78.0% 15.0-60.0% 20.0-60.0% 20.0-60.0% 25.0-65.0% 30.0-59.0% 28.0-70.0% 20.0-60.0% 45.0-82.0%	129 32 126 As above As above As above As above As above 126 As above 127 128 As above 129 126 As above As above As above As above 101 47 67 67 67 67 67 67

Fraction of F	SW living with	h HIV with a suppr	essed viral load		
15-49	2019	51.6%	(41.3-61.7%)	30.0-70.0%	14
Fraction of N	ASM living wit	h HIV with a supp	ressed viral load		
15-49	2014	30.0%	(18.3-45.0%)	10.0-60.0%	47
15-24	2020	40.0%	(27.5-44.8%)	20.0-65.0%	32
25-49	2020	48.1%	(37.0-59.2%)	30.0-70.0%	32
Number of co	onventional H	IV tests done each y	year (females and m	ales combined	
15-59	2015	393,007	N.A.	(196,504-	Programmatic data reported by
				786,014)	countries to UNAIDS's
					Shyny90 ¹²⁶
15-59	2016	400,005	N.A.	(200,003-	As above
				800,010)	
15-59	2017	476,098	N.A.	(238,049-	As above
				952,196)	
15-59	2018	565,838	N.A.	(282,919-	As above
				1,131,676)	
15-59	2019	504,414	N.A.	(252,207-	As above
				1,008,828)	
Fraction of c	onventional H		n are positive (femal	es and males c	
15-59	2015	2.3%	N.A.	(1.2-4.6%)	Programmatic data reported by
					countries to UNAIDS's
					Shyny90 ¹²⁶
15-59	2016	1.7%	N.A.	(0.9-3.5%)	As above
15-59	2017	2.6%	N.A.	(1.3-5.1%)	As above
15-59	2018	2.3%	N.A.	(1.2-4.6%)	As above
15-59	2019	2.5%	N.A.	(1.2-5.0%)	As above

MSMW: men who have sex with men as well as female partners; MSME: men who have sex with men exclusively. N.A.: Not available

Fitting data (Senegal)

		raphic, epidemiological, ar			
Population	Year	Point estimate	Original	Prior	Reference
or age group			95%CI	constraint	
Population siz					
Total number	1970	2.18 million	N.A.	Initial value	From ⁴
of 15-	1980	2.74 million		for 1970 and	
59years-old	1990	3.64 million		direct	
-	2000	4.92 million		calibration	
	2010	6.56 million		using growth	
	2020	8.81 million		rate between	
				1970 and	
				2020	
				estimates	
Age distributi		15–59-year-old females			
	1970	15-24 years: 35.7%	N.A.	Used for	From ⁴
		25-49 years: 53.0%		comparison	
		50-59 years: 11.3%			
	1980	15-24 years: 37.2%	N.A.	Used for	As above
		25-49 years: 51.4%		comparison	
		50-59 years: 11.4%			
	1990	15-24 years: 39.3%	N.A.	Used for	As above
		25-49 years: 49.8%		comparison	
		50-59 years: 10.9%			
	2000	15-24 years: 40.4%	N.A.	Used for	As above
		25-49 years: 50.1%		comparison	
		50-59 years: 9.5%			
	2010	15-24 years: 37.8%	N.A.	Used for	As above
		25-49 years: 52.5%		comparison	
		50-59 years: 9.7%		1	
	2020	15-24 years: 35.6%	N.A.	27.4-46.3%	Fitted from ⁴
		25-49 years: 54.2%		41.6-70.5%	
		50-59 years: 10.2%		6.8-15.3%	
Age distributi	on among 1	15–59-year-old males			
	1970	15-24 years: 35.7%	N.A.	Initial value	From ⁴
	1770	25-49 years: 53.8%	1,11,21	from data	
		50-59 years: 10.5%			
	1980	15-24 years: 37.3%	N.A.	Used for	As above
	1900	25-49 years: 51.6%	1 (1.	comparison	
		50-59 years: 11.1%		inpution	
	1990	15-24 years: 40.4%	N.A.	Used for	As above
	1770	25-49 years: 48.8%	11.71.	comparison	As above
		50-59 years: 10.8%		comparison	
	2000	15-24 years: 42.8%	N.A.	Used for	As above
	2000	25-49 years: 48.2%	1 1. / 1 .	comparison	
		50-59 years: 9.0%		comparison	
	2010	15-24 years: 41.4%	N.A.	Used for	As above
	2010	25-49 years: 50.0%	IN.A.	comparison	A3 0000C
				comparison	
	2020	50-59 years: 8.6%	NT A	20 1 50 00/	Eitted from ⁴
	2020	15-24 years: 39.1%	N.A.	30.1-50.8%	Fitted from ⁴
		25-49 years: 52.3%		40.2-68.0%	
TTTX7 . •		50-59 years: 8.6%		5.7-12.9%	
		Ill adult females (except f			21
15-24	2005	0.5%	(0.1-0.8%)	0.1-3.0%	
15-24	2011	0.3%	(0.1-0.5%)	0.1-3.0%	22

15-24	2017	0.2%	(0.0-0.5%)	0.0-1.0%	24
25-49	2005	0.8%	(0.4-1.3%)	0.4-6.0%	21
25-49	2011	0.8%	(0.4-1.1%)	0.4-5.0%	22
25-49	2017	0.7%	(0.5-1.3%)	0.5-1.5%	24
HIV prevalence	ce among a	ll adult males			
15-24	2005	0.1%	(0.0-0.2%)	0.0-1.5%	21
15-24	2011	0.1%	(0.0-0.1%)	0.0-1.5%	22
15-24	2017	0.1%	(0.0-0.2%)	0.0-1.0%	24
25-49	2005	0.7%	(0.1-1.2%)	0.1-5.0%	21
25-49	2011	0.7%	(0.3-1.2%)	0.1-5.0%	22
25-49	2017	0.6%	(0.3-1.0%)	0.1-2.0%	24
50-59	2011	0.8%	(0.1-1.4%)	0.0-5.0%	22
50-59	2017	1.2%	(0.3-2.1%)	0.0-3.0%	24
		ll female sex workers			
15-59	1988	16.1%	(14.5-18.0%)	5.0-60.0%	132
15-59	1989	3.1%	N.A.	1.0-60.0%	133
15-59	1994	10.1%	N.A.	2.0-60.0%	133
15-59	2000	20.1%	(18.0-22.4%)	5.0-60.0%	134
15-59	2006	19.8%	(16.8-23.1%)	5.0-60.0%	76
15-59	2010	18.5%	N.A.	5.0-50.0%	75
15-59	2015	6.6%	(5.4-8.7%)	2.0-30.0%	74
15-59	2015	3.3%	(1.5-5.2%)	2.0-30.0%	78 107
15-59	2017	8.1%	N.A.	3.0-40.0%	73
15-59	2019	5.8%	(4.0-7.0%)	10.0-40.0%	15
		lients of sex workers	(2.2.5.0%)	1.0.00.00/	135
15-59	1999	4.4%	(3.3-5.8%)	1.0-30.0%	
15-59	2015	1.2%	(0.2-2.5%)	0.5-10.0%	IBBS surveys ⁷⁸ (personal
					communication of estimated from
LIV Drovolon	a among N	ASM			the unpublished client survey)
HIV Prevalence All 15-59	2012	38.6%	(30.2-47.8%)	15.0-60.0%	136
All 15-59	2012	23.5%	(30.2-47.8%) (18.6-28.4%)	10.0-40.0%	⁷⁸ (RDS-adjusted estimates)
All 15-24	2010	17.7%	(14.9-20.8%)	5.0-30.0%	54
All 15-24	2014	19.4%	(14.9-20.8%) (16.6-22.5%)	5.0-35.0%	⁵⁵ (data fitted among
All 13-24	2017	17.470	(10.0-22.570)	5.0-55.070	MSMW/MSME separately)
All 25-49	2014	18.1%	(14.5-22.4%)	5.0-50.0%	54
All 25-49	2014	39.5%	(35.0-44.1%)	16.0-60.0%	55
All MSMW	2017	20.2%	(16.6-24.4%)	5.0-60.0%	50
All MSMW	2004	19.3%	(10.0-24.4%) (15.5-23.7%)	5.0-50.0%	79
All MSMW	2007	24.1%	(13.3-23.7%) (21.4-27.0%)	15.0-35.0%	55
All MSME	2017	34.1%	(21.5-49.4%)	5.0-70.0%	50
All MSME	2004	29.0%	(21.9-37.3%)	13.0-70.0%	79
All MSME	2007	37.7%	(32.0-43.7%)	25.0-50.0%	55
		100 susceptible-year)	(2=:0 10:770)		
15-59	1990	0.036	(0.028-0.046)	0.010-0.12	67
15-59	1995	0.072	$(0.028 \cdot 0.018)$ (0.058 - 0.088)	0.018-0.160	As above
15-59	2000	0.094	$(0.030 \cdot 0.000)$ $(0.080 \cdot 0.112)$	0.030-0.192	As above
15-59	2005	0.064	(0.052 - 0.076)	0.022-0.146	As above
15-59	2010	0.018	(0.014-0.022)	0.007-0.052	As above
15-59	2015	0.010	(0.008-0.013)	0.004-0.045	As above
15-59	2020	0.010	(0.088-0.014)	0.004-0.030	As above
Number of new					
15-59	1990	1400	(1100-1800)	300-4500	67
15-59	1995	3300	(2600-3900)	1600-7000	As above
15-59	2000	4900	(4100-5800)	2100-9800	As above
15-59	2005	3800	(3100-4500)	2100-8500	As above
15-59	2010	1200	(0-1500)	0-3500	As above
15-59					
10 07	2015	500	(0-1000)	0-3000	As above
15-59	2015 2020	500 700	(0-1000) (0-1300)	0-3000 0-2600	As above As above

Number of H	IV-related d	leaths			
15-59	1990	100	(0-500)	0-2000	67
15-59	1995	500	(0-1000)	0-3000	As above
15-59	2000	1300	(1100-1700)	500-3700	As above
15-59	2005	2400	(2000-2900)	1000-3900	As above
15-59	2010	1200	(0-1600)	0-3000	As above
15-59	2015	1600	(1200-2000)	600-4000	As above
15-59	2020	800	(0-1000)	0-1500	As above
		er tested for HIV		0.0.77	127
15-49	2000	3.0%	(2.4-3.8%)	0.0-20.0%	137
15-49	2014	42.6%	(40.0-45.2%)	25.0-80.0%	27
15-49	2015	42.6%	(40.1-45.1%)	25.0-80.0%	26 25
15-49	2016	39.8%	(36.8-42.8%)	10.0-50.0%	23
		t living with HIV ever		0.5.00.004	21
15-49	2005	2.8%	(2.2-3.6%)	0.5-20.0%	138
15-49	2010	27.3%	(25.3-29.4%)	15.0-70.0%	138 24
15-49	2017	46.1%	(44.1-48.1%)	32.0-80.0%	27
		ing with HIV ever test		0.0.40.004	126
15-49	2005	6.7%	N.A.	2.0-40.0%	
15-49	2010	50.0%	N.A.	25.0-80.0%	As above
15-49 Fraction of a	2017	82.2% tested for HIV	N.A.	70.0-99.0%	As above
Fraction of al 15-49			(17.5-22.7%)	12.0.70.00/	27
15-49 15-49	2014 2015	20.0% 21.8%	· · · · · ·	12.0-70.0% 12.0-70.0%	26
15-49	2015 2016	21.8% 19.8%	(19.2-24.7%) (17.3-22.4%)	12.0-70.0%	25
15-49	2018	19.8%	(17.3-22.4%) (15.8-20.1%)	10.0-70.0%	23
		living with HIV ever te	· · · · · · · · · · · · · · · · · · ·	10.0-00.070	
15-49	2005	3.7%	(2.8-4.9%)	1.0-20.0%	21
15-49	2010	16.7%	(15.1-18.6%)	5.0-60.0%	138
15-49	2017	19.0%	(17.3-20.8%)	15.0-70.0%	24
Fraction of al	ll males livin	g with HIV ever tested	l for HIV		107
15-49	2005	4.9%	N.A.	1.0-40.0%	126
15-49	2010	30.0%	N.A.	10.0-80.0%	As above
15-49	2017	55.7%	N.A.	35.0-90.0%	As above
Fraction of F			NT -	10.0.00.00	76
15-59	2006	63.2%	N.A.	10.0-90.0%	76 75
15-59	2010	73.6%	N.A.	20.0-95.0%	75 39
15-59	2013	58.0%	N.A. $(69.5, 76.00\%)$	25.0-90.0%	59 78
15-59	2015	72.4%	(68.5-76.0%)	30.0-95.0%	139
15-59 Erection of M	2018	79.4%	(72.3-85.0%)	40.0-95.0%	
Fraction of M 15-59	<u>151vi ever tes</u> 2003	13.3%	(8.9-19.5%)	3.0-60.0%	104
15-59	2003	10.8%	(8.9-19.5%) (8.1-14.0%)	3.0-60.0% 3.0-50.0%	50
15-59	2004 2007	34.1%	(30.1-38.4%)	3.0-30.0% 10.0-70.0%	74,79
15-59	2007	86.6%	(30.1-38.4%) (79.3-91.6%)	10.0-70.0% 55.0-99.0%	136
15-59	2012	72.6%	(79.3-91.0%) N.A.	30.0-90.0%	140
15-59	2014	69.1%	N.A.	50.0-90.0%	74
15-59	2014	70.2%	(66.7-74.4%)	50.0-95.0%	78
15-59	2013	82.6%	(80.2-84.7%)	60.0-95.0%	55
15-59	2018	54.0%	(46.6-61.3%)	40.0-90.0%	139
		ing with HIV which a			
15-59	2015	70.0%	(62.0-78.0%)	45.0-90.0%	126
15-59	2016	74.0%	(66.0-83.0%)	50.0-90.0%	As above
15-59	2017	79.0%	(71.0-89.0%)	55.0-95.0%	As above
15-59	2018	86.0%	(77.0-96.0%)	65.0-99.0%	As above
15-59	2019	92.0%	(83.0-99.0%)	70.0-99.0%	As above
15-59	2020	95.0%	(85.0-99.0%)	80.0-99.0%	As above
		g with HIV which are			
15-59	2015	48.0%	(42.0-54.0%)	25.0-75.0%	126

15-59	2016	52.0%	(46.0-58.0%)	30.0-75.0%	As above
15-59	2017	56.0%	(50.0-63.0%)	35.0-80.0%	As above
15-59	2018	61.0%	(54.0-67.0%)	40.0-85.0%	As above
15-59	2019	65.0%	(58.0-72.0%)	45.0-90.0%	As above
15-59	2020	68.0%	(61.0-77.0%)	56.0-85.0%	As above
Fraction of a	ll FSW living v	with HIV with a dia	agnosed infection		
15-59	2000	5.1%	(1.4-16.9%)	0.0-40.0%	141
15-59	2002	29.3%	(23.6-35.8%)	5.0-70.0%	142
15-59	2010	12.5%	(7.8-19.3%)	5.0-80.0%	75
15-59	2015	53.8%	(37.4-69.6%)	20.0-90.0%	139
15-59	2015	67.5%	(52.0-79.9%)	20.0-90.0%	143
15-59	2016	55.0%	(39.8-69.3%)	30.0-80.0%	78
Fraction of a	ll MSM living	with HIV with a di	iagnosed infection		
15-59	2014	48.8%	(34.2-63.5%)	20.0-85.0%	136
15-59	2016	13.2%	(9.4-18.4%)	5.0-80.0%	78
15-59	2018	63.4%	N.A.	40.0-90.0%	6
		g with HIV with a			
15-49	2015	56.0%	(50.0-63.0%)	20.0-90.0%	67
15-49	2020	95.0%	(85.0-99.0%)	85.0-99.0%	67
		with HIV with a tr			
15-49	2015	35.0%	(31.0-39.0%)	10.0-80.0%	67
15-49	2020	61.0%	(54.0-69.0%)	45.0-75.0%	67
		with HIV with a tro		1010 701070	
15-59	2016	37.5%	(24.2-53.0%)	20.0-53.0%	78
		with HIV with a tr	· /	20.0 55.070	
15-59	2016	10.0%	(24.2-53.0%)	20.0-53.0%	78
15-59	2010	38.0%	N.A.	10.0-60.0%	6
		h HIV with a supp		10.0 00.070	
15-49	2019	48.0%	(38.5-57.7%)	35.0-60.0%	73
			year (females and m		
15-59	2016	611,175	N.A.	(305,588-	Programmatic data reported by
15-59	2010	011,175	N.A.	1,222,350)	countries to UNAIDS's Shyny90 ¹²⁶
15-59	2017	550,386	N.A.	(275,193-	As above
		,		1,100,772)	
15-59	2018	669,438	N.A.	(334,719-	As above
		,		1,338,876)	
15-59	2019	684,635	N.A.	(342,318-	As above
		,		1,369,270)	
Fraction of c	onventional H	IV tests done which	h are positive (femal		ombined)
15-59	2016	1.5%	N.A.	(0.7-2.9%)	Programmatic data reported by countries to UNAIDS's
15 50	2017	1 (0/	NT A	(0, 0, 2, 20)	Shyny90 ¹²⁶
15-59	2017	1.6%	N.A.	(0.8-3.3%)	As above
15-59	2018	1.1%	N.A.	(0.5-2.1%)	As above
15-59	2019	1.2%	N.A.	(0.6-2.4%)	As above

MSMW: men who have sex with men as well as female partners; MSME: men who have sex with men exclusively. N.A.: Not available

Methods: simulated HIVST scenarios

Number of HIVST distributed by ATLAS over 2019-2021

A total of 187,914 HIVST were distributed by ATLAS in Côte d'Ivoire over 2019-2021, including 105,904 tests (56%) through FSW channels, 53,864 (29%) through MSM channels, and 28,146 (15%) through other channels (48% of them within STI clinics, 48% to partners of PLHIV, and 3% to people who use drugs (PwUD)). Individuals reached by ATLAS received an average of two test kits, and it was expected that they would distribute some or sometimes all (e.g., PLHIV already aware of their status) their tests to their sexual partners or friends.

This analysis only used programmatic data on number of HIVST distributed through the FSW and MSM channels. We used the channel-specific age-distribution of individuals receiving the tests from the ATLAS programmatic data. The age distribution of HIVST distributed over 2019-2021 through the FSW and MSM channels of the three ATLAS countries, under our assumptions, is shown in **Table S3** and **Figure S2**.

Table S3: Number of HIV self-test (HIVST) kits distributed over 2019-2021 in each ATLAS										
country by distribution channel and age (% by group for each country)										
	Female sex workers (FSW) channel Men who have sex with men (MSM)									
					channel					
Age (years)	15-24	25-49	50+	15-24	25-49	50+				
Côte d'Ivoire	46 300	58 900	800	26 200	27 400	200				
	(29%)	(37%)	(1%)	(16%)	(17%)	(<1%)				
Mali	48 200	58 900	3100	8800	11 900	200				
	(37%)	(45%)	(2%)	(7%)	(9%)	(<1%)				
Senegal	8100	20 500	1300	5900	9800	200				
	(18%)	(45%)	(3%)	(13%)	(21%)	(<1%)				

Primary and secondary distribution

The first stage of an ATLAS phone survey, carried out between March and June 2021, administered sociodemographic questionnaires by telephone to individuals reporting having received ATLAS HIVST kits¹⁴⁴. In the survey, the HIVST distribution channel corresponding to the test used by a participant was identified using a survey serial number printed on survey flyers distributed with HIVST kits. The proportion of tests being received by individuals from the different modelled risk groups was calculated using two scenarios that reflect uncertainties related to the characteristics of individuals receiving the tests. This uncertainty was partly due to the poor reporting of specific behaviours such as paying or receiving money for sex, or sex between men in the region.

Both scenarios assumed that the age group of the individual (directly or indirectly) receiving a test is the same age group as the individual that directly received the test in the programmatic data (groups are 15-24, 25-49, 50+ years old). A specific sensitivity analysis is looking at the predicted impact of HIVST scale-up when using the age distribution from the phone survey and not the programmatic data (see Figure S2). The model assumes that the fraction of HIVST used among those received is the same across risk groups (80% in most scenarios, see specific section), thus the age/risk distribution of people who received the tests is the same as the one who used the tests.

All our base case scenarios used the sex distribution of the phone survey (1st stage) participants by HIVST distribution channel and reflected the distribution of HIVST within the different risk groups (through primary and secondary distribution) accounting for reporting biases described in qualitative studies. The **Table S4a** reports the fraction of HIVST distributed within each channel by risk group under the base case scenario.

In the phone survey, 52% of respondents receiving HIVST from a FSW channel reported being females, and 48% being males. Our base case scenarios assumed that 90% of females receiving the test through the FSW channels were female sex workers, with the remaining 10% being non-FSW females having multiple sexual partners in the model ("intermediate-risk females"). For the tests received by male participants trough an FSW channel, we assumed that the 67% (2/3) were received by clients of FSW (as these males are likely to have received the tests from a FSW through secondary distribution), and the remaining 33% non-client males that have 3+ partners per year in the model to ("intermediate risk males").

In the phone survey data, 91% of respondents using a test delivered through an MSM channel reported being males. We further assumed that all males receiving HIVST through the MSM channels were MSM and that 66% of them (60% of the total) also had female partners (MSMW). This assumption was based on country-level data on the fraction of MSMW among MSM, as well as the fraction (68%, 334/494) of male phone survey participants from the MSM channel reporting having both male and female partners among those reporting male partners. Out of the 9% of females receiving HIVST from the MSM channel, we assumed that 60% were lower-risk females, 40% were intermediate-risk females, and none were FSW. This was based on the likeliness of MSM having monogamous female partners, whilst in the phone survey, ~55% of females having received HIVST through an MSM channel reported 1 or 2 partners, and 30% reported having 3+ partners.

countries combined)									
	All females (52%)			All males (48%)					
FSW channel	Lower-	Intermediate-	FSW	Lower-	Intermediate-	Clients	MSMW	MSME	
	risk	risk females		risk	risk males	of			
channel	females			males		FSW			
	0%	5%	47%	0%	16%	32%	0%	0%	
	All females (9%)			All males (91%)					
MSM channel	Lower-	Intermediate-	FSW	Lower-	Intermediate-	Clients	MSMW	MSME	
	risk	risk females		risk	risk males	of			
	females			males		FSW			
	5%	4%	0%	0%	0%	0%	61%	30%	

Table S4a: Fraction of tests distributed through the ATLAS FSW and MSM channels across risk groups in the base-case scenarios, based on the ATLAS phone survey (1st stage) data (all ATLAS countries combined)

FSW: female sex workers; MSMW: men who have sex with men as well as female partners; MSME: men who have sex with men exclusively.

HIVST distribution under the sensitivity scenario

A sensitivity scenario reflected the empirical outcomes of the ATLAS phone survey (1st stage) more accurately without accounting for likely reporting biases more self-tests distributed to non-KP. The **Table S4b** reports the fraction of HIVST distributed within each channel by risk group under the sensitivity scenario.

For the FSW channel, only 40% (250/620) of female phone survey respondents reported having received money in exchange for sex in the past year and were considered as FSW (only 25% of

females reported having 3 or more partners). The fraction of tests distributed through the FSW ultimately received by lower risk females was assumed to be 28% as it is the fraction of phone survey female participants (FSW channel) reporting not having partners. Regarding the tests received by males trough an FSW channel, only 24% of males reported having paid for sex in the last year, and were considered to be FSW clients in the model. Around 6% of males reported only having male partners, and 6% both male and female partners, proportions which were used to quantify the fraction of tests from FSW channels given to MSME and MSMW. Around 16% of males survey participants reported having no partners and were considered to correspond to lower-risk populations in the model. The fraction of HIVST from the FSW channel which ended up being received by intermediate risk females and males were calculated from the total number of tests distributed to each gender, and the fraction received by the other groups.

The sensitivity scenario assumed that 91% of individuals receiving HIVST from the MSM channels were males, still based on the phone survey (1st stage). Around 16% (160/997) and 34% (334/997) of men respondents reported having only male partners, and both male and female partners, respectively. The fraction of HIVST received by clients of FSW (12%) was assumed to be half the fraction of men reporting having paid for sex in the past 12 months (236/947/2), as reporting exchanging sex for money between two male partners is not uncommon in the region. The fraction of tests distributed through the MSM channels that were received by lower-risk (heterosexual) male was calculated as the fraction of men reporting no sexual partners (14%, 139/997). Around 24% (22/92) of female participants having received a test through the MSM channel reported having received money for sex in the past year and were considered FSW, whereas 15% reported not having any partner and were considered as low-risk females.

groups in the sensitivity scenario (presented in the sensitivity analysis), based on the ATLAS phone									
survey da	survey data (all ATLAS countries combined)								
FSW	All females (52%)			All males (48%)					
	Lower-	Intermediate-	FSW	Lower-	Intermediate-	Clients	MSMW	MSME	
	risk	risk females		risk	risk males	of			
channel	females			males		FSW			
	15%	17%	20%	8%	23%	12%	3%	3%	
	All females (9%)			All males (91%)					
MSM channel	Lower-	Intermediate-	FSW	Lower-	Intermediate-	Clients	MSMW	MSME	
	risk	risk females		risk	risk males	of			
	females			males		FSW			
	2%	5%	2%	13%	22%	11%	30%	15%	

Table S4b: Fraction of tests distributed through the ATLAS FSW and MSM channels across risk

FSW: female sex workers; MSMW: men who have sex with men as well as female partners; MSME: men who have sex with men exclusively.

National HIVST scale-up from January 2022

Within each HIVST distribution scenario, we modelled the scale-up of the WHO objectives of 95% of KP testing twice a year for HIV¹⁴⁵, but only considering HIVST. We calculated the number of HIVST needed to be distributed each year through FSW and MSM channels so that 95% of FSW and 95% of MSM not living with HIV or living with HIV but not on ART (="eligible" population) receive 2 HIVST each year from 2025. Our analysis assumed a linear scale-up from January 2022 and a plateau from 2025. The size of the target population and number of HIVST to distribute each year were calculated in January 2022 and varied across simulations because sizes of KPs and coverage of ART

vary from one simulation to another. Population growth was not accounted for when calculating the size of the target population in future years (but this assumption was tested in our sensitivity analysis), nor was the potential increase in ART coverage over time. The actual coverages in the model are different from the coverages as estimated in January 2022 because 1) large fractions of self-tests distributed through a KP channel were not kept by the target population (e.g. half of HIVST distributed to FSW end up in the hands of males), and 2) the size of the target population may change over time, partly due to the intervention.

As an example, if 50,000 FSW are not living with HIV or living with HIV but not on ART in January 2022, the model will represent a scale-up of HIVST over time so that 95% of 55,000 FSW (size of target population assuming population growth) receive two tests in 2025 through a FSW HIVST distribution channel ($0.95 \times 55,000 \times 2=104,500$ HIVST to distribute into the FSW channel).

All model scenarios assumed the same number of tests distributed into each channel each year, except in a specific sensitivity analysis scenario where it increases over time, according to population growth.

Other HIVST assumptions

Assumptions regarding HIVST uptake and linkage to care are described in **Figure 1** and **Table S5**. The independent influence of several assumptions on the estimated HIVST scale-up impacts were tested within specific sensitivity analyses.

Our main scenarios assumed that:

- 80% of distributed HIVST were used, based on the experience of STAR¹⁴⁶, although an higher fraction was estimated during a study among FSW in Senegal¹³⁹. This fraction was the same across all population strata.
- 20% (Côte d'Ivoire), 30% (Mali), and 40% (Senegal) of HIVST were "substitute" tests, which were discounted from the number of conventional tests (see specific section on HIVST assumptions) performed during the year by the same population strata. This was based on analysis of subnational-level programmatic data during ATLAS¹⁰⁸, although these reductions were not statistically significant in the analysis. The fraction in Mali was simply calculated as the average between the fractions in Côte d'Ivoire and Senegal.
- Uptake of HIVST within a specific risk/age group combination did not depend on the history of testing nor HIV status, except that PLHIV on ART did not receive HIVST. A sensitivity analysis assumed that people that have never tested were twice more likely to receive a self-test compared to people with the same characteristics who ever had an HIV test.
- Only half of people had a confirmation test following a reactive test, with an average time of two months between the tests, whereas those subsequently receiving a positive confirmation test initiated ART after a month. These assumptions were derived from ATLAS phone survey (2nd stage), which aimed at measuring linkage to care among people experiencing a reactive self-test¹¹⁰. A sensitivity analysis looked at the change in estimated impact if the fraction of confirmed reactive tests was increased from 50% to 80%.
- The sensitivity and specificity of the "OraQuick HIV Self-Tests" used during ATLAS were assumed to be 92% and 99%, according to manufacturer data¹⁰⁹. Real-world studies have estimated lower sensitivity^{147,148} when the tests are performed by the intended users, due to variable literacy levels and limited exposure to HIVST. Since we assumed that only 50% of reactive HVIST would be followed by a confirmation test, further reducing the sensitivity had a minimal impact.

Table S5: main assumptions of scenarios.				
Parameter	Ass	umptions	Comment	
	Base-case scenario	Sensitivity analysis scenario)		
Number of HIVST kits distributed over 2019- 2021	"Counterfactual": No HIVST distributed "ATLAS-only" and "HIVST scale-up": HIVST distribution		The number of kits distributed each year matches ATLAS programmatic data for FSW and MSM outreach channels (shown in Table S3)	
Number of HIVST kits distributed over 2022- 2038	"Counterfactual" and "ATLAS-only": No HIVST distributed "HIVST scale-up": linear increase up to 2025, then plateau		"HIVST scale-up": target in 2025 defined as two self-tests to 95% of "eligible" HIVST users (i.e. people without HIV or untreated PLHIV, regardless of their awareness of HIV status)	
Numbers of kits distributed to KP every year from 2025 account for growth of population size	No i.e. annual number of kits distributed constant over time	Yes, the annual number of kits distributed from 2025 increases by ~3% annually	Based on country-specific UNPD estimates of population growth ⁴	
Fraction of kits distributed through the FSW and MSM channels received by each risk group	Shown in Table S4a: assumption accounting for biases in reported high risk behaviours in the ATLAS phone survey ¹⁴⁴ , where $< 20\%$ of distributed kits end up	Shown in Table S4b: assumption not accounting for biases in the ATLAS phone survey (1 st stage) ¹⁴⁴ , where around 50% of distributed kits end up in the hands of non-KP	Assumption reflecting most plausible secondary distribution of self-tests among ATLAS participants. See Tables S4a,b	

	in the hands of non-KP		
Age distribution of people receiving self- tests kits	Matches programmatic data shown in Table S3	Shown in Figure S2: Matches ATLAS phone survey data among HIVST users ¹⁴⁴	Age distributions are comparable in the two datasets overall, but MSM participating to the phone survey are slightly younger than in the programmatic data, see Figure S2.
Fraction of all tests used	80% (constant across population strata)	100%	Based on STAR Malawi (80%) ¹⁴⁶ . Sensitivity assumption based on a survey among FSW in Senegal (~94% HIVST used) ¹³⁹ .
HIVST distributed to PLHIV on ART	No	No	Assumed
HIVST uptake (likelihood of receiving a kit) by HIV infection, diagnosis, and treatment status.	Uptake independent of history of testing diagnosis and treatment.	 4 specific uptake scenarios: 1) twice higher among those never tested vs ever tested 2) PLHIV with a diagnosed infection don't receive tests 3) twice higher among PLHIV on ART vs others 4) twice higher among PLHIV with an undiagnosed infection vs others 	Uptake assumptions modelled as independent relative risks all = 1 in the base-case.
Fraction of reactive HIVST of undiagnosed PLHIV followed by a confirmatory test	50%	80%	Base-case assumption derived from ATLAS phone survey data ¹¹⁰ . Sensitivity analysis assumption assumes improvements in use of HIVST (improved kit user manual, experience with COVID self-tests kits)
Time from reactive to confirmatory test (for those eventually confirming) and from confirmatory test to ART initiation	2 months and 1 month		ATLAS phone survey data (2 nd stage) ¹¹⁰

Test substitution fraction: HIVST substitute/replace conventional tests	20% (Côte d'Ivoire) 30% (Mali) 40% (Senegal)	No substitution	Analysis of subnational programmatic data in Côte d'Ivoire and Senegal ¹⁰⁸ during ATLAS. Fraction for Mali was assumed to be the average of the estimates from the two other countries. Note that the estimated levels of substitution were not statistically significant.
HIVST sensitivity/specificity	92% / 99%	100%	Manufacturer data ¹⁰⁹ .




Figure S2: Proportions of HIV self-tests distributed through FSW and MSM outreach to different age groups in the programmatic data (white bars, base-case scenarios) in each ATLAS country, and in the ATLAS phone survey (stage 1) data (dark grey bars, sensitivity analysis scenarios) all countries combined.




Figure S3: HIVST distribution from mid-2019 in each ATLAS country. Panels a-c) Number of HIVST distributed by ATLAS over 2019-2021 and over 2022-2038 during a hypothetical scale-up of HIVST through female sex workers (blue), and men who have sex with men (green) outreach channels. Panels d-f) Median number of HIVST received each year per FSW (blue) and MSM (green) not living with HIV or living with an untreated HIV infection. The decrease in numbers per capita on panels d-f) from 2025 is because the population is assumed to grow at a constant rate whereas the number of kits distributed over time is constant.

Results: model fits (Côte d'Ivoire)




Figure S4a: Côte d'Ivoire model fitting to the size of the female and male population aged 15-59 years old over time. Blue curves represent model estimates and red squares the estimates from UNPD⁴.




Figure S4b: Côte d'Ivoire model fitting to the age distribution of the female and male population aged 15-59 years old over time. Curves represent model estimates and the squares the estimates from UNPD.

Demography




Figure S4c: Côte d'Ivoire model fitting to the size of key populations and their clients, with fractions of a) FSW among all females aged 15-59 years, b) FSW clients among all males aged 15-59 years, c) MSM among all males aged 15-59 years, and d) MSMW (men who have sex with men and women) among all MSM aged 15-59 years old over time. Blue curves and shades represent median and 90% UI (5thth and 95th percentiles across model fits), whereas squares and intervals represent empirical estimates (with 95% CI). Estimates in panel b) were reported from household surveys and were only use for comparison, whereas the FSW clients population size in the model was calculated using the multiplier method as in¹.






Figure S4d: Côte d'Ivoire model fitting to the HIV prevalence among all females aged a) 15-24, b) 25-49, and c) 50-59 years old (excluding FSW), as well as all males aged d) 15-24, e) 25-49 years, and f) 50-59 years old. Blue curves and shades represent median and 90% UI (5th and 95th percentiles across model fits), red squares and intervals represent empirical estimates used for model fitting (with 95% CI), and the grey square and intervals in panel a) are estimates from a recent survey about violence against children and youth in Côte d'Ivoire¹¹² included for comparison (not used to fit the model).




Figure S4e: Estimates of HIV prevalence among a) all adults aged over 15 years old, fits to b) HIV incidence rate per susceptible, c) annual number of new HIV infections and d) annual HIV-related deaths in Côte d'Ivoire from UNAIDS Data 2018. Blue curves and shades represent median and 90% UI (5th and 95th percentiles across model fits), red squares and intervals represent empirical estimates used for model fitting (with 95%CI), whereas the dark squares and intervals in panel a) represent estimates from UNAIDS used for comparison.




Figure S4f: Comparison of estimates of HIV incidence in the Côte d'Ivoire PHIA survey among a) females aged 15-24 years old, b) males aged 15-24 years old, c) females aged 25-49 years old, d) males aged 25-49 years old. Blue curves and shades represent median and 90% UI (5th and 95th percentiles across model fits), whereas squares and intervals represent empirical estimates from the PHIA survey (with 95% CI).




Figure S4g: Côte d'Ivoire model fitting to HIV prevalence estimates among all a) FSW, b) clients of FSW, c) MSM, as well as c) MSM aged 15-24 years old, and d) aged 25-49 years old. Blue curves and shades represent median and 90% UI (5th and 95th percentiles across model fits), red squares and intervals represent empirical estimates used for model fitting (with 95%CI), whereas dark estimates in panel c) represent estimates fitted among MSMW and MSME separately (see Figure S4h).





Figure S4h: Côte d'Ivoire model fitting to HIV prevalence estimates among all a) MSMW (men having sex with both men and women) and b) MSME (men having sex with another men) MSM. Blue

curves and shades represent median and 90% UI (5th and 95th percentiles across model fits), whereas red squares and intervals represent empirical estimates (with 95%CI).



HIV treatment cascade

Figure S4i: Côte d'Ivoire model fitting to the fraction ever having tested for HIV among all females aged 15-49 years old a) not living with HIV, and b) living with HIV, and males aged 15-49 years old c) not living with HIV, and d) living with HIV. Blue curves and shades represent median and 90% UI (5th and 95th percentiles across model fits), red squares and intervals represent empirical estimates used for model fitting (with 95% CI), whereas green squares represent estimates from UNAIDS Shiny90 which were only used for comparison.




Figure S4j: Côte d'Ivoire model fitting to the fraction ever having tested for HIV among a) all FSW, b) FSW aged 15-24 years, c) FSW aged 25-49 years, and d) MSM. Blue curves and shades represent median and 90% UI (5th and 95th percentiles across model fits), red squares and intervals represent empirical estimates used for model fitting (with 95% CI), whereas dark squares in panel a) represent overall fraction from study outcomes shown in panels b) and c).




Figure S4k: Côte d'Ivoire model fitting to the fraction of a) all females living with HIV and b) all males living with HIV diagnosed (aware of their status). Blue curves and shades represent median and

90% UI (5th and 95th percentiles across model fits), red squares and intervals represent estimates from UNAIDS Shiny90 used for model fitting¹²⁶, whereas grey squares and intervals represent estimates from PHIA³¹, which were underestimates because this fraction of people diagnosed (reporting being aware of their positive status) lower than the fraction of PLHIV having traces of ARV drugs in their blood in the survey.




Figure S4I: Côte d'Ivoire model fitting to the fraction of a) all FSW living with HIV, b) all male clients of FSW living with HIV, and c) all MSM living with HIV diagnosed. Blue curves and shades represent median and 90% UI (5th and 95th percentiles across model fits), whereas red squares and intervals represent estimates from empirical surveys (with 95% CI).




Figure S4m: Côte d'Ivoire model fitting to ART coverage among a) all females and b) all males aged 15-59 years old living with HIV. Blue curves and shades represent median and 90% UI (5thth and 95th percentiles across model fits), whereas red squares and intervals represent estimates from UNAIDS (with 95%CI).




Figure S4n: Côte d'Ivoire model fitting to ART coverage among a) all FSW, b) all male clients of FSW, and c) all MSM living with HIV. Blue curves and shades represent median and 90% UI (5th and 95th percentiles across model fits), whereas red squares and intervals represent empirical estimates from local surveys (with 95% CI)¹¹⁸. Estimates in grey represent estimates from an STI clinic¹¹⁵, which were assumed to be overestimates and not included for model fitting but shown for comparison.




Figure S40: Côte d'Ivoire model fitting to HIV viral load suppression coverage among a) all females, b) all males, c) all FSW, and d) all MSM living with HIV aged 15-49 years. Blue curves and shades represent median and 90% UI (5th and 95th percentiles across model fits), whereas red squares and intervals represent empirical estimates from local surveys.




Figure S4p: Côte d'Ivoire model fitting to HIV viral load suppression coverage among MSM aged a) 15-24 years and b) 25-49 years living with HIV. Blue curves and shades represent median and 90% UI (5th and 95th percentiles across model fits). No data was available.




Figure S4q: Côte d'Ivoire model fitting to fractions of a) females and b) males PLHIV on ART which are virally suppressed (the third UNAIDSs "95%" indicator) over time. Blue curves and shades represent median and 90% UI (5th and 95th percentiles across model fits), whereas red squares and intervals represent estimates from UNAIDS used as parameters and not at fitting targets. The grey dashed line corresponds to the UNAIDS's third "95%" target whereby 95% of PLHIV on ART should be virally suppressed in 2025.




Figure S4r: Côte d'Ivoire model fitting to programmatic data⁶⁷ on the total number of conventional tests among a) all females and b) all males. Proportions of positive conventional tests among c) all females, and d) all males. Blue curves and shades represent median and 90% UI (5th and 95th percentiles across model fits), whereas red squares represent programmatic data communicated by UNAIDS.

Results: model fits (Mali)

Demography




Figure S5a: Mali model fitting to the size of the female and male population aged 15-59 years old over time. Blue curves represent model estimates and red squares the estimates from UNPD⁴.




Figure S5b: Mali model fitting to the size of the female and male population aged 15-59 years old over time. Blue curves represent model estimates and red squares the estimates from UNPD⁴.




Figure S5c: Mali model fitting to the size of key populations and their clients, with fractions of a) FSW among all females aged 15-59 years, b) FSW clients among all males aged 15-59 years, c) MSM among all males aged 15-59 years, and d) MSMW (men who have sex with men and women) among all MSM aged 15-59 years old over time. Blue curves and shades represent median and 90% UI (5thth and 95th percentiles across model fits), whereas squares and intervals represent empirical estimates (with 95% CI). Estimates in panel b) were reported from household surveys and were only use for comparison, whereas the FSW clients population size in the model was calculated using the multiplier method as in¹.

HIV epidemiology




Figure S5d: Mali model fitting to the HIV prevalence among all females aged a) 15-24, b) 25-49, and c) 50-59 years old (excluding FSW), as well as all males aged d) 15-24, e) 25-49 years, and f) 50-59 years old. Blue curves and shades represent median and 90% UI (5th and 95th percentiles across model fits), red squares and intervals represent empirical estimates used for model fitting (with 95% CI).




Figure S5e: Estimates of HIV prevalence among a) all adults aged over 15 years old, fits to b) HIV incidence rate, c) annual number of new HIV infections and d) annual HIV-related deaths in Mali from UNAIDS. Blue curves and shades represent median and 90% UI (5th and 95th percentiles across model fits), red squares and intervals represent empirical estimates used for model fitting, whereas the dark squares and intervals in panel a) represent estimates from UNAIDS only used for comparison.




Figure S5f: Mali model fitting to HIV prevalence estimates among all a) FSW, b) clients of FSW, c) MSM, as well as c) MSM aged 15-24 years old, and d) aged 25-49 years old. Blue curves and shades represent median and 90% UI (5th and 95th percentiles across model fits), red squares and intervals represent empirical estimates used for model fitting, whereas the dark square on panel c) represents the estimate fitted by age.




Figure S5g: Mali model estimates of the HIV prevalence among all a) MSMW (men having sex with both men and women) and b) MSME (men having sex with another men) MSM. Blue curves and shades represent median and 90% UI (5th and 95th percentiles across model fits). No data was available.

HIV treatment cascade




Figure S5h: Mali model fitting to the fraction ever having tested for HIV among all females aged 15-49 years old a) not living with HIV, b) living with HIV, and males aged 15-49 years old c) not living with HIV, d) living with HIV. Blue curves and shades represent median and 90% UI (5th and 95th percentiles across model fits), red squares and intervals represent estimates from UNAIDS Shiny90¹²⁶ used for model fitting (green=Shiny90 estimates used for comparison), whereas grey squares represent estimates from PLHIV from DHS surveys.




Figure S5i: Mali model fitting to the fraction ever having tested for HIV among a) all FSW, b) FSW aged 15-24 years, c) FSW aged 25-49 years, and d) MSM. Blue curves and shades represent median and 90% UI (5th and 95th percentiles across model fits), red squares and intervals represent empirical estimates used for model fitting, the grey square for 2020 in panel d) was an estimate of the fraction of MSM having had an HIV test in the last year, which was used for comparison.




Figure S5j: Mali model fitting to the fraction of a) all females living with HIV and b) all males living with HIV being diagnosed. Blue curves and shades represent median and 90% UI (5th and 95th

percentiles across model fits), red squares and intervals represent estimates from UNAIDS Shiny90 used for model fitting.




Figure S5k: Mali model fitting to the fraction of a) all FSW living with HIV, b) all male clients of FSW living with HIV, and c) all MSM living with HIV diagnosed. Blue curves and shades represent median and 90% UI (5th and 95th percentiles across model fits), red squares and intervals represent estimates from empirical surveys^{47,101}, whereas grey squares represent national estimates for which no report or underlying study could be identified, and which were only used for comparison.




Figure S5I: Mali model fitting to ART coverage among a) all females and b) all males living with HIV. Blue curves and shades represent median and 90% UI (5th and 95th percentiles across model fits), whereas red squares and intervals represent estimates from UNAIDS.



Figure S5m: Mali model fitting to ART coverage among a) all FSW, b) all male clients of FSW, and c) all MSM living with HIV. Blue curves and shades represent median and 90% UI (5th and 95th percentiles across model fits), whereas red squares and intervals represent empirical estimates from local surveys. Dark point and interval in panel c) represent self-reported use of ART, and all study participants reporting being on ART were virally suppressed (which was fitted by age in our model). Grey squares in panels a) and c) represent estimates for which no report or underlying study could be identified. Although no ART coverage data was used, we fitted the Mali model to estimates of viral suppression in the country.




Figure S5n: Mali model fitting to HIV viral load suppression coverage among a) all females, b) all males, c) all FSW, and d) all MSM aged 15-49 years living with HIV. Blue curves and shades represent median and 90% UI (5th and 95th percentiles across model fits), whereas red squares and intervals represent empirical estimates from local surveys. The black square in panel d) was only used for comparison; it was aggregated from the age-stratified 2020 estimates used at the fitting stage (see figure S50).




Figure S50: Mali model fitting to HIV viral load suppression coverage among MSM living with HIV aged a) 15-24 years and b) 25-49 years. Blue curves and shades represent median and 90% UI (5th and 95th percentiles across model fits), whereas red squares and intervals represent empirical estimates.




Figure S5p: Mali model estimates of the fraction of a) females and b) males living with HIV on ART which are virally suppressed (the third UNAIDSs "95%" indicator) over time, which is used as a parameter in our model. There were no available estimates of this fraction, and the plausible fractions were estimated by using the relationship between the 1st and 3rd "95%" indicators in Côte d'Ivoire and Senegal and applying this relationship to the estimate of the 1st "95%" indicator in Mali. The grey dashed line corresponds to the UNAIDS's third "95%" target whereby 95% of PLHIV on ART should be virally suppressed in 2025.




Figure S5q: Mali model fitting to programmatic data⁶⁷ on a) the total number of conventional tests and b) proportion of these tests which were positive. Blue curves and shades represent median and 90% UI (5th and 95th percentiles across model fits), whereas red squares represent programmatic data from UNAIDS⁶⁷.

Results: model fits (Senegal)

Demography




Figure S6a: Senegal model fitting to the size of the (left) female and (right) male populations aged 15-59 years old over time. Blue curves represent model estimates, while red squares show estimates from UNPD.




Figure S6b: Senegal model fitting to the age distribution of (left) females and (right) male populations aged 15-59 years old over time. Curves represent model estimates while squares show estimates from UNPD.




Figure S6c: Senegal model fitting to the size of key populations and their clients, with the fraction of a) FSW among all females aged 15-59 years, b) FSW clients among all males aged 15-59 years, c) MSM among all males aged 15-59 years, and d) MSMW (men who have sex with men and women) among all MSM aged 15-59 years old over time. Blue curves and shades represent median and 90% UI (5thth and 95th percentiles across model fits), whereas squares and intervals represent empirical estimates.

HIV epidemiology




Figure S6d: Senegal model fitting to the HIV prevalence among all females aged a) 15-24, b) 25-49, and c) 50-59 years old (excluding FSW), as well as all males aged d) 15-24, e) 25-49 years, and f) 50-59 years old. Blue curves and shades represent median and 90% UI (5th and 95th percentiles across model fits), whereas red squares and intervals represent empirical estimates used for model fitting.




Figure S6e: Estimates of HIV prevalence among a) all adults aged over 15 years old, fits to b) HIV incidence rate, c) annual number of new HIV infections and d) annual HIV-related deaths in Senegal from UNAIDS. Blue curves and shades represent median and 90% UI (5th and 95th percentiles across model fits), red squares and intervals represent empirical estimates used for model fitting, whereas the dark squares and intervals in panel a) represent estimates from UNAIDS only used for comparison.




Figure S6f: Senegal model fitting to HIV prevalence estimates among a) all FSW, b) all clients of FSW, c) MSM, as well as c) MSM aged 15-24 years old, and d) aged 25-49 years old. Blue curves and shades represent median and 90% UI (5th and 95th percentiles across model fits), red squares and intervals represent empirical estimates used for model fitting. Dark squares for FSW correspond to estimates which could not be sourced to a particular study or report and were only used for comparison, whereas those on panel c-d) represent estimates fitted by age and for bisexuals/exclusive MSM separately.





Figure S6g: Senegal model fitting to HIV prevalence estimates among all a) MSMW (men having sex with both men and women) and b) MSME (men having sex with other men exclusively) MSM. Blue curves and shades represent median and 90% UI (5th and 95th percentiles across model fits), whereas red squares and intervals represent empirical estimates.



HIV treatment cascade

Figure S6h: Senegal model fitting to the fraction ever having tested for HIV among all females aged 15-49 years old a) not living with HIV, and b) living with HIV, and males aged 15-49 years old c) not living with HIV, and d) living with HIV. Blue curves and shades represent median and 90% UI (5th and 95th percentiles across model fits), red squares and intervals represent estimates from UNAIDS Shiny90 used for model fitting (green=those used for comparison), whereas grey squares represent estimates among PLHIV from DHS surveys. Our model estimates among PLHIV were higher than empirical estimates because of high coverage of ART in the data.




Figure S6i: Senegal model fitting to the fraction ever having tested for HIV among a) all FSW, b) FSW aged 15-24 years, c) FSW aged 25-49 years, and d) all MSM. Blue curves and shades represent median and 90% UI (5th and 95th percentiles across model fits), red squares and intervals represent empirical estimates used for model fitting, whereas the grey squares in panel a) corresponded to studies from STI clinics, which were only used for comparison.




Figure S6j: Senegal model fitting to the fraction of a) all females living with HIV and b) all males living with HIV being diagnosed. Blue curves and shades represent median and 90% UI (5th and 95th percentiles across model fits), red squares and intervals represent estimates from UNAIDS Shiny90 used for model fitting.




Figure S6k: Senegal model fitting to the fraction of a) all FSW living with HIV, b) all male clients of FSW living, and c) all MSM living with HIV being diagnosed. Blue curves and shades represent median and 90% UI (5th and 95th percentiles across model fits), red squares and intervals represent estimates from empirical surveys, whereas grey square in panel a) represent estimates from an STI clinic.




Figure S6I: Senegal model fitting to ART coverage among a) all females and b) all males. Blue curves and shades represent median and 90% UI (5th and 95th percentiles across model fits), whereas red squares and intervals represent estimates from UNAIDS.




Figure S6m: Senegal model fitting to ART coverage among a) all FSW, b) all male clients of FSW, and c) all MSM. Blue curves and shades represent median and 90% UI (5th and 95th percentiles across model fits), whereas red squares and intervals represent empirical estimates from local surveys. Dark point and interval in panel c) represent self-reported use of ART (as opposed to estimates using viral load data), and all study participants reporting being on ART were virally suppressed (which was fitted by age in our model). Grey squares in panels a) and c) represent estimates from the UNAIDS key population atlas for which no report or underlying study could be identified.




Figure S6n: Senegal model fitting to HIV viral load suppression coverage among a) all females, b) all males, c) all FSW, and d) all MSM aged 15-49 years living with HIV. Blue curves and shades represent median and 90% UI (5th and 95th percentiles across model fits), whereas red squares and intervals in panel c) represent empirical estimate from a local survey.




Figure S60: Senegal model fitting to HIV viral load suppression coverage among all MSM aged a) 15-24 years and b) 25-49 years. Blue curves and shades represent median and 90% UI (5th and 95th percentiles across model fits. No data was available.




Figure S6p: Senegal model fitting to fractions of a) females and b) males living with HIV on ART which are virally suppressed (the third UNAIDSs "95%" indicator) over time. Blue curves and shades represent median and 95% UI (5th and 95th percentiles across model fits), whereas red squares and intervals represent estimates from UNAIDS used as parameters. The grey dashed line corresponds to the UNAIDS's third "95%" target whereby 95% of PLHIV on ART should be virally suppressed in 2025. The estimate for 2017 was assumed to be an outlier and not considered in our analysis.




Figure S6q: Senegal model fitting to programmatic data on a) the total number of conventional tests among and b) proportion of these tests which were positive. Blue curves and shades represent median and 90% UI (5th and 95th percentiles across model fits), whereas red squares represent programmatic data communicated by UNAIDS.

Results: HIVST distribution and impact




Figure S7: Empirical (dots and intervals) and modelled (lines) proportion of diagnosed PLHIV from different risk groups over 2000-2040 in Côte d'Ivoire (blue), Mali (red) and Senegal (green). Plain lines represent median estimates across model fits of a counterfactual scenario ("no HIVST"). Dashed lines represent median estimates under our scenario 3 representing ATLAS distribution of HIVST kits to FSW and MSM over 2019-2021, followed by a scale-up and plateau in HIVST distribution from 2025.




Figure S8: Estimated impact (in absolute numbers) of the ATLAS-only scenario compared to the counterfactual ("no-HIVST" scenario): a) additional new HIV diagnoses over the three-year intervention (2019-2021) and numbers of b) HIV infections (c) and HIV-related deaths averted by ATLAS over 2019-2021 (green bars) and 2019-2028 (light blue bars). Bars height represent median of model estimates, whereas error bars represent 90% UI of estimates (5th and 95th percentiles of estimates across model simulations).




Figure S9: Estimated impact (in absolute numbers) of a) ATLAS and b) HIVST scale-up scenario compared to the counterfactual (no-HIVST scenario): additional new ART initiations over a) 2019-2021 (light blue bars) and 2019-2028 (dark blue bars), and b) over 2019-2028 (light blue bars) and 2019-2038 (dark blue bars). Bars height represent median of model, whereas error bars represent 90% UI of estimates (5th and 95th percentiles of estimates across model simulations).




Figure S10: Estimated impact (in absolute numbers) of the HIVST scale-up scenario compared to the counterfactual (no-HIVST scenario): a) additional new HIV diagnoses over 2019-2021 (light blue bars) and 2019-2028 (dark blue bars) and numbers of b) HIV infections (c) and HIV-related deaths averted by ATLAS over 2019-2028 and 2019-2038. Bars height represent median of model estimates, whereas error bars represent 90% UI of estimates (5th and 95th percentiles of estimates across model simulations). "All" is the sum of all risk groups, including non-key populations. The negative numbers of new HIV diagnoses in panel a) are because, in the long term, the intervention decreases the number of HIV infections that can be diagnosed by decreasing the number of new HIV infections, while the intervention particularly increases new HIV diagnoses among key populations.




Figure S11a: Estimated distributions of infections averted by ATLAS scale-up by risk group over 2019-2038 in a) Cote d'Ivoire, b) Mali, and C) Senegal




Figure S11b: Estimated distributions of HIV-related averted by ATLAS scale-up by risk group over 2019-2038 in a) Cote d'Ivoire, b) Mali, and C) Senegal

Table S6a: Estimated increase in HIV diagnosis coverage (expressed in percentage points) due to ATLAS and HIVST scale-up among KP in Côte d'Ivoire, Mali, and										
Senegal from 2019 compared to a counterfactual scenario with no HIVST. Median and 90% UI (5th and 95th percentiles) of estimates are shown.										
		Côte d'Ivoire			Mali			Senegal		
HIVST distribution scenario	Population	After 3 years	After 10 years	After 20 years	After 3 years	After 10 years	After 20 years	After 3 years	After 10 years	After 20 years
ATLAS-only (2019-2021)	Overall	0.2pp (0.2-0.3)	0.1pp (0.07-0.2)	0.03pp (0.01-0.07)	0.9 pp (0.5-1.5)	0.7pp (0.4-1.4)	0.4pp (0.2-0.9)	1.1 pp (0.3-2.7)	0.9pp (0.2-2.3)	0.04pp (-0.1-0.6)
	FSW	2.0pp (1.2-3.6)	0.3pp (0.1-0.7)	0.05pp (0.02-0.1)	7.7 pp (2.9-14.6)	1.4pp (0.5-3.9)	0.6pp (0.2-1.8)	0.0 pp (0.1-1.1)	0.1pp (0.06-0.6)	0.0pp (0.0-0.1)
	Clients	0.3pp (0.2-0.4)	0.2pp (0.1-0.4)	0.04pp (-0.002-0.1)	0.5 pp (0.3-1.1)	1.0pp (0.5-1.8)	0.4pp (0.1-1.0)	0.1 pp (0.0-0.1)	0.1pp (0.07-0.3)	0.09pp (0.04-0.3)
	MSM	4.6pp (3.1-8.3)	3.2pp (1.7-5.7)	1.1pp (0.4-2.6)	9.3 pp (3.9-14.7)	4.7pp (1.6- 9.6)	1.5pp (0.4-4.9)	5.7 pp (1.0-17.2)	2.5pp (0.6-8.1)	0.1pp (-0.1-1.4)
HIVST scale-up (2019-2038)	Overall	0.2pp (0.2-0.3)	1.3pp (0.8-1.9)	1.2pp (0.7-2.0)	0.9 pp (0.5-1.5)	3.6pp (2.0-6.4)	4.8pp (2.5- 9.7)	1.1 pp (0.3-2.7)	10.6pp (5.3-16.8)	13.6pp (6.3-21.4)
	FSW	2.0pp (1.2-3.6)	7.6pp (4.2-11.7)	5.8pp (3.3-9.2)	7.7 pp (2.9-14.6)	13.7pp (5.9-24.2)	12.1pp (4.7-24.0)	0.0 pp (0.1-1.1)	4.1pp (0.8-14.7)	3.1pp (1.1-13.2)
	Clients	0.3pp (0.2-0.4)	2.3pp (1.7-3.3)	2.6pp (1.6-4.0)	0.5 pp (0.3-1.1)	4.1pp (2.4-6.6)	5.7pp (3.2-10.2)	0.1 pp (0.0-0.1)	1.6pp (1.0-2.7)	2.7pp (1.6-4.3)
	MSM	4.6pp (3.1-8.3)	30.3pp (20.0-45.4)	27.1pp (16.0-46.0)	9.3 pp (3.9-14.7)	31.3pp (19.9-44.8)	32.1pp (18.0-49.1)	5.7 pp (1.0-17.2)	40.5pp (23.3-59.6)	36.2pp (19.7-57.2)


Table S6b: Estimated proportion of averted infections due to ATLAS and HIVST scale-up among KP in Côte d'Ivoire, Mali and Senegal from 2019 compared to a										
counterfactual scenario with no HIVST. Median and 90% UI (5 th and 95 th percentiles) of estimates are shown.										
		Côte d'Ivoire			Mali			Senegal		
HIVST	Population	Over	Over 10	Over 20	Over	Over 10	Over 20	Over	Over 10	Over 20
distribution	-	ATLAS	years	years	ATLAS	years	years	ATLAS	years	years
scenario		(2019-2021)	(2019-2028)	(2019-2038)	(2019-2021)	(2019-2028)	(2019-2038)	(2019-2021)	(2019-2028)	(2019-2038)
ATLAS-only	Overall	0.1%	0.4%	0.4%	0.7%	2.1%(2.2%	1.4%	3.3%	2.7%
(2019-2021)		(0.09-0.2)	(0.3-0.6)	(0.2-0.6)	(0.4-1.2)	1.1-3.7)	(1.2-4.1)	(0.8-2.3)	(1.7-6.3)	(1.2-6.1)
	FSW	0.2%	0.6%	0.6%	0.4%	2.2%(2.5%	0.2%	0.6%	0.7%
		(0.1-0.3)	(0.4-1.1)	(0.3-1.1)	(0.2-0.8)	1.1-3.6)	(1.2-4.4)	(0.1-0.3)	(0.3-1.1)	(0.4-1.6)
	Clients	0.4%	0.7%	0.5%	2.0%	3.9%	3.4%	0.6%	1.0%	1.0%
		(0.2-0.8)	(0.4-1.6)	(0.3-1.3)	(0.8-3.4)	(1.8-7.1)	(1.6-6.8)	(0.4-1.1)	(0.6-2.0)	(0.6-2.5)
	MSM	1.5%	4.6%	4.3%	4.0%	9.7%	8.7%	3.1%	5.9%	3.7%
		(1.0-2.7)	(3.1-7.5)	(2.7-6.9)	(1.8-6.5)	(4.4-16.1)	(3.7-16.3)	(1.6-5.7)	(2.6-11.5)	(1.5-8.3)
HIVST	Overall	0.1%	1.6%	2.9%	0.7%	5.3%	9.3%	1.4%	16.2%	29.2%
scale-up		(0.09-0.2)	(1.0-2.4)	(1.7-4.6)	(0.4-1.2)	(3.0-8.9)	(5.2-16.6)	(0.8-2.3)	(10.0-23.1)	(17.8-40.1)
(2019-2038)	FSW	0.2%	2.3%	4.9%	0.4%	4.8%	9.3%	0.2%	2.7%	6.9%
		(0.1-0.3)	(1.6-3.6)	(3.1-7.4)	(0.2-0.8)	(2.7-7.7)	(5.0-16.1)	(0.1-0.3)	(1.7-4.5)	(4.2-10.4)
	Clients	0.4%	3.4%	5.5%	2.0%	10.0%	14.0%	0.6%	5.9%	11.6%
		(0.2-0.8)	(1.8-5.9)	(2.9-9.1)	(0.8-3.4)	(5.1-17.6)	(7.4-23.9)	(0.4-1.1)	(3.7-9.9)	(7.0-17.2)
	MSM	1.5%	20.5%	31.4%	4.0%	27.3%	42.2%	3.1%	28.0%	41.9%
		(1.0-2.7)	(15.3-27.6)	(22.6-41.8)	(1.8-6.5)	(18.0-36.2)	(28.6-55.4)	(1.6-5.7)	(21.3-37.5)	(31.2-54.4)

Table S6c: Estimated proportion of averted HIV-related deaths due to ATLAS and HIVST scale-up among KP in Côte d'Ivoire, Mali and Senegal from 2019 compared to a counterfactual scenario with no HIVST. Median and 90% UI (5 th and 95 th percentiles) of estimates are shown.										
		Côte d'Ivoire			Mali			Senegal		
HIVST	Population	Over	Over 10	Over 20	Over	Over 10	Over 20	Over	Over 10	Over 20
distribution	-	ATLAS	years	years	ATLAS	years	years	ATLAS	years	years
scenario		(2019-2021)	(2019-2028)	(2019-2038)	(2019-2021)	(2019-2028)	(2019-2038)	(2019-2021)	(2019-2028)	(2019-2038)
ATLAS-only	Overall	0.05%	0.2%	0.3%	0.09%	0.7%	1.1%	0.2%	1.5%	1.9%
(2019-2021)		(0.02 - 0.09)	(0.1-0.3)	(0.2-0.4)	(0.03-0.2)	(0.4-1.3)	(0.6-2.1)	(0.06-0.5)	(0.8-3.1)	(1.0-4.3)
× /	FSW	0.5%	1.4%	1.1%	0.6%	3.9%	3.5%	0.2%	0.6%	0.6%
		(0.1-1.0)	(0.6-2.6)	(0.5-1.8)	(-0.02-2.2)	(1.7-8.5)	(1.7-7.4)	(0.05 - 0.5)	(0.3-1.3)	(0.4-1.2)
	Clients	0.05%	0.3%	0.4%	0.08%	0.7%	1.4%	0.01%	0.1%	0.3%
		(0.02 - 0.09)	(0.2-0.5)	(0.2-0.7)	(0.04-0.2)	(0.4-1.3)	(0.7-2.5)	(0.004 - 0.04)	(0.08-0.3)	(0.2-0.5)
	MSM	0.9%	3.5%	3.7%	1.2%	6.6%	7.5%	1.0%	5.0%	5.0%
		(0.4-1.4)	(2.2-5.7)	(2.2-5.9)	(0.2-3.4)	(2.9-12.3)	(3.3-12.8)	(0.2-2.2)	(2.1-10.9)	(2.0-10.5)
HIVST	Overall	0.05%	0.7%	1.7%	0.09%	1.5%	3.8%	0.2%	5.5%	15.1%
scale-up		(0.02 - 0.09)	(0.4-1.3)	(1.1-2.6)	(0.03-0.2)	(0.8-2.7)	(2.0-6.2)	(0.06-0.5)	(3.2-9.4)	(9.1-24.8)
(2019-2038)	FSW	0.5%	4.7%	8.5%	0.6%	8.8%	13.7%	0.2%	2.7%	6.3%
()		(0.1-1.0)	(2.2-8.6)	(4.6-12.9)	(-0.02-2.2)	(4.0-16.8)	(7.3-23.9)	(0.05 - 0.5)	(1.5-5.9)	(3.8-11.5)
	Clients	0.05%	0.9%	2.7%	0.08%	1.4%	4.5%	0.01%	0.4%	2.2%
		(0.02-0.09)	(0.6-1.3)	(1.8-3.9)	(0.04-0.2)	(0.8-2.4)	(2.7-7.5)	(0.004 - 0.04)	(0.2-0.8)	(1.4-3.5)
	MSM	0.9%	13.2%	24.2%	1.2%	15.9%	29.7%	1.0%	18.4%	37.8%
		(0.4-1.4)	(7.7-18.0)	(17.0-31.3)	(0.2-3.4)	(9.3-26.6)	(20.0-43.3)	(0.2-2.2)	(12.4-27.4)	(26.9-50.1)

Sensitivity analysis

We conducted a sensitivity analysis to assess the influence of key assumptions of our main HIVST scale-up scenario on the secondary distribution of self-tests by risk groups (i.e., approximatively doubling the fraction of tests received by non-KPs, **Tables S4a,b**), age distribution of HIVST users (based on a phone survey conducted by ATLAS¹⁴⁴ instead of programmatic data, with little change in average age of population, **Figure S2**), more HIVST distributed over time (reflecting population growth, instead of a constant number of kits distributed annually) (**Table S5**), higher uses of distributed tests (100% instead of 80%), twice higher likelihood of receiving a HIVST kit for people having never tested for HIV and undiagnosed PLHIV (instead of the uniform likelihood of receiving a kit), higher rate of confirmation of reactive HIVST (80% instead of 50%), less substitutions of conventional test for HIVST (none instead of 20-40%), and higher accuracy of self-tests (i.e., 100%/100% sensitivity/specificity instead of 92/99%).

The estimated fraction of new HIV infections and deaths averted by scaling up HIVST among KP remained qualitatively similar for all alternative assumptions explored and countries (**Figures S12a,b**). The largest difference was observed when doubling the uptake of HIVST among undiagnosed PLHIV compared to HIV-uninfected populations (around 1.7-times more new HIV infections are averted over 10 years). Interestingly, assuming higher levels of secondary distribution of HIVST towards non-KP compared to the base-case (so that ~36% of self-tests kits are used by non-KP during scale-up, vs ~66% in the base-case) reduced the fraction of infections or deaths averted over 2019-2028 by ~1.3-fold compared to the base-case).



*assumes simplified secondary distribution of HIVST, age distribution from programmatic data, KP population growth not taken into account, 80% of HIVST are used, with uniform uptake across population groups, 50% of reactive self-lests are confirmed, 204.0% of self-tests replace conventional tests, and self tests have 92/9% sensitivity/secificity

Figure S12a: Estimated fraction of new HIV infections averted by a scale-up of HIVST among KP over 2019-2028 in the three ATLAS countries within our base-case scenario (top row) as well as sensitivity scenarios. The impact was calculated overall (black squares and intervals), as well as among FSW (blue squares and intervals) and MSM (green squares and intervals). Squares represent median estimates across model fits, whereas error bars represent 90% UI of estimates (5th and 95th percentiles of estimates across model simulations).




Figure S12b: Estimated fraction of HIV-related deaths averted by a scale-up of HIVST among KP over 2019-2028 in the three ATLAS countries within our base-case scenario (top row) as well as sensitivity scenarios. The impact was calculated overall (black squares and intervals), as well as among FSW (blue squares and intervals) and MSM (green squares and intervals). Squares represent median estimates across model fits, whereas error bars represent 90% UI of estimates (5th and 95th percentiles of estimates across model simulations). Impacts are larger among MSM because of greater numbers of tests distributed to them on average (see Figure S3), and because new diagnosis decreases the risk of MSM to die from HIV and prevent more infections among their partners.

References

- 1. Maheu-Giroux M, Vesga JF, Diabate S, et al. Changing Dynamics of HIV Transmission in Cote d'Ivoire: Modeling Who Acquired and Transmitted Infections and Estimating the Impact of Past HIV Interventions (1976-2015). *J Acquir Immune Defic Syndr*. Aug 15 2017;75(5):517-527.
- 2. Maheu-Giroux M, Diabate S, Boily MC, et al. Cost-Effectiveness of Accelerated HIV Response Scenarios in Cote d'Ivoire. *J Acquir Immune Defic Syndr*. Apr 15 2019;80(5):503-512.
- 3. Maheu-Giroux M, Vesga JF, Diabaté S, et al. Population-level impact of an accelerated HIV response plan to reach the UNAIDS 90-90-90 target in Côte d'Ivoire: Insights from mathematical modeling. *PLOS Medicine*. 2017;14(6):e1002321.
- 4. UNPD. 2019 Revision of World Population Prospects. 2022; <u>https://population.un.org/wpp/</u>. Accessed 04/07, 2021.
- 5. Vuylsteke B, Vandenhoudt H, Langat L, et al. Capture-recapture for estimating the size of the female sex worker population in three cities in Côte d'Ivoire and in Kisumu, western Kenya. *Trop Med Int Health.* Dec 2010;15(12):1537-1543.
- 6. UNAIDS. Key Populations Atlas. 2021; <u>https://kpatlas.unaids.org/dashboard</u>. Accessed 07/11, 2021.
- 7. Xu C, Jing F, Lu Y, et al. Summarizing methods for estimating population size for key populations: a global scoping review for human immunodeficiency virus research. *AIDS Research and Therapy*. 2022/02/19 2022;19(1):9.
- 8. Reniers G, Slaymaker E, Nakiyingi-Miiro J, et al. Mortality trends in the era of antiretroviral therapy: evidence from the Network for Analysing Longitudinal Population based HIV/AIDS data on Africa (ALPHA). *Aids*. Nov 2014;28 Suppl 4(4):S533-542.
- 9. Zanou B. *Rapport d'analyse du recensement général de la population et de l'habitation 1998. Thème 2: Migrations.* Abidjan, Côte d'Ivoire: Institut national de la statistique;2001.
- 10. République de Côte d'Ivoire. *Enquête Démographique et de Santé et à Indicateurs Multiples de Côte d'Ivoire 2011-2012*. Calverton, MD: Institut National de la Statistique et ICF International;2012.
- République de Côte d'Ivoire. Enquête sur les Indicateurs du Sida, Côte d'Ivoire 2005.
 Calverton, MD: Institut National de la Statistique (INS), Ministère de la Lutte contre le Sida [Côte d'Ivoire] et ORC Macro.;2006.
- 12. République de Côte d'Ivoire. *Enquête Démographique et de Santé, Côte d'Ivoire 1998-1999*. Calverton, MD: Institute National de la Statistique et ORC Macro;2001.
- 13. N'Cho S, Kouassi L, Koffi A, et al. *Enquête Démographique et de Santé, Côte d'Ivoire 1994*. Calverton, MD: Institut National de la Statistique et Macro International Inc.;1995.
- 14. République du Mali. *Etude Bio-comportementale IST, VIH et tuberculose chez les femmes travailleuses du sexe et les routiers au Mali 2017-2019*: CELLULE SECTORIELLE DE LUTTE CONTRE LE VIH /SIDA LA TUBERCULOSE ET LES HEPATITES VIRALES; 2019 2019.
- 15. République du Mali. Enquête Démographique et de Santé (EDSM V) Mali 2012-2013. 2014/05/01 2014.
- 16. République du Mali. Enquête Démographique et de Santé du Mali 2006 (EDSM-IV). 2007/12/01 2007.
- 17. République du Mali. Mali Enquête Démographique et de Santé (EDSM-III) 2001. 2002/06/01 2002.
- 18. Coulibaly S, Dicko F, Traoré SM, Sidibé O, Seroussi M. Mali Enquête Démographique et de Santé 1995-1996. 1996/12/01 1996.
- 19. Ndiaye S, Diouf PD, Ayad M. *Sénégal Enquête Démographique et de Santé (EDS-II)* 1992/93. Dakar, Sénégal: Ministère de l'Economie, des Finances et du Plan/Sénégal and Macro International;1994.

- 20. Ndiaye S, Ayad M, Gaye A. *Sénégal Enquête Démographique et de Santé (EDS-III) 1997*. Dakar, Sénégal: Ministère de l'Économie, des Finances et du Plan/Sénégal and Macro International;1997.
- 21. République du Sénégal. Enquête Démographique et de Santé Sénégal 20052005.
- 22. République du Sénégal. *Enquête Démographique et de Santé à Indicateurs Multiples Sénégal* (*EDS-MICS*) 2010-2011. Claverton, Maryland, USA: ANSD and ICF International;2012.
- 23. Agence Nationale de la Statistique et de la Démographie/ANSD, ICF. Senegal: Enquête Démographique et de Santé Continue (EDS-Continue 2018. Dakar, Sénégal: ANSD/ICF;2020.
- 24. République du Sénégal. *Senegal: Enquête Démographique et de Santé Continue (EDS-Continue) 2017.* Dakar, Sénégal: ANSD and ICF;2018.
- 25. République du Sénégal. *Enquête Démographique et de Santé Continue (EDS-Continue) Senegal 2016.* Dakar, Sénégal: ANSD and ICF;2017.
- 26. République du Sénégal. *Enquête Démographique et de Santé Continue (EDS-Continue) Senegal 2015.* Rockville, Maryland, USA: ANSD/Sénégal and ICF;2016.
- 27. République du Sénégal. *Sénégal Enquête Démographique et de Santé Continue (EDS-Continue)* 2014. Rockville, Maryland, USA: ANSD/Senegal and ICF International;2015.
- 28. Agence Nationale de la Statistique et de la Démographie ANSD/Sénégal, ICF International. Senegal Enquête Démographique et de Santé Continue (EDS-Continue) 2012-2013. Calverton, Maryland, USA: ANSD/Sénégal and ICF International;2013.
- 29. Vandepitte J, Lyerla R, Dallabetta G, Crabbé F, Alary M, Buvé A. Estimates of the number of female sex workers in different regions of the world. *Sex Transm Infect.* Jun 2006;82 Suppl 3:iii18-25.
- 30. PEPFAR. *Côte d'Ivoire Country Operational Plan (COP/ROP) 2019 Strategic Direction Summary*: PEPFAR; 2019 2019.
- 31. Ministère de la Santé et de l'Hygiène Publique (MSHP). *Côte d'Ivoire Population-Based HIV Impact Assessment (CIPHIA) 2017-2018: Final Report*. Abidjan: MSHP;2021.
- 32. République du Mali. Cartographie et Estimation de la taille des Professionnelles de Sexe (PS) et des Hommes ayant des rapports Sexuels avec d'autres Hommes (HSH) couplées à l'étude bio-comportementale chez les HSH en matière de VIH au Mali: MINISTERE DE LA LUTTE CONTRE LE SIDA; 2020 2020.
- 33. Mukandavire C, Walker J, Schwartz S, et al. Estimating the contribution of key populations towards the spread of HIV in Dakar, Senegal. *J Int AIDS Soc.* Jul 2018;21 Suppl 5:e25126.
- 34. Hawes SE, Critchlow CW, Faye Niang MA, et al. Increased risk of high-grade cervical squamous intraepithelial lesions and invasive cervical cancer among African women with human immunodeficiency virus type 1 and 2 infections. *J Infect Dis.* Aug 15 2003;188(4):555-563.
- 35. République de Côte d'Ivoire. Étude sur le VIH et les facteurs de risques associés chez les hommes ayant des rapports sexuels avec des hommes à Abidjan, Côte d'Ivoire. Abidjan, Côte d'Ivoire: Ministère de la Santé et de la Lutte contre le VIH/SIDA. Programme de lutte contre le Sida en direction des populations hautement vulnérables.;2012.
- 36. République de Côte d'Ivoire. *Etude biologique et comportementale des IST, du VIH et du sida chez les hommes ayant des rapports sexuels avec des hommes (HSH) des villes d'Abidjan, Agboville, Bouaké, Gagnoa, et Yamoussoukro: MSLS; 2016 2016.*
- 37. République de Côte d'Ivoire. Estimation De La Taille Des Travailleuses Du Sexe, Hommes Ayant Des Rapports Sexuels Avec D'autres Hommes, Usagers De Drogues Et Transgenres En Côte D'Ivoire. 2020.
- 38. Inghels M, Kouassi AK, Niangoran S, et al. Cascade of Provider-Initiated Human Immunodeficiency Virus Testing and Counselling at Specific Life Events (Pregnancy, Sexually Transmitted Infections, Marriage) in Côte d'Ivoire. Sexually Transmitted Diseases. January 2020 2020;47(1):54–61.
- 39. République du Sénégal. *Rapport de situation sur la riposte nationale a l'épidemie de VIH/SIDA Sénégal 2013-20142015*.

- 40. Hakim AJ, Aho J, Semde G, et al. The Epidemiology of HIV and Prevention Needs of Men Who Have Sex with Men in Abidjan, Cote d'Ivoire. *PLoS One*. 2015;10(4):e0125218.
- 41. Aho J, Hakim A, Vuylsteke B, et al. Exploring Risk Behaviors and Vulnerability for HIV among Men Who Have Sex with Men in Abidjan, Cote d'Ivoire: Poor Knowledge, Homophobia and Sexual Violence. *PLoS ONE*. 2014-6-24 2014;9(6).
- 42. Moran A, Scheim A, Lyons C, et al. Characterizing social cohesion and gender identity as risk determinants of HIV among cisgender men who have sex with men and transgender women in Côte d'Ivoire. *Annals of Epidemiology*. February 1, 2020 2020;42:25-32.
- 43. Diabaté S, Kra O, Biékoua YJ, et al. Pre-exposure prophylaxis among men who have sex with men in Côte d'Ivoire: a quantitative study of acceptability. *AIDS Care*. 2020-06-30 2020:1-9.
- 44. USAID. Cartographie Programmatique et Estimation de la Taille des HSH à Abidjan utilisant la méthode PLACE avancée: USAID; 2017 2017.
- 45. Eubanks A, Dembélé Keita B, Anoma C, et al. Reaching a Different Population of MSM in West Africa With the Integration of PrEP Into a Comprehensive Prevention Package (CohMSM-PrEP ANRS 12369-Expertise France). *Journal of Acquired Immune Deficiency Syndromes (1999)*. 2020-11-01 2020;85(3):292-301.
- 46. République de Côte d'Ivoire. *Enquête bio-comportementale chez les hommes ayant des rapports sexuels ave d'autres hommes (HSH) dans les villes de Divo, Daloa, Abengourou, Bouafle et Korhogo2020.*
- 47. Hakim AJ, Coy K, Patnaik P, et al. An urgent need for HIV testing among men who have sex with men and transgender women in Bamako, Mali: Low awareness of HIV infection and viral suppression among those living with HIV. *PloS One.* 2018 2018;13(11):e0207363.
- 48. Kounta CH, Sagaon-Teyssier L, Coulaud P-J, et al. Transactional sex among men who have sex with men participating in the CohMSM prospective cohort study in West Africa. *PLoS ONE*. 2019-11-6 2019;14(11).
- 49. Lahuerta M, Patnaik P, Ballo T, et al. HIV Prevalence and Related Risk Factors in Men Who Have Sex with Men in Bamako, Mali: Findings from a Bio-behavioral Survey Using Respondent-Driven Sampling. *AIDS and behavior*. 2018-7 2018;22(7):2079-2088.
- 50. Wade AS, Kane CT, Diallo PA, et al. HIV infection and sexually transmitted infections among men who have sex with men in Senegal. *AIDS*. Dec 02 2005;19(18):2133-2140.
- 51. Niang CK, Tapsoba P, Weiss E, et al. 'It's raining stones': stigma, violence and HIV vulnerability among men who have sex with men in Dakar, Senegal. *Culture, Health & Sexuality*. 2003;5(6):499-512.
- 52. Larmarange J, Wade AS, Diop AK, et al. Men who have sex with men (MSM) and factors associated with not using a condom at last sexual intercourse with a man and with a woman in Senegal. *PLoS One*. Oct 05 2010;5(10).
- 53. Ndiaye P, Fall A, Tal-Dia A, Faye A, Diongue M. Knowledge, attitudes and practices related to STD and HIV/AIDS: men having sex with men in Senegal. *Rev Epidemiol Sante Publique*. Oct 2011;59(5):305-311.
- 54. République du Sénégal. *Rapport Enquete Combinee Chez Les Hommes Ayant Des Rapports Sexuels Avec Des Hommes (HSH) Au Senegal (2014)*2014.
- 55. République du Sénégal. Enquete Combinee Chez Les Hommes Ayant Des Rapports Sexuels Avec Des Hommes (HSH) Au Senegal2017.
- 56. Lyons CE, Olawore O, Turpin G, et al. Intersectional stigmas and HIV-related outcomes among a cohort of key populations enrolled in stigma mitigation interventions in Senegal. *AIDS*. 2020;34.
- 57. UNICEF. *LA SITUATION DES FEMMES ET DES ENFANTS EN CÔTE D'IVOIRE*: MINISTÈRE DU PLAN ET DU DÉVELOPPEMENT; 2016 2016.
- 58. République du Mali. Demographic and Health Survey Mali 2018. 2019/08/01 2019.
- 59. République du Sénégal. *Senegal Enquête Démographique et de Santé Continue (EDS-Continue) 2012-2013.* Calverton, Maryland, USA: ANSD/Sénégal and ICF International;2013.

- 60. Garnett GP, Anderson RM. Balancing sexual partnerships in an age and activity stratified model of HIV transmission in heterosexual populations. *IMA J Math Appl Med Biol.* 1994;11(3):161-192.
- 61. Anderson RM, May RM. *Infectious diseases of humans*: Oxford University Press, USA; 1992.
- 62. Lei JH, Liu LR, Wei Q, et al. Circumcision Status and Risk of HIV Acquisition during Heterosexual Intercourse for Both Males and Females: A Meta-Analysis. *PLoS One*. 2015;10(5):e0125436.
- 63. Mackelprang RD, Baeten JM, Donnell D, et al. Quantifying ongoing HIV-1 exposure in HIV-1-serodiscordant couples to identify individuals with potential host resistance to HIV-1. *J Infect Dis.* Oct 2012;206(8):1299-1308.
- 64. Naicker N, Kharsany AB, Werner L, et al. Risk Factors for HIV Acquisition in High Risk Women in a Generalised Epidemic Setting. *AIDS Behav.* Jul 2015;19(7):1305-1316.
- 65. Bellan SE, Dushoff J, Galvani AP, Meyers LA. Reassessment of HIV-1 Acute Phase Infectivity: Accounting for Heterogeneity and Study Design with Simulated Cohorts. *PLOS Medicine*. 2015;12(3):e1001801.
- 66. Rodger AJ, Cambiano V, Bruun T, et al. Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. *The Lancet.* 2019;393(10189):2428-2438.
- 67. UNAIDS. AIDSInfo. 2021; <u>https://aidsinfo.unaids.org/</u>. Accessed 09/11, 2021.
- 68. Ghys PD, Diallo MO, Ettiègne-Traoré V, et al. Increase in condom use and decline in HIV and sexually transmitted diseases among female sex workers in Abidjan, Côte d'Ivoire, 1991–1998. *AIDS*. January 25th, 2002 2002;16(2):251–258.
- 69. Bamba A, Grover E, Ezouatchi R, et al. *Étude biologique et comportementale des IST/VIH/SIDA chez les professionnelles du sexe du district d'Abidjan et examen des interventions en direction des populations clefs en Côte d'Ivoire*: Ministère de la Santé et de la Lutte contre le SIDA, ENDA Santé, Johns Hopkins University;2014.
- 70. Lo Y, Sidibe C, Soro B, Kariburyo J. *Prévention et prise en charge de l'infection du VHI/SIDA et des autres IST ciblant les professionnels du sexe et leurs partenaires en Côte d'Ivoire: rapport de la mission technique d'appui OMS.* Geneva, Switzerland: Organisation mondiale de la Santé;2009.
- 71. MSLS. Analyse des connaissances, attitudes et pratiques des professionnels(les) du sexe dans dix-huit villes de Côte d'Ivoire. Abidjan, Côte d'Ivoire: Ministère de la Santé et de la Lutte contre le Sida;2012.
- 72. Ministère de la Santé du Mali. Enquête Integrée Sur La Prévalence Et Les Comportements En Matière D'IST (ISBS) Menée Au Mali D'avril a Juin 2009, Rapport Final. Bamako, Mali2010.
- 73. ENSC. Enquete Nationale de Surveillance Combinee des IST et du VIH/SIDA (ENSC 2019), Composante Comportementale, Groupe Cible: PS2020.
- 74. ENSC. ENQUÊTE NATIONALE DE SURVEILLANCE COMBINEE DES IST ET DU VIH/SIDA, ENSC 20152015.
- 75. ENSC. ENQUÊTE NATIONALE DE SURVEILLANCE COMBINEE DES ISTET DU VIH/SIDA, ENSC 20102010.
- 76. ENSC. ENQUÊTE NATIONALE DE SURVEILLANCE COMBINEE DES IST ET DU VIH/SIDA, ENSC 20062006.
- 77. Vuylsteke BL, Ghys PD, Traoré M, et al. HIV prevalence and risk behavior among clients of female sex workers in Abidjan, Côte d'Ivoire. *AIDS (London, England)*. 2003-07-25 2003;17(11):1691-1694.
- 78. Lyons CE, Ketende S, Diouf D, et al. Potential Impact of Integrated Stigma Mitigation Interventions in Improving HIV/AIDS Service Delivery and Uptake for Key Populations in Senegal. *J Acquir Immune Defic Syndr*. Jan 01 2017;74 Suppl 1:S52-S59.
- 79. Larmarange J, Desgrées du Loû A, Enel C, Wade A. Homosexualité et bisexualité au Sénégal : une réalité multiforme. *Population*. 2009;64(4):723-756.

- 80. Wandel S, Egger M, Rangsin R, et al. Duration from seroconversion to eligibility for antiretroviral therapy and from ART eligibility to death in adult HIV-infected patients from low and middle-income countries: collaborative analysis of prospective studies. *Sex Transm Infect.* Aug 2008;84 Suppl 1(Suppl_1):i31-i36.
- 81. Hughes JP, Baeten JM, Lingappa JR, et al. Determinants of per-coital-act HIV-1 infectivity among African HIV-1-serodiscordant couples. *J Infect Dis.* Feb 01 2012;205(3):358-365.
- 82. Boily MC, Baggaley RF, Wang L, et al. Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies. *Lancet Infect Dis.* Feb 2009;9(2):118-129.
- 83. Boily MC, Dimitrov D, Abdool Karim SS, Masse B. The future role of rectal and vaginal microbicides to prevent HIV infection in heterosexual populations: implications for product development and prevention. *Sex Transm Infect*. Dec 2011;87(7):646-653.
- 84. Weller S, Davis K. Condom effectiveness in reducing heterosexual HIV transmission. *Cochrane Database Syst Rev.* 2001(3):CD003255.
- 85. DIPE. *Rapport annuel VIH/Sida du secteur santé en Côte d'Ivoire 2007-2008*. Abidjan, Côte d'Ivoire: Direction de l'Information, de la Planification et de l'Évaluation. Ministère de la Santé et de l'Hygiène Publique;2009.
- 86. DIPE. *Rapport annuel des indicateurs VIH du secteur santé en Côte d'Ivoire 2009*. Abidjan, Côte d'Ivoire: Direction de l'Information, de la Planification et de l'Évaluation. Ministère de la Santé et de l'Hygiène Publique.;2010.
- 87. DIPE. *Rapport annuel des indicateurs VIH du secteur Santé en Côte d'Ivoire 2010*. Abidjan, Côte d'Ivoire: Direction de l'Information, de la Planification et de l'Évaluation. Ministère de la Santé et de l'Hygiène Publique.;2011.
- 88. DIPE. *Rapport annuel des indicateurs VIH du secteur santé en Côte d'Ivoire 2011*. Abidjan, Côte d'Ivoire: Direction de l'Information, de la Planification, et de l'Évaluation. Ministère de la Santé et de la Lutte contre le Sida;2012.
- 89. DIPE. *Rapport annuel des indicateurs VIH du secteur santé en Côte d'Ivoire 2012*. Abidjan, Côte d'Ivoire: Direction de l'Information, de la Planification et de l'Évaluation. Ministère de la Santé et de la Lutte contre le SIDA.;2013.
- 90. DIPE. *Rapport annuel des indicateurs VIH du secteur santé en Côte d'Ivoire 2013*. Abidjan, Côte d'Ivoire: Direction de l'Information, de la Planification et de l'Évaluation;2014.
- 91. DIPE. *Rapport annuel des indicateurs VIH du secteur santé en Côte d'Ivoire 2014 Non consolidé*. Abidjan, Côte d'Ivoire: Direction de l'Information, de la Planification et de l'Évaluation. Ministère de la santé et de la lutte contre le sida.;2015.
- 92. Vuylsteke B, Semdé G, Auld AF, et al. Retention and Risk Factors for Loss to Follow-up of Female and Male Sex Workers on Antiretroviral Treatment in Ivory Coast: A Retrospective Cohort Analysis. *Journal of acquired immune deficiency syndromes (1999)*. 2015-3-01 2015;68(Suppl 2):S99-S106.
- 93. MEF. *Enquête Ivoirienne sur la fécondité 1980-81 Rapport Principal. Volume I.* Abidjan, Côte d'Ivoire: Ministère de l'Économie et des Finances. Direction de la Statistique;1984.
- 94. MEF. *Enquête Ivoirienne sur la fécondité 1980-81 Rapport Principal. Volume II.* Abidjan, Côte d'Ivoire: Ministère de l'Économie et des Finances. Direction de la Statistique.;1984.
- 95. Schwartz S, Papworth E, Thiam-Niangoin M, et al. An Urgent Need for Integration of Family Planning Services Into HIV Care: The High Burden of Unplanned Pregnancy, Termination of Pregnancy, and Limited Contraception Use Among Female Sex Workers in Côte d'Ivoire. *JAIDS Journal of Acquired Immune Deficiency Syndromes*. March 1st, 2015 2015;68:S91.
- 96. Diallo D, Sangare O, Traore M, Dolo A. FRÉQUENCE DES MST/SIDA CHEZ LES PROSTITUÉES A BAMAKO. *Médecine d'Afrique Noire*. 1997 1997;44(6).
- 97. Mulanga-Kabeya C, Morel E, Patrel D, et al. Prevalence and risk assessment for sexually transmitted infections in pregnant women and female sex workers in Mali: is syndromic approach suitable for screening? *Sexually Transmitted Infections*. 1999-10 1999;75(5):358-359.
- 98. Trout CH, Dembélé O, Diakité D, et al. West African female sex workers in Mali: reduction in HIV prevalence and differences in risk profiles of sex workers of differing nationalities of

origin. Journal of Acquired Immune Deficiency Syndromes (1999). 2015-03-01 2015;68 Suppl 2:S221-231.

- 99. Keita A. Etude Integree Sur La Prevalence Des IST/VIH et Des Comportements Sexuels De Cinq Populations Cibles Au Mali: FACULTE DE MEDECINE, DE PHARMACIE ET D' ODONTO-STOMATOLOGIE, UNIVERSITE DU MALI; 2005.
- 100. M. K, S. C, Y.I. C, et al. First indirect measure of incidence and risk factors for recent infections with HIV-1 among female sex workers in the district of Bamako, Mali. *American Journal of Tropical Medicine and Hygiene*. 2013 2013;89(5 SUPPL. 1):233.
- 101. Tounkara FK, Téguété I, Guédou FA, Keita B, Alary M. Prevalence and Factors Associated With HIV and Sexually Transmitted Infections Among Female Sex Workers in Bamako, Mali. Sexually Transmitted Diseases. 2020-10 2020;47(10):679-685.
- 102. Ndoye I, Mboup S, De Schryver A, et al. Diagnosis of sexually transmitted infections in female prostitutes in Dakar, Senegal. *Sex Transm Infect.* Jun 1998;74 Suppl 1:S112-117.
- 103. Hakim A, Patnaik P, Telly N, et al. High Prevalence of Concurrent Male-Male Partnerships in the Context of Low Human Immunodeficiency Virus Testing Among Men Who Have Sex With Men in Bamako, Mali. *Sexually transmitted diseases*. 2017-9 2017;44(9):565-570.
- 104. Moreau A, Placide Tapsoba, Abdoulaye Ly, Cheikh Ibrahima Niang, Diop AK. Implementing STI/HIV prevention and care interventions for men who have sex with men in Senegal. *Horizons Research Summary*. 2007.
- 105. Aho J, Koushik A, Diakité SL, Loua KM, Nguyen VK, Rashed S. Biological validation of self-reported condom use among sex workers in Guinea. *AIDS Behav.* Dec 2010;14(6):1287-1293.
- 106. Woolf-King SE, Muyindike W, Hobbs MM, et al. Vaginal Prostate Specific Antigen (PSA) Is a Useful Biomarker of Semen Exposure Among HIV-Infected Ugandan Women. *AIDS Behav.* Jul 2017;21(7):2141-2146.
- 107. Lépine A, Treibich C, Ndour CT, Gueye K, Vickerman P. HIV infection risk and condom use among sex workers in Senegal: evidence from the list experiment method. *Health Policy Plan.* May 1 2020;35(4):408-415.
- 108. Fotso AS, Johnson C, Vautier A, et al. Routine programmatic data show a positive population-level impact of HIV self-testing: the case of Côte d'Ivoire and implications for implementation. *Aids.* Jul 18 2022.
- 109. U.S. Food & Drug Administration. OraQuick In-Home HIV Test. 2020; https://www.fda.gov/vaccines-blood-biologics/approved-blood-products/informationregarding-oraquick-home-hiv-test. Accessed Nov., 2021.
- 110. Larmarange J, On behalf of the ATLAS team. Self-Testing, Empowerment and Self-Care: perspectives from lessons learned in implementing HIV self-testing in West Africa. Paper presented at: AIDS Self-testing symposium; 29 July 2022, 2022; Montresl, QC, Canada.
- 111. Benoit SN, Gershy-Damet GM, Coulibaly A, et al. Seroprevalence of HIV infection in the general population of the Côte d'Ivoire, West Africa. *Journal of Acquired Immune Deficiency Syndromes*. 1990 1990;3(12):1193-1196.
- 112. Ministry of Women Family and Children. *Violence Against Children and Youth In Côte d'Ivoire. Findings from a National survey*2020.
- 113. Koffi K, Gershy-Damet GM, Peeters M, Soro B, Rey JL, Delaporte E. Rapid spread of HIV infections in Abidjan, Ivory Coast, 1987-1990. European Journal of Clinical Microbiology & Infectious Diseases: Official Publication of the European Society of Clinical Microbiology. 1992-03 1992;11(3):271-273.
- 114. Mastro TD. Increase in condom use and decline in HIV and sexually transmitted diseases among female sex workers in Abidjan, Côte d'Ivoire, 1991-1998, by Ghys et al. *AIDS*. 2003;17 Suppl 4:S121-122.
- 115. Bastien V. Espace Confiance: des services orientés vers la santé sexuelle. Dispositifs innovants des associations de lutte contre le VIH/sida en Afrique de l'Ouest. Paris, France: SIDACTION;2013.

- 116. Vuylsteke B, Semdé G, Sika L, et al. HIV and STI Prevalence among Female Sex Workers in Côte d'Ivoire: Why Targeted Prevention Programs Should Be Continued and Strengthened. *PLoS ONE*. 2012-3-5 2012;7(3).
- 117. USAID. LINKAGES CÔTE D'IVOIRE Summary of Achievements: USAID; 2019 2019.
- 118. République de Côte d'Ivoire. Enquête bio-comportementale et cartographique en direction des travailleuses de sexe dans cinq localités de la Côte d'Ivoire : Katiola, Yamoussoukro, Soubré, Aboisso, Agboville.2020.
- 119. République de Côte d'Ivoire. *PLAN STRATEGIQUE NATIONAL DE LA SURVEILLANCE DU VIH ET DES IST 2020-2024*: DIRECTION DE L'INFORMATIQUE ET DE ET DE L'INFORMATION SANITAIRE; 2019 2019.
- 120. UNAIDS. UNAIDS data 2018.
- 121. UNICEF. *Enquête à Indicateurs Mulitples MICS2000 Côte d'Ivoire*. Abidjan, Côte d'Ivoire: UNICEF;2000.
- 122. UNICEF. UNICEF Multiple Indicator Cluster Surveys (MICS). 2021; https://microdata.worldbank.org/index.php/catalog/MICS. Accessed 15/03, 2021.
- 123. INS, UNFPA. Enquête sur les connaissances, les attitudes et les pratiques des jeunes de 10-24 ans en matière de santé de la reproduction et d'insertion socio-économique. Abidjan, Côte d'Ivoire: Institut National de la Statistique, Fonds des Nations Unies pour la Population;2009.
- 124. Sika G, N'Guessan K. Comportements sexuels des PS face au risque du VIH/SIDA: une étude de la situation dans 8 villes de Côte d'Ivoire. Paper presented at: Sixth African Population Conference2011; Ouagadougou, Burkina Faso.
- 125. Thomann M, Grosso A, Wilson PA, Chiasson MA. 'The only safe way to find a partner': rethinking sex and risk online in Abidjan, Côte d'Ivoire. *Critical Public Health.* 2020-01-01 2020;30(1):53-67.
- 126. UNAIDS. UNAIDS Shiny90. 2021; https://shiny90.unaids.org/, 2021.
- 127. Peeters M, Koumare B, Mulanga C, et al. Genetic Subtypes of HIV Type 1 and HIV Type 2 Strains in Commercial Sex Workers from Bamako, Mali. *AIDS Research and Human Retroviruses.* January 1, 1998 1998;14(1):51-58.
- 128. Sullivan GP, Camara N, Dembele B, et al. P703 Pregnancy intention and prevalence according to HIV status among female sex workers in mali. *Sexually Transmitted Infections*. 2019/07/01 2019;95(Suppl 1):A307-A307.
- 129. M. L, P. P, T. B, et al. HIV Prevalence and Related Risk Factors in Men Who Have Sex with Men in Bamako, Mali: Findings from a Bio-behavioral Survey Using Respondent-Driven Sampling. *AIDS and behavior*. 2018 2018;22(7):2079-2088.
- 130. UNICEF. Enquête par grappes à indicateurs multiples (MICS), Rapport Final2010.
- UNICEF. Enquête par grappes à Indicateurs Multiples (MICS), Rapport de Résultats Clés. 2016.
- 132. Kanki P, M'Boup S, Marlink R, et al. Prevalence and risk determinants of human immunodeficiency virus type 2 (HIV-2) and human immunodeficiency virus type 1 (HIV-1) in west African female prostitutes. *Am J Epidemiol.* Oct 01 1992;136(7):895-907.
- 133. UNAIDS. Epidemiological fact sheets: Senegal. 2004.
- 134. République du Sénégal. Bulletin Epidemiologique n° 9 de Surveillance du VIH/SIDA2002.
- 135. Gomes Do Espirito Santo ME, Etheredge GD. How to reach clients of female sex workers: a survey "by surprise" in brothels in Dakar, Senegal. *Bull World Health Organ.* 2002;80:709-713.
- 136. Drame FM, Crawford EE, Diouf D, Beyrer C, Baral SD. A pilot cohort study to assess the feasibility of HIV prevention science research among men who have sex with men in Dakar, Senegal. *J Int AIDS Soc.* Dec 02 2013;16 Suppl 3:18753.
- 137. Gouvernement du Sénégal. *Rapport de l'enquete sur les objectifs de la fin de decennie sur l'enfance (MICS II 2000)2000.*
- 138. DHS-MICS. 2010-11 Demographic and Health Survey and Multiple Indicator Cluster Survey2010.

- 139. Lyons CE, Coly K, Bowring AL, et al. Use and Acceptability of HIV Self-Testing Among First-Time Testers at Risk for HIV in Senegal. *AIDS and Behavior*. 2019/09/01 2019;23(2):130-141.
- 140. Poteat T, Ackerman B, Diouf D, et al. HIV prevalence and behavioral and psychosocial factors among transgender women and cisgender men who have sex with men in 8 African countries: A cross-sectional analysis. *PLoS Medicine*. 2017-11-7 2017;14(11).
- 141. Laurent C, Seck K, Coumba N, et al. Prevalence of HIV and other sexually transmitted infections, and risk behaviours in unregistered sex workers in Dakar, Senegal. *AIDS*. Aug 15 2003;17(12):1811-1816.
- 142. Wang C, Hawes SE, Gaye A, et al. HIV prevalence, previous HIV testing, and condom use with clients and regular partners among Senegalese commercial sex workers. *Sex Transm Infect*. Dec 2007;83(7):534-540.
- 143. Twahirwa Rwema JO, Lyons CE, Ketende S, et al. Characterizing the Influence of Structural Determinants of HIV Risk on Consistent Condom Use Among Female Sex Workers in Senegal. *J Acquir Immune Defic Syndr*. May 1 2019;81(1):63-71.
- 144. Simo Fotso A, Kra AK, Maheu-Giroux M, et al. Is it possible to recruit HIV self-test users for an anonymous phone-based survey using passive recruitment without financial incentives? Lessons learned from a pilot study in Côte d'Ivoire. *Pilot and Feasibility Studies*. 2022/01/06 2022;8(1):4.
- 145. World Health Organisation. Consolidated Guidelines On HIV Prevention, Testing, Treatment, Service Delivery And Monitoring: Recommendations For A Public Health Approach. Geneva2021.
- 146. Choko AT, MacPherson P, Webb EL, et al. Uptake, Accuracy, Safety, and Linkage into Care over Two Years of Promoting Annual Self-Testing for HIV in Blantyre, Malawi: A Community-Based Prospective Study. *PLOS Medicine*. 2015;12(9):e1001873.
- 147. Figueroa C, Johnson C, Ford N, et al. Reliability of HIV rapid diagnostic tests for self-testing compared with testing by health-care workers: a systematic review and meta-analysis. *Lancet HIV*. Jun 2018;5(6):e277-e290.
- 148. Kapaku KN, Neuman M, Maluzi K, et al. Is OraQuick® HIV-self-testing valid among intended users? Analysis from a clinical performance study in Lusaka, Zambia. *9th International AIDS Society Conference on HIV Science*. Paris, France2017.